Scholars@Duke
Gary Herbert Lyman

Gary Herbert Lyman

Adjunct Professor in the Department of Medicine
Medicine, Medical Oncology
gary.lyman@duke.edu
Duke Box 2736, 2424 Erwin Road, Durham, NC 27705
2424 Erwin Road, Suite 205, Durham, NC 27705

Selected Publications

The evolving value assessment of cancer therapies: Results from a modified Delphi study

Journal Article Health Policy OPEN · December 1, 2024 The move toward early detection and treatment of cancer presents challenges for value assessment using traditional endpoints. Current cancer management rarely considers the full economic and societal benefits of therapies. Our study used a modified Delphi ... Full text Cite

Drug development for major chronic health conditions-aligning with growing public health needs: Proceedings from a multistakeholder think tank.

Journal Article Am Heart J · April 2024 The global pharmaceutical industry portfolio is skewed towards cancer and rare diseases due to more predictable development pathways and financial incentives. In contrast, drug development for major chronic health conditions that are responsible for a larg ... Full text Link to item Cite

Heterogeneity and Utility of Pharmaceutical Company Sharing of Individual-Participant Data Packages.

Journal Article JAMA Oncol · December 1, 2023 IMPORTANCE: The pharmaceutical industry has made substantial investments in developing processes for sharing individual-participant data (IPD) from clinical trials. However, the utility and completeness of shared IPD and supporting documents must be evalua ... Full text Link to item Cite

Intervention Nonadherence in the TrACER (S1415CD) Study: A Pragmatic Randomized Trial of a Standardized Order Entry for CSF Prescribing.

Journal Article JCO Oncol Pract · December 2023 PURPOSE: We conducted a pragmatic, cluster-randomized trial to test whether a guideline-based standing order entry (SOE) improves use of primary prophylactic CSF (PP-CSF) prescribing for patients receiving myelosuppressive chemotherapy. We investigated var ... Full text Link to item Cite

Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study.

Journal Article Elife · October 17, 2023 BACKGROUND: Limited information is available for patients with breast cancer (BC) and coronavirus disease 2019 (COVID-19), especially among underrepresented racial/ethnic populations. METHODS: This is a COVID-19 and Cancer Consortium (CCC19) registry-based ... Full text Open Access Link to item Cite

Impact of treatment experience on patient knowledge of colony-stimulating factors among patients receiving cancer chemotherapy: evidence from S1415CD-a large pragmatic trial.

Journal Article Support Care Cancer · September 28, 2023 PURPOSE: Primary prophylactic granulocyte colony-stimulating factors (PP-CSFs) are prescribed alongside chemotherapy regimens that carry a significant risk of febrile neutropenia (FN). As part of S1415CD, a prospective, pragmatic trial evaluating the impac ... Full text Link to item Cite

Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile Neutropenia and Infection After High-Risk Chemotherapy.

Journal Article J Natl Compr Canc Netw · September 2023 BACKGROUND: Prophylactic growth-factor therapy with granulocyte colony-stimulating factor (G-CSF) reduces the risk of febrile neutropenia (FN) in patients with breast cancer initiating myelosuppressive chemotherapy. However, little is known about the prote ... Full text Link to item Cite

Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship.

Journal Article Nat Rev Clin Oncol · August 2023 Despite the importance of chemotherapy-associated adverse events in oncology practice and the broad range of interventions available to mitigate them, limited systematic efforts have been made to identify, critically appraise and summarize the totality of ... Full text Open Access Link to item Cite

Biosimilar Use Among 38 ASCO PracticeNET Practices, 2019-2021.

Journal Article JCO Oncol Pract · July 2023 PURPOSE: Biosimilars offer increased patient choice and potential cost-savings, compared with originator biologics. We studied 3 years of prescribed biologics among US physician practices to determine the relationship of practice type and payment source to ... Full text Link to item Cite

ASCO Policy Statement on Biosimilar and Interchangeable Products in Oncology.

Journal Article JCO Oncol Pract · July 2023 As the voice of cancer care clinicians and the patients they serve, ASCO has taken steps to elevate awareness about biosimilar products and their use in oncology. In 2018, ASCO released its Statement on Biosimilars in Oncology which was subsequently publis ... Full text Link to item Cite

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update.

Journal Article J Clin Oncol · June 1, 2023 PURPOSE: To conduct an update of the ASCO venous thromboembolism (VTE) guideline. METHODS: After publication of potentially practice-changing clinical trials, identified through ASCO's signals approach to updating, an updated systematic review was performe ... Full text Link to item Cite

Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer.

Journal Article J Clin Oncol · May 20, 2023 PURPOSE: Although representing the majority of newly diagnosed cancers, patients with breast cancer appear less vulnerable to COVID-19 mortality compared with other malignancies. In the absence of patients on active cancer therapy included in vaccination t ... Full text Link to item Cite

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH).

Journal Article Clin Cancer Res · April 14, 2023 Over the past decade, multiple trials, including the precision medicine trial National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131, NCT02465060) have sought to determine if treating cancer based on specific genomic alterations ... Full text Link to item Cite

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

Other · April 14, 2023 <div>Abstract<p>Over the past decade, multiple trials, including the precision medicine trial National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131, NCT02465060) have sought to determine if treating cancer b ... Full text Cite

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

Other · April 14, 2023 <div>Abstract<p>Over the past decade, multiple trials, including the precision medicine trial National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131, NCT02465060) have sought to determine if treating cancer b ... Full text Cite

Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial.

Journal Article JAMA Netw Open · April 3, 2023 IMPORTANCE: Trastuzumab has been the standard of care for the treatment of patients with ERBB2-positive breast cancer; however, cardiac events have been reported. This long-term follow-up study provides clinical evidence supporting the similarity of a tras ... Full text Link to item Cite

Grade 4 Neutropenia Frequency as a Binary Risk Predictor for Adverse Clinical Consequences of Chemotherapy‑Induced Neutropenia: A Meta-analysis.

Journal Article Cancer Invest · April 2023 Neutropenia is the major toxicity of myelosuppressive cancer chemotherapy. Grade 4 neutropenia (Gr4N) is a measure of chemotherapy-induced neutropenia (CIN) severity. We conducted a meta-analysis of CIN data. Gr4N incidence was significantly correlated wit ... Full text Link to item Cite

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

Other · April 1, 2023 <div>Abstract<p>Over the past decade, multiple trials, including the precision medicine trial National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131, NCT02465060) have sought to determine if treating cancer b ... Full text Cite

Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma.

Journal Article BMC Cancer · March 23, 2023 INTRODUCTION: COVID-19 particularly impacted patients with co-morbid conditions, including cancer. Patients with melanoma have not been specifically studied in large numbers. Here, we sought to identify factors that associated with COVID-19 severity among ... Full text Link to item Cite

Risk of chemotherapy-induced febrile neutropenia in intermediate-risk regimens: Clinical and economic outcomes of granulocyte colony-stimulating factor prophylaxis.

Journal Article J Manag Care Spec Pharm · February 2023 BACKGROUND: Chemotherapy-induced neutropenia increases the risk of febrile neutropenia (FN) and infection with resultant hospitalizations, with substantial health care resource utilization (HCRU) and costs. Granulocyte-colony stimulating factor (GCSF) is r ... Full text Link to item Cite

Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial.

Journal Article J Clin Oncol · January 10, 2023 PURPOSE: Older women with high-risk early breast cancer (EBC) benefit from adjuvant chemotherapy, but their treatment is frequently complicated by toxic side effects, resulting in dose reductions and delays. This makes it challenging for oncologists to mai ... Full text Link to item Cite

Risk Model Development and Validation in Clinical Oncology: Lessons Learned.

Journal Article Cancer Invest · January 2023 Reliable risk models can greatly facilitate patient-centered inferences and decisions. Herein we summarize key considerations related to risk modeling in clinical oncology. Often overlooked challenges include data quality, missing data, effective sample si ... Full text Link to item Cite

Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary.

Journal Article Clin Pharmacol Ther · January 2023 The approval and adoption of biosimilar products are essential to contain increasing healthcare costs and provide more affordable choices for patients. Despite steady progress in the number of the US Food and Drug Administration (FDA) biosimilar approvals ... Full text Link to item Cite

Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology-ASCO Guideline.

Journal Article J Clin Oncol · December 1, 2022 PURPOSE: The aim of this joint guideline is to provide evidence-based recommendations to practicing physicians and other health care providers on integrative approaches to managing pain in patients with cancer. METHODS: The Society for Integrative Oncology ... Full text Link to item Cite

An evaluation of stakeholder engagement in comparative effectiveness research: lessons learned from SWOG S1415CD.

Journal Article J Comp Eff Res · December 2022 Aim: Stakeholder engagement is central to comparative effectiveness research yet there are gaps in definitions of success. We used a framework developed by Lavallee et al. defining effective engagement criteria to evaluate stakeholder engagement during a p ... Full text Link to item Cite

Mitigating acute chemotherapy-associated adverse events in patients with cancer.

Journal Article Nat Rev Clin Oncol · November 2022 Despite the enthusiasm surrounding novel targeted agents and immunotherapies, chemotherapy remains the mainstay treatment for most human malignancies, either alone or in combination. Yet, the burden of chemotherapy-associated adverse events (CAAEs) remains ... Full text Link to item Cite

Effects of a Guideline-Informed Clinical Decision Support System Intervention to Improve Colony-Stimulating Factor Prescribing: A Cluster Randomized Clinical Trial.

Journal Article JAMA Netw Open · October 3, 2022 IMPORTANCE: Colony-stimulating factors are prescribed to patients undergoing chemotherapy to reduce the risk of febrile neutropenia. Research suggests that 55% to 95% of colony-stimulating factor prescribing is inconsistent with national guidelines. OBJECT ... Full text Link to item Cite

Characterization of older adults with cancer seeking acute emergency department care: A prospective observational study.

Journal Article J Geriatr Oncol · September 2022 INTRODUCTION: Disparities in care of older adults in cancer treatment trials and emergency department (ED) use exist. This report provides a baseline description of older adults ≥65 years old who present to the ED with active cancer. MATERIALS AND METHODS: ... Full text Link to item Cite

Webinar as an Informational Resource on Trastuzumab Biosimilars: Planning, Promotion, Execution, and Evaluation.

Journal Article Cancer Invest · August 2022 Despite the incorporation of trastuzumab biosimilars (to treat HER2-positive breast cancer) in clinical practice guidelines, gaps remain such as patient and clinician education. We hosted a webinar comprised of a panel of biosimilars experts, oncologists, ... Full text Link to item Cite

Palliative Care Needs and Clinical Outcomes of Patients with Advanced Cancer in the Emergency Department.

Journal Article J Palliat Med · July 2022 Background: Older adults with cancer use the emergency department (ED) for acute concerns. Objectives: Characterize the palliative care needs and clinical outcomes of advanced cancer patients in the ED. Design: A planned secondary data analysis of the Comp ... Full text Link to item Cite

Association Between Granulocyte Colony-Stimulating Factor (G-CSF) Use and Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Among Elderly Patients with Breast, Lung, or Prostate Cancer.

Journal Article Adv Ther · June 2022 INTRODUCTION: Patients diagnosed with cancer have an increased risk both for myelodysplastic syndromes (MDS) and for acute myeloid leukemia (AML) following treatment. METHODS: Using SEER-Medicare data, we selected patients aged 66 years and older who compl ... Full text Link to item Cite

Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19.

Journal Article Blood Cancer Discov · May 5, 2022 UNLABELLED: Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVI ... Full text Link to item Cite

NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022.

Journal Article J Natl Compr Canc Netw · May 2022 The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapy-induced thrombocytopenia (CIT), and chemotherapy-induced anemia (CIA ... Full text Link to item Cite

Successes and challenges of implementing a cancer care delivery intervention in community oncology practices: lessons learned from SWOG S1415CD.

Journal Article BMC Health Serv Res · April 1, 2022 BACKGROUND: Cancer Care Delivery (CCD) research studies often require practice-level interventions that pose challenges in the clinical trial setting. The SWOG Cancer Research Network (SWOG) conducted S1415CD, one of the first pragmatic cluster-randomized ... Full text Link to item Cite

Use of Biosimilar Medications in Oncology.

Journal Article JCO Oncol Pract · March 2022 PURPOSE: The increased number and expanded utilization of biosimilars raise important considerations for their safe and appropriate use in oncology practice. This report provides an update on currently approved oncology biosimilars and identifies current k ... Full text Link to item Cite

Coinfections in Patients with Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study

Journal Article Open Forum Infectious Diseases · March 1, 2022 Background: The frequency of coinfections and their association with outcomes have not been adequately studied among patients with cancer and coronavirus disease 2019 (COVID-19), a high-risk group for coinfection. Methods: We included adult (≥18 years) pat ... Full text Cite

Abstract P2-13-04: Final survival analysis of a phase 3 study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer

Conference Cancer Research · February 15, 2022 AbstractBackground: SB3 (trastuzumab-dttb) is a biosimilar approved globally based on its similarity with reference trastuzumab (TRZ) demonstrated by thorough comparability exercises in analytical, biologica ... Full text Cite

Observation unit use among patients with cancer following emergency department visits: Results of a multicenter prospective cohort from CONCERN.

Journal Article Acad Emerg Med · February 2022 PURPOSE: Emergency department (ED) visits by patients with cancer frequently end in hospitalization. As concerns about ED and hospital crowding increase, observation unit care may be an important strategy to deliver safe and efficient treatment for eligibl ... Full text Link to item Cite

Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic.

Journal Article Cancer Invest · February 2022 Patients with cancer are at significantly greater risk of COVID-19 and its complications than the general population. Since IgG antibodies remain detectable well after infection with the SARS-CoV-2 virus, seroprevalence can be used to estimate the proporti ... Full text Link to item Cite

Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.

Journal Article J Clin Oncol · January 20, 2022 ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development pro ... Full text Link to item Cite

Expenditures in Young Adults with Hodgkin Lymphoma: NCI-Designated Comprehensive Cancer Centers versus Other Sites.

Journal Article Cancer Epidemiol Biomarkers Prev · January 2022 BACKGROUND: Outcomes among Hodgkin lymphoma (HL) patients diagnosed between 22 and 39 years are worse than among those diagnosed <21 years, and have not seen the same improvement over time. Treatment at an NCI-designated Comprehensive Cancer Center (CCC) m ... Full text Link to item Cite

Outcomes of Patients with COVID-19 from a Specialized Cancer Care Emergency Room.

Journal Article Cancer Invest · January 2022 PURPOSE: Our goal was to identify discrete clinical characteristics associated with safe discharge from an emergency department/urgent care for patients with a history of cancer and concurrent COVID-19 infection during the SARS-CoV-2 pandemic and prior to ... Full text Link to item Cite

Predictive models for thromboembolic events in giant cell arteritis: A US veterans health administration population-based study.

Journal Article Front Immunol · 2022 Giant cell arteritis (GCA) that affects older patients is an independent risk factor for thromboembolic events. The objective of this study was to identify predictive factors for thromboembolic events in patients with GCA and develop quantitative predictiv ... Full text Link to item Cite

COVID-19 and Cancer: A Review of the Registry-Based Pandemic Response.

Journal Article JAMA Oncol · December 1, 2021 IMPORTANCE: The COVID-19 pandemic has had consequences for patients with cancer worldwide and has been associated with delays in diagnosis, interruption of treatment and follow-up care, and increases in overall infection rates and premature mortality. OBSE ... Full text Link to item Cite

How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines.

Journal Article Blood Adv · November 23, 2021 Trustworthy health guidelines should provide recommendations, document the development process, and highlight implementation information. Our objective was to develop a guideline manuscript template to help authors write a complete and useful report. The M ... Full text Link to item Cite

Trends in pegfilgrastim average sales price and cost-effectiveness of primary prophylaxis for patients at intermediate risk for febrile neutropenia.

Conference Journal of Clinical Oncology · October 1, 2021 58 Background: The introduction of biosimilar colony-stimulating factors has led to the reduction in prices for these historically expensive therapies. To understand the impact of recent pricing trends on delivering efficient car ... Full text Cite

The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19.

Journal Article J Thromb Haemost · October 2021 BACKGROUND: Hospitalized patients with COVID-19 have increased risks of venous (VTE) and arterial thromboembolism (ATE). Active cancer diagnosis and treatment are well-known risk factors; however, a risk assessment model (RAM) for VTE in patients with both ... Full text Link to item Cite

Prophylaxis and treatment strategies for optimizing chemotherapy relative dose intensity.

Journal Article Expert Rev Anticancer Ther · October 2021 INTRODUCTION: A decrease in relative-dose intensity (RDI) of chemotherapy has been shown to be associated with poor patient outcomes in solid tumors and non-Hodgkin's lymphoma. The actual delivered chemotherapy dose received by patients can be influenced b ... Full text Link to item Cite

Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?

Journal Article Frontiers in Immunology · August 17, 2021 Background: Sargramostim [recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF)] was approved by US FDA in 1991 to accelerate bone marrow recovery in diverse settings of bone marrow failure and is designated on the list of FDA Ess ... Full text Cite

Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis.

Journal Article JCO Oncol Pract · August 2021 PURPOSE: Temporary COVID-19 guideline recommendations have recently been issued to expand the use of colony-stimulating factors in patients with cancer with intermediate to high risk for febrile neutropenia (FN). We evaluated the cost-effectiveness of prim ... Full text Link to item Cite

Cancer pain management in the emergency department: a multicenter prospective observational trial of the Comprehensive Oncologic Emergencies Research Network (CONCERN).

Journal Article Support Care Cancer · August 2021 PURPOSE: Many patients with cancer seek care for pain in the emergency department (ED). Prospective research on cancer pain in this setting has historically been insufficient. We conducted this study to describe the reported pain among cancer patients pres ... Full text Link to item Cite

Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era

Journal Article Frontiers in Oncology · July 8, 2021 Chemotherapy-induced damage of hematopoietic stem and progenitor cells (HPSCs) often results in myelosuppression that adversely affects patient health and quality of life. Currently, chemotherapy-induced myelosuppression is managed with chemotherapy dose d ... Full text Cite

Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update.

Journal Article J Clin Oncol · June 20, 2021 PURPOSE: To provide recommendations for appropriate dosing of systemic antineoplastic agents in obese adults with cancer. METHODS: A systematic review of the literature collected evidence regarding dosing of chemotherapy, immunotherapy, and targeted therap ... Full text Link to item Cite

A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.

Journal Article Eur Urol Oncol · June 2021 BACKGROUND: While immune checkpoint inhibitors (ICIs) are approved in the first-line (1L) setting for cisplatin-unfit patients with programmed death-ligand 1 (PD-L1)-high tumors or for platinum (cisplatin/carboplatin)-unfit patients, response rates remain ... Full text Link to item Cite

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.

Journal Article Ann Oncol · June 2021 BACKGROUND: Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of patients with cancer and coronavirus 2019 (COVID-19) reported to the COVID-19 and ... Full text Link to item Cite

Expenditures among young adults with acute lymphoblastic leukemia by site of care.

Journal Article Cancer · June 1, 2021 BACKGROUND: Individuals diagnosed with acute lymphoblastic leukemia (ALL) between the ages of 22 and 39 years experience worse outcomes than those diagnosed when they are 21 years old or younger. Treatment at National Cancer Institute-designated Comprehens ... Full text Link to item Cite

Association of febrile neutropenia (FN) risk factors (RFs) with incident FN in U.S. commercial and Medicare advantage patients receiving intermediate-risk chemotherapy for non-myeloid cancers between 2009 and 2019.

Conference Journal of Clinical Oncology · May 20, 2021 e18607 Background: FN after myelosuppressive chemotherapy may result in significant morbidity/mortality and increase healthcare costs due to interventions such as hospitalization. For patients receiving chemotherapy at intermedia ... Full text Cite

Concomitant infections in patients with cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) study.

Conference Journal of Clinical Oncology · May 20, 2021 6561 Background: COVID-19 has been associated with immune modulation that may predispose infected patients to bacterial, viral, or fungal co-infections. Due to critical illness, > 70% of patients with severe COVID-19 receive e ... Full text Cite

Racial and ethnic disparities among patients with breast cancer and COVID-19.

Conference Journal of Clinical Oncology · May 20, 2021 6500 Background: Racial/ethnic minorities have disproportionately increased risk of contracting COVID-19 and experiencing severe illness; they also have worse breast cancer (BC) outcomes. COVID-19 outcomes among racial/ethnic min ... Full text Cite

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group.

Journal Article Clin Cancer Res · May 1, 2021 PURPOSE: Performance status (PS) is one of the most common eligibility criteria. Many trials are limited to patients with high-functioning PS, resulting in important differences between trial participants and patient populations with the disease. In additi ... Full text Link to item Cite

Missing Data in Figure

Journal Article JAMA Oncology · May 1, 2021 Full text Cite

Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta-analysis of cohort studies.

Journal Article Cancer · May 1, 2021 BACKGROUND: Heterogeneous evidence exists on the effect of coronavirus disease 2019 (COVID-19) on the clinical outcomes of patients with cancer. METHODS: A systematic review was performed using the Medline, Embase, and CENTRAL databases and the World Healt ... Full text Link to item Cite

Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees.

Journal Article Leuk Lymphoma · May 2021 With tyrosine kinase inhibitor (TKI) therapy, chronic myelogenous leukemia (CML) is now a chronic disease. CML patients treated with TKIs (n = 1200) were identified from the OptumLabs® Data Warehouse (de-identified claims and electronic health records) bet ... Full text Link to item Cite

Outcomes of Patients with Sarcoma and COVID-19 Infection: A Single Institution Cohort Analysis.

Journal Article Cancer Invest · April 2021 Outcomes for patients (pts) with sarcoma and COVID-19 are unknown. This is a single institution retrospective study of adults with sarcoma and COVID-19. Ten pts [median age 60 (range 24-69)] were identified. Five were hospitalized; two died from COVID-19 c ... Full text Link to item Cite

Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice.

Journal Article Support Care Cancer · April 2021 OBJECTIVES: To evaluate the use of granulocyte colony-stimulating factor (G-CSF) prophylaxis in US patients with selected metastatic cancers and chemotherapy-induced febrile neutropenia (FN) incidence and associated outcomes among the subgroup who did not ... Full text Link to item Cite

Health Care Cost Associated With Contemporary Chronic Myelogenous Leukemia Therapy Compared With That of Other Hematologic Malignancies.

Journal Article JCO Oncol Pract · March 2021 PURPOSE: Given the widespread introduction of tyrosine kinase inhibitors (TKIs), we evaluated the cost associated with chronic myelogenous leukemia (CML) care compared with the cost of care for patients with hematologic malignancies (HEM) and for patients ... Full text Link to item Cite

Challenges and Opportunities for COVID-19 Vaccines in Patients with Cancer.

Journal Article Cancer Invest · March 2021 Given the rapidly expanding global spread of the SARS-Co-V-2 virus and the expanding number of individuals with the serious and potentially fatal illness, COVID-19, there is an urgent need for safe and effective vaccines. Based on compelling evidence that ... Full text Link to item Cite

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.

Journal Article Blood Adv · February 23, 2021 BACKGROUND: Venous thromboembolism (VTE) is a common complication among patients with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and mortality. OBJECTIVE: These evidence-based guidelines of the American Society of H ... Full text Link to item Cite

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update.

Journal Article J Clin Oncol · February 20, 2021 PURPOSE: The aim of this work is to update key recommendations of the ASCO guideline adaptation of the Cancer Care Ontario guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer and adjuvant targeted therapy for breast ... Full text Link to item Cite

Supportive care in patients with cancer during the COVID-19 pandemic.

Journal Article ESMO Open · February 2021 Cancer care has been profoundly impacted by the global pandemic of severe acute respiratory syndrome coronavirus 2 disease (coronavirus disease 2019, COVID-19), resulting in unprecedented challenges. Supportive care is an essential component of cancer trea ... Full text Link to item Cite

Healthcare costs of patients with cancer stratified by Khorana score risk levels.

Journal Article J Med Econ · 2021 AIMS: Patients with cancer are at high risk of venous thromboembolism (VTE), which entails a high economic burden. The risk of cancer-associated VTE can be assessed using the Khorana score (KS), a validated VTE risk prediction algorithm. This study compare ... Full text Link to item Cite

Opportunities and Challenges of Observational Studies and Randomized Controlled Trials for Evaluating the Therapeutic Efficacy of COVID-19 Convalescent Plasma.

Journal Article Cancer Invest · 2021 Large randomized controlled trials (RCTs) remain the gold standard for evaluating treatment efficacy. However, observational studies, including non-randomized cohort studies, as well as small RCTs have gained increasing attention especially during the SARS ... Full text Link to item Cite

A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance.

Journal Article Cancer Cell · December 14, 2020 When the COVID-19 pandemic began, formal frameworks to collect data about affected patients were lacking. The COVID-19 and Cancer Consortium (CCC19) was formed to collect granular data on patients with cancer and COVID-19 at scale and as rapidly as possibl ... Full text Open Access Link to item Cite

Economic Evaluations in National Cancer Institute-Sponsored Network Cancer Clinical Trials.

Journal Article Value Health · December 2020 OBJECTIVES: Amid a rapid increase in cancer care costs, we examined the extent to which economic evaluations (EEs) were conducted for new treatments evaluated in clinical trials at SWOG, a large National Cancer Institute-sponsored cancer research network. ... Full text Link to item Cite

Association of Generic Imatinib Availability and Pricing With Trends in Tyrosine Kinase Inhibitor Use in Patients With Chronic Myelogenous Leukemia.

Journal Article JAMA Oncol · December 1, 2020 This cohort study identifies trends in tyrosine kinase inhibitor use in patients with chronic myelogenous leukemia and the association those treatment choices have with health care costs. ... Full text Link to item Cite

Correction to: Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3.

Journal Article Target Oncol · December 2020 The article Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3. ... Full text Link to item Cite

Errata

Journal Article Journal of Clinical Oncology · November 10, 2020 Full text Cite

Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis

Conference Blood · November 5, 2020 Background: Patients with hematologic malignancy (HM) are hypothesized to be at high risk of poor outcomes with coronavirus disease 2019 (COVID-19), due to disease and therapy-related immunosuppression. Despite this, there are minimal reported data ... Full text Cite

Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry

Conference Blood · November 5, 2020 Introduction: Hospitalized patients with COVID-19 may have increased risk of venous thromboembolism (VTE) and pulmonary embolism (PE). Cancer and anti-cancer therapies are well-known additional risk factors for VTE. Nonetheless, the VTE risk in pat ... Full text Cite

Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer.

Journal Article J Geriatr Oncol · November 2020 PURPOSE: Evaluate the relationship between duration of primary prophylactic short-acting granulocyte colony-stimulating factor (PP-sG-CSF) and risk of neutropenia-related hospitalization (NRH) in older patients receiving myelosuppressive chemotherapy. METH ... Full text Link to item Cite

Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels.

Journal Article Cancer Med · November 2020 BACKGROUND: The Khorana score (KS) clinical algorithm is used to predict VTE risk in cancer patients. The study objective was to evaluate VTE and survival rates among patients newly diagnosed with cancer and stratified by KS in a real-world population. MET ... Full text Link to item Cite

Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis.

Journal Article Lancet Haematol · October 2020 BACKGROUND: Study-level meta-analyses provide high-certainty evidence that heparin reduces the risk of symptomatic venous thromboembolism for patients with cancer; however, whether the benefits and harms associated with heparin differ by cancer type is unc ... Full text Link to item Cite

Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study.

Journal Article Cancer Discov · October 2020 Among 2,186 U.S. adults with invasive cancer and laboratory-confirmed SARS-CoV-2 infection, we examined the association of COVID-19 treatments with 30-day all-cause mortality and factors associated with treatment. Logistic regression with multiple adjustme ... Full text Link to item Cite

Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism.

Journal Article Blood Adv · September 8, 2020 Guidelines provide differing recommendations regarding direct-acting oral anticoagulants vs low-molecular-weight heparin (LMWH) for treatment of cancer-associated thrombosis (CAT). This study was undertaken to evaluate the effectiveness and safety of rivar ... Full text Link to item Cite

Variations in hospitalization and emergency department/observation stays using the oncology care model methodology in Medicare data.

Journal Article Curr Med Res Opin · September 2020 OBJECTIVE: To assess variations in hospitalizations, emergency department/observational (ED/OB) stays not resulting in hospitalization, reasons for hospitalization, and hospitalization discharge destinations after chemotherapy, information not provided as ... Full text Link to item Cite

Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic.

Journal Article J Natl Compr Canc Netw · September 1, 2020 Hematopoietic growth factors, including erythrocyte stimulating agents (ESAs), granulocyte colony-stimulating factors, and thrombopoietin mimetics, can mitigate anemia, neutropenia, and thrombocytopenia resulting from chemotherapy for the treatment of canc ... Full text Link to item Cite

Antiemetics: ASCO Guideline Update.

Journal Article J Clin Oncol · August 20, 2020 PURPOSE: To update the guideline to include new anticancer agents, antiemetics, and antiemetic regimens and to provide recommendations on the use of dexamethasone as a prophylactic antiemetic in patients receiving checkpoint inhibitors (CPIs). METHODS: ASC ... Full text Link to item Cite

Biologic Drug Quality Assurance to Optimize HER2 + Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3.

Journal Article Target Oncol · August 2020 SB3 is a biosimilar of trastuzumab that has been approved for use in the treatment of human epidermal growth factor 2-positive breast cancer and human epidermal growth factor 2-positive gastric cancer. Antibody-dependent cellular cytotoxicity is one of sev ... Full text Link to item Cite

Anticoagulants for the treatment of venous thromboembolism in patients with cancer: A comprehensive systematic review, pairwise and network meta-analysis.

Journal Article Crit Rev Oncol Hematol · August 2020 Cancer-associated venous thromboembolism (VTE) is associated with high VTE recurrence and bleeding. We included all randomized clinical trials that evaluated the efficacy and safety of various anticoagulants in cancer-associated VTE. Trial-level data were ... Full text Link to item Cite

The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis.

Journal Article J Thromb Haemost · August 2020 BACKGROUND: Oncology guidelines suggest using the Khorana score to select ambulatory cancer patients receiving chemotherapy for primary venous thromboembolism (VTE) prevention, but its performance in different cancers remains uncertain. OBJECTIVE: To exami ... Full text Link to item Cite

Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.

Journal Article J Urol · July 2020 PURPOSE: Urinary tract cancer can be pure urothelial carcinoma, pure nonurothelial carcinoma or variant urothelial carcinoma (defined here as mixed urothelial carcinoma). Little is known regarding outcomes for patients with variant urothelial carcinoma rec ... Full text Link to item Cite

Clinical practice guidelines for the treatment and prevention of cancer-associated thrombosis.

Conference Thromb Res · July 2020 The risk of venous thromboembolism (VTE) is increased in patients with cancer and is greatest in those with cancers of the pancreas, stomach, brain, lung and ovary, late stage disease and in those undergoing treatment including chemotherapy, hormonal thera ... Full text Link to item Cite

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

Journal Article Lancet · June 20, 2020 BACKGROUND: Data on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness. METHODS: In this cohort s ... Full text Link to item Cite

Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19).

Conference Journal of Clinical Oncology · June 20, 2020 LBA110 Background: There are limited data on COVID-19 in patients with cancer. We characterize the outcomes of patients with cancer and COVID-19 and identify potential prognostic factors. Methods: The COVID-19 and Cancer Consorti ... Full text Cite

Crowdsourcing in Crisis: Rising to the Occasion.

Journal Article JCO Clin Cancer Inform · June 2020 Full text Link to item Cite

Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences.

Journal Article Blood Adv · May 26, 2020 BACKGROUND: Methods for the development of clinical guidelines have advanced dramatically over the past 2 decades to strive for trustworthiness, transparency, user-friendliness, and rigor. The American Society of Hematology (ASH) guidelines on venous throm ... Full text Link to item Cite

Obtaining and managing data sets for individual participant data meta-analysis: scoping review and practical guide.

Journal Article BMC Med Res Methodol · May 12, 2020 BACKGROUND: Shifts in data sharing policy have increased researchers' access to individual participant data (IPD) from clinical studies. Simultaneously the number of IPD meta-analyses (IPDMAs) is increasing. However, rates of data retrieval have not improv ... Full text Link to item Cite

Crowdsourcing a crisis response for COVID-19 in oncology.

Journal Article Nat Cancer · May 2020 Crowdsourcing efforts are currently underway to collect and analyze data from patients with cancer who are affected by the COVID-19 pandemic. These community-led initiatives will fill key knowledge gaps to tackle crucial clinical questions on the complexit ... Full text Link to item Cite

Providing oncology care during the COVID-19 pandemic.

Journal Article Clin Adv Hematol Oncol · May 2020 Link to item Cite

Errors in Figure 3 and Omission in Additional Contributions

Journal Article JAMA Network Open · April 30, 2020 Full text Cite

Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States.

Journal Article Cancer · April 15, 2020 BACKGROUND: Randomized controlled trials (RCTs) have demonstrated that low-dose direct oral anticoagulants (DOACs), including rivaroxaban and apixaban, may help reduce the incidence of cancer-associated venous thromboembolism (VTE). METHODS: A cost-utility ... Full text Link to item Cite

Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.

Journal Article JAMA Netw Open · April 1, 2020 IMPORTANCE: Chimeric antigen receptor (CAR) T-cell therapies are currently administered at a limited number of cancer centers and are primarily delivered in an inpatient setting. However, variations in total costs associated with these therapies remain unk ... Full text Link to item Cite

Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.

Journal Article Cancer · March 15, 2020 BACKGROUND: Immune checkpoint inhibitors (ICIs) represent an appealing treatment for patients with advanced urothelial cancer (aUC) and a poor performance status (PS). However, the benefit of ICIs for patients with a poor PS remains unknown. It was hypothe ... Full text Link to item Cite

Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years.

Journal Article Curr Med Res Opin · March 2020 Filgrastim prophylaxis, both primary and secondary, was rapidly incorporated into clinical practice in the 1990s. When pegfilgrastim became available in 2002, it quickly replaced filgrastim as the colony-stimulating factor (CSF) of choice for prophylaxis. ... Full text Link to item Cite

Abstract OT1-05-01: The incidence of febrile neutropenia (FN) for chemotherapy patients receiving pegfilgrastim by an on-body injector (pegfilgrastim OBI) versus other FN prophylaxis strategies

Conference Cancer Research · February 15, 2020 AbstractFor safety reasons, pegfilgrastim should be administered the day after chemotherapy for prophylaxis of chemotherapy-induced FN (Lyman et al, Cancer. 2017;25:2619-2629). Because this is inconvenient, ... Full text Cite

Abstract P2-08-24: Risk of chemotherapy-induced febrile neutropenia (FN) in patients with metastatic cancer of the breast or other sites not receiving colony-stimulating factor prophylaxis (CSF) in US clinical practice

Conference Cancer Research · February 15, 2020 AbstractBackground: Clinical practice guidelines recommend CSF prophylaxis for patients receiving chemotherapy regimens with a high risk of FN (&gt;20%), and consideration of CSF prophylaxis for those re ... Full text Cite

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.

Journal Article J Clin Oncol · February 10, 2020 PURPOSE: To provide updated recommendations about prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer. METHODS: PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) and meta-analyses of RCTs pu ... Full text Link to item Cite

Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer.

Conference Support Care Cancer · February 2020 PURPOSE: The effects of chemotherapy dose intensity on survival in patients with advanced non-small-cell lung cancer (NSCLC) are poorly understood. We retrospectively analyzed dose delays/reduction, relative dose intensity (RDI), and the association betwee ... Full text Link to item Cite

NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020.

Journal Article J Natl Compr Canc Netw · January 2020 Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, an ... Full text Link to item Cite

The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma.

Journal Article Ann Hematol · January 2020 It is uncertain if different immunomodulatory drugs (IMID) pose distinct thrombotic risk in patients with newly diagnosed multiple myeloma (MM). Among 2397 MM patients from the SEER-Medicare database from 2007 to 2013, 78% received lenalidomide, and 22% re ... Full text Link to item Cite

Research methods: Systematic reviews and meta-analysis in geriatric oncology

Chapter · January 1, 2020 Cancer is largely a disease of aging with increasing incidence with age for most malignancies and the majority of cancer patients diagnosed after age 65. At the same time, aging is associated with a progressive increase in the number of major medical comor ... Full text Cite

Proposal for Value-Based, Tiered Reimbursement for Tumor Biomarker Tests to Promote Innovation and Evidence Generation.

Journal Article JCO Precis Oncol · December 2019 Cancer precision medicine depends on high-quality tumor biomarker tests (TBTs) for treatment selection. TBT reimbursement within the United States in the current regulatory environment is not tied to premarket evidence of clinical utility, resulting in a v ... Full text Link to item Cite

Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis.

Journal Article J Thromb Haemost · December 2019 BACKGROUND: It is unclear if direct oral anticoagulant (DOAC) is efficacious and safe for prophylaxis of venous thromboembolism (VTE) in ambulatory patients with cancer. METHODS: We performed a systematic review using EMBASE, MEDLINE, and CENTRAL. Inclusio ... Full text Link to item Cite

Cancer Associated Thrombosis Is Associated with Higher Mortality across All Khorana Score Risk Levels

Conference Blood · November 13, 2019 Introduction: Venous thromboembolism (VTE) is directly and indirectly associated with mortality in cancer patients. Cancer patients who experience VTE are known to be at higher risk for mortality than cancer patients without VTE, yet information re ... Full text Cite

Effectiveness of Prophylaxis with Granulocyte Colony-Stimulating Factor Among Cancer Patients Receiving Myelosuppressive Chemotherapy in US Clinical Practice

Conference Blood · November 13, 2019 Introduction: Clinical practice guidelines recommend prophylaxis with granulocyte colony-stimulating factor (G-CSF) for most patients receiving chemotherapy with an intermediate risk or high risk for febrile neutropenia (FN). In real-world settings ... Full text Cite

Meta-Analysis and Cost-Effectiveness Analysis of Low-Dose Direct Oral Anticoagulant for the Prevention of Cancer Associated Thrombosis

Conference Blood · November 13, 2019 Introduction: Randomized controlled trials (RCTs) have shown similar yet conflicting primary outcomes for the use of low-dose direct oral anticoagulant (DOAC), including rivaroxaban and apixaban, in the prevention of cancer-associated thrombosis (C ... Full text Cite

Safety and Effectiveness of Rivaroxaban Versus Low Molecular Weight Heparin for Treatment of Cancer-Associated Venous Thrombosis: A SEER-Medicare-Linked Data Analysis

Conference Blood · November 13, 2019 Introduction: Venous thromboembolism (VTE) affects ~20% of patients with cancer prior to death and may be present in up to half of cancer patients upon autopsy. International Society of Thrombosis and Haemostasis (ISTH) guidelines recommend oral fa ... Full text Cite

Health Care Costs Associated with Contemporary Chronic Myelogenous Leukemia (CML) Therapy Compared to Other Hematologic Malignancies (HEM)

Conference Blood · November 13, 2019 Introduction:CML accounts for 15-20% of leukemias. Tyrosine kinase inhibitor (TKI) therapy has led to significant improvement in survival rates, approaching the life expectancy of the general public in some settings ... Full text Cite

Predictors of Febrile Neutropenia Among Cancer Patients Receiving Myelosuppressive Chemotherapy in US Clinical Practice

Conference Blood · November 13, 2019 Introduction: Febrile neutropenia (FN) is a common and serious complication of myelosuppressive chemotherapy. Assessment of FN risk has typically focused on the chemotherapy course or the first cycle of chemotherapy, and r ... Full text Cite

Letter in reply.

Journal Article J Comp Eff Res · November 2019 Full text Link to item Cite

Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline.

Journal Article J Clin Oncol · November 1, 2019 PURPOSE: The aim of this work is to provide evidence-based guidance on the management of osteoporosis in survivors of adult cancer. METHODS: ASCO convened a multidisciplinary Expert Panel to develop guideline recommendations based on a systematic review of ... Full text Link to item Cite

Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer.

Journal Article Eur J Cancer · October 2019 BACKGROUND: We assessed long-term cardiac safety and efficacy in patients with human epidermal growth factor receptor 2-positive early breast cancer treated with a trastuzumab biosimilar (SB3) or its reference product, trastuzumab (TRZ), in a phase 3 study ... Full text Link to item Cite

How biosimilars will impact costs and care in oncology.

Journal Article Clin Adv Hematol Oncol · October 2019 Link to item Cite

A cost-effectiveness analysis of primary prophylaxis (PP) versus secondary prophylaxis (SP) with biosimilar myeloid growth factors (MGFs) for preventing chemotherapy-induced febrile neutropenia (FN) in non-Hodgkin lymphoma (NHL) patients at intermediate risk.

Conference Journal of Clinical Oncology · September 20, 2019 107 Background: Historically, PP with a MGF was recommended in patients with a ≥40% risk for developing chemotherapy-induced FN, based on clinical and regimen-related factors. Previous economic studies provided evidence to lower ... Full text Cite

Validation of the Emergency Severity Index (Version 4) for the Triage of Adult Emergency Department Patients With Active Cancer.

Journal Article J Emerg Med · September 2019 BACKGROUND: Patients with active cancer account for a growing percentage of all emergency department (ED) visits and have a unique set of risks related to their disease and its treatments. Effective triage for this population is fundamental to facilitating ... Full text Link to item Cite

Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study.

Journal Article BMC Cancer · August 9, 2019 BACKGROUND: Febrile neutropenia (FN) is a serious complication of myelosuppressive chemotherapy. Clinical practice guidelines recommend routine prophylactic coverage with granulocyte colony-stimulating factor (G-CSF)-such as pegfilgrastim-for most patients ... Full text Link to item Cite

Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States.

Journal Article Thromb Res · August 2019 INTRODUCTION: While trials have demonstrated non-inferiority of direct oral anticoagulant drugs (DOAC) to low-molecular-weight heparins (LMWH) for the treatment of cancer associated thrombosis (CAT), it is unclear if the newer intervention is cost-effectiv ... Full text Link to item Cite

Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma.

Journal Article J Natl Compr Canc Netw · July 1, 2019 BACKGROUND: Although venous thromboembolism (VTE) is a significant complication for patients with multiple myeloma (MM) receiving immunomodulatory drugs (IMiDs), no validated clinical model predicts VTE in this population. This study aimed to derive and va ... Full text Link to item Cite

Patterns of Surveillance Advanced Imaging and Serum Tumor Biomarker Testing Following Launch of the Choosing Wisely Initiative.

Journal Article J Natl Compr Canc Netw · July 1, 2019 BACKGROUND: The purpose of this study was to assess advanced imaging (bone scan, CT, or PET/CT) and serum tumor biomarker use in asymptomatic breast cancer survivors during the surveillance period. PATIENTS AND METHODS: Cancer registry records for 2,923 wo ... Full text Link to item Cite

Effective stakeholder engagement: design and implementation of a clinical trial (SWOG S1415CD) to improve cancer care.

Journal Article BMC Med Res Methodol · June 11, 2019 BACKGROUND: The Fred Hutchinson Cancer Research Center has engaged an External Stakeholder Advisory Group (ESAG) in the planning and implementation of the TrACER Study (S1415CD), a five-year pragmatic clinical trial assessing the effectiveness of a guideli ... Full text Link to item Cite

Risk of neutropenia-related hospitalization (NRH) related to duration of short-acting granulocyte colony stimulating factor (sG-CSF) for primary prophylaxis.

Conference Journal of Clinical Oncology · May 20, 2019 e18181 Background: In clinical trials, efficacy of 10–11 days of primary prophylactic (PP) sG-CSF is similar to a single dose of pegfilgrastim for preventing febrile neutropenia (FN). However, most patients receive < 10 days o ... Full text Cite

Longitudinal treatment patterns and adverse events (AEs) in younger patients (Pts) with metastatic triple-negative breast cancer (mTNBC): A real-world landscape analysis.

Conference Journal of Clinical Oncology · May 20, 2019 e12562 Background: While no uniform standard of care exists for mTNBC, conventional chemotherapy remains the treatment mainstay. This retrospective analysis of U.S. commercial claims data was conducted to characterize real-world ... Full text Cite

Evaluation of survival by ADCC status: Subgroup analysis of SB3 (Trastuzumab Biosimilar) and reference trastuzumab in patients with HER2-positive early breast cancer at three-year follow-up.

Conference Journal of Clinical Oncology · May 20, 2019 580 Background: SB3 is an approved biosimilar of reference trastuzumab (TRZ). At additional 2-year follow-up after completing neoadjuvant and adjuvant treatment, there was a difference in event-free survival (EFS), but no differe ... Full text Cite

Outcomes of patients (pts) with metastatic urothelial cancer (mUC) and poor performance status (PS) receiving anti-PD(L)1 agents.

Conference Journal of Clinical Oncology · May 20, 2019 4525 Background: Anti-PD(L)1 immune checkpoint inhibitors (ICI) prolong overall survival (OS) after platinum chemotherapy in mUC. However, clinical outcomes in pts with poor PS at time of ICI initiation are unknown. We hypothesiz ... Full text Cite

Hypertension and use of bevacizumab among patients treated in community settings.

Conference Journal of Clinical Oncology · May 20, 2019 e18279 Background: CancerLinQ Discovery (CLQD) is a real-world dataset (RWD) derived from electronic health records across the US. This analysis builds on the prior observation of cautioned use of bevacizumab (Bev) among older ad ... Full text Cite

New Biosimilar Approvals for Myeloid Growth Factors and Anemia.

Conference J Natl Compr Canc Netw · May 1, 2019 Biosimilars are here to stay, but whether they will enjoy widespread uptake remains to be seen. The FDA sets a high bar for approval of biosimilar products, yet many clinicians remain skeptical about the efficacy and safety of these agents. Favorable exper ... Full text Link to item Cite

Biosimilars: what the oncologist should know.

Journal Article Future Oncol · April 2019 As originator biologic medicines lose patent protection, some biopharmaceutical companies are focusing on developing similar versions of these costly and complex therapies with a goal of providing more affordable treatment options. Many of these molecules, ... Full text Link to item Cite

Multi-gene assays: effect on chemotherapy use, toxicity and cost in estrogen receptor-positive early stage breast cancer.

Journal Article J Comp Eff Res · April 2019 AIM: To assess multi-gene assay (MGA) effects on chemotherapy use, toxicities, recurrences, and costs in estrogen receptor-positive early breast cancer. METHODS: Meta-analysis performed using data from public databases. Results: Studies included 12,202 wom ... Full text Link to item Cite

Analysis of Diagnoses, Symptoms, Medications, and Admissions Among Patients With Cancer Presenting to Emergency Departments.

Journal Article JAMA Netw Open · March 1, 2019 IMPORTANCE: Better understanding of the emergency care needs of patients with cancer will inform outpatient and emergency department (ED) management. OBJECTIVE: To provide a benchmark description of patients who present to the ED with active cancer. DESIGN ... Full text Link to item Cite

External validation of three risk stratification rules in patients presenting with pulmonary embolism and cancer.

Journal Article Support Care Cancer · March 2019 Numerous risk stratification rules exist to predict post-pulmonary embolism (PE) mortality; however, few were designed for use in cancer patients. In the EPIPHANY registry, adapted versions of common rules (the Hestia criteria, Pulmonary Embolism Severity ... Full text Link to item Cite

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.

Journal Article N Engl J Med · February 21, 2019 BACKGROUND: Ambulatory patients receiving systemic cancer therapy are at varying risk for venous thromboembolism. However, the benefit of thromboprophylaxis in these patients is uncertain. METHODS: In this double-blind, randomized trial involving high-risk ... Full text Link to item Cite

How Biosimilars Affect Health Care

Journal Article CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY · 2019 Cite

Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis.

Journal Article Thromb Res · January 2019 INTRODUCTION: It is unclear if direct oral anticoagulants (DOACs) are effective and safe alternatives to low-molecular-weight heparin (LMWHs) for the treatment of cancer-associated venous thromboembolism (VTE). We aim to synthesize existing literature that ... Full text Link to item Cite

Polypharmacy and medication costs at end of life among commercially insured adults age 65 and older with cancer.

Conference Journal of Clinical Oncology · December 1, 2018 65 Background: Polypharmacy, or the concurrent use of multiple medications, may expose patients to drug-drug interactions and excessive costs. There are limited data on polypharmacy for commercially insured older adults, primaril ... Full text Cite

Lessons From Reporting National Performance Measures in a Regional Setting: Washington State Community Cancer Care Report.

Journal Article J Oncol Pract · December 2018 Regional public reporting of performance measures in oncology can facilitate local decision making across stakeholders, but small numbers of patients and clinics pose a challenge to creating statistically robust measures. In this article, we describe our d ... Full text Link to item Cite

The HAS-RISC Score for Venous Thromboembolism (VTE) Risk Stratification in Newly Diagnosed Multiple Myeloma Patients Starting Immunomodulatory Drugs (IMID)

Conference Blood · November 29, 2018 AbstractIntroduction: Patients with newly diagnosed multiple myeloma (MM) have high risk of venous thromboembolism (VTE) when starting initial treatment that contains immunomodulatory drugs (IMID) such as le ... Full text Cite

The Incidence of Thromboembolism for Lenalidomide Versus Thalidomide in Older Patients with Newly Diagnosed Multiple Myeloma

Conference Blood · November 29, 2018 AbstractIntroduction: Chemotherapy backbones with immunomodulatory drugs have become the standard of care for the treatment of multiple myeloma (MM). Despite improved survival outcomes, thrombotic complicati ... Full text Cite

Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)

Conference Blood · November 29, 2018 AbstractBackground: Patients on systemic therapy for cancer are at varying risk for venous thromboembolism (VTE) and its consequences. Thromboprophylaxis is recommended in hospitalized medical and surgical c ... Full text Cite

Cost of Care at NCI-Designated Comprehensive Cancer Centers Vs. Other Treatment Sites for Young Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia (ALL)

Conference Blood · November 29, 2018 AbstractBackground: Young adults (22-39y) with ALL treated at an NCI-designated Comprehensive Cancer Center (CCC) have a superior survival when compared with those treated at a non-CCC site. (Wolfson et al, ... Full text Cite

Healthcare Costs in Patients with Cancer Increase with Increasing Risk of Venous Thromboembolism

Conference Blood · November 29, 2018 AbstractIntroduction: Venous thromboembolism (VTE) is a cause of significant morbidity and mortality in cancer patients and its prevalence in this population is increasing. The risk of VTE varies with differ ... Full text Cite

The Rate of Venous Thromboembolism in Cancer Patients Varies By Khorana Risk Category

Conference Blood · November 29, 2018 AbstractIntroduction: Venous thromboembolism (VTE) is common in cancer patients and associated with adverse consequences. Risk factors for cancer-associated VTE are multifactorial and a validated tool, the K ... Full text Cite

Depression and Health Care Utilization at End of Life Among Older Adults With Advanced Non-Small-Cell Lung Cancer.

Journal Article J Pain Symptom Manage · November 2018 CONTEXT: Limited data exist regarding how depression diagnosed at different times relative to a cancer diagnosis may affect healthcare utilization at end of life (EOL). OBJECTIVES: To assess the relationship between depression and health care utilization a ... Full text Link to item Cite

From A to Xeloda: Practical considerations for implementing a chemotherapy regimen ordering system intervention.

Conference Journal of Clinical Oncology · October 20, 2018 57 Background: SWOG S1415CD (NCT02728596) is a pragmatic trial comparing outcomes of colony stimulating factor (CSF) use in usual care with care that uses guideline-informed standing CSF orders for protocol chemotherapy regimens. ... Full text Cite

Hospitalization and hospital discharge destinations after chemotherapy: Using the Oncology Care Model (OCM) methodology in 2012–2015 Medicare data.

Conference Journal of Clinical Oncology · October 20, 2018 113 Background: The Medicare OCM gives financial incentives for efficient, high-quality care. Hospitalizations of cancer patients receiving chemotherapy substantially increases costs. We assessed reasons for hospitalization and h ... Full text Cite

Implementing an EHR guideline–based intervention in paper ordering systems.

Conference Journal of Clinical Oncology · October 20, 2018 56 Background: Studies show Colony Stimulating Factor (CSF) prescribing is inconsistent with national guidelines. SWOG trial S1415CD is a pragmatic study comparing outcomes of CSF use in usual care with care that uses guideline-i ... Full text Cite

Lessons from Reporting National Performance Measures in a Regional Setting: Washington State Community Cancer Care Report.

Conference Journal of Clinical Oncology · October 20, 2018 105 Background: While many quality metrics are generated and reported at a national level, regionally reported metrics may be more meaningful to stakeholders and more amenable to locally-generated interventions aimed at improving ... Full text Cite

Impact of clinic characteristics on the adoption of a guideline-based standing order algorithm and patient accrual in the pragmatic cluster-randomized trial SWOG S1415CD (NCT02728596).

Conference Journal of Clinical Oncology · October 20, 2018 60 Background: The S1415CD intervention requires the integration of guideline-based prescribing recommendations and standing orders for primary prophylactic colony stimulating factors into existing chemotherapy order systems at c ... Full text Cite

The influence of patient engagement on the design and implementation of a clinical trial to improve cancer care delivery.

Conference Journal of Clinical Oncology · October 20, 2018 223 Background: We have engaged 10 patient partners in the development and implementation of S1415CD, a five-year pragmatic clinical trial currently in year 3 assessing the effectiveness of a guideline-based colony stimulating fa ... Full text Cite

The Washington State Community Cancer Care Report: A multi-stakeholder effort to characterize quality of care and costs for Washington State oncology practices.

Conference Journal of Clinical Oncology · October 20, 2018 31 Background: Although many quality measures exist in oncology, there have been few efforts to prioritize, measure, and report quality and costs for an entire region. Here, we report the results of a multi-year, multi-stakeholde ... Full text Cite

Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer.

Journal Article Clin Breast Cancer · October 2018 BACKGROUND: The effects of chemotherapy dose intensity on patient outcomes in advanced cancer are not well understood. We studied the association between chemotherapy relative dose intensity (RDI) and overall survival (OS) among patients with advanced brea ... Full text Link to item Cite

Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support.

Journal Article Ann Oncol · September 1, 2018 BACKGROUND: The use of supportive granulocyte colony-stimulating factor (G-CSF) to reduce the risk of neutropenic complications in high-risk cancer patients is consistently recommended by several clinical practice guidelines. However, in a previous meta-an ... Full text Link to item Cite

Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline.

Journal Article J Clin Oncol · September 1, 2018 Purpose The Society for Integrative Oncology (SIO) produced an evidence-based guideline on use of integrative therapies during and after breast cancer treatment that was determined to be relevant to the American Society of Clinical Oncology (ASCO) membersh ... Full text Link to item Cite

American Society of Clinical Oncology's Global Oncology Leadership Task Force: Findings and Actions.

Journal Article J Glob Oncol · September 2018 In response to rising cancer incidence and mortality rates in low- and middle-income countries and the increasingly global profile of ASCO's membership, the ASCO Board of Directors appointed the Global Oncology Leadership Task Force (Task Force) to provide ... Full text Link to item Cite

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update.

Journal Article J Clin Oncol · August 10, 2018 Purpose To update key recommendations of the ASCO guideline adaptation of the Cancer Care Ontario guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer and adjuvant targeted therapy for breast cancer. Methods An Exper ... Full text Link to item Cite

Reply to S.D. Lucio.

Journal Article J Clin Oncol · July 10, 2018 Full text Link to item Cite

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).

Conference J Clin Oncol · July 10, 2018 Purpose Venous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneous low molecular weight heparin has been standard treatment for such patients. The purpose of this study was to assess if an oral factor Xa inhibitor, rivarox ... Full text Link to item Cite

Immune-related Adverse Events in Cancer Patients.

Journal Article Acad Emerg Med · July 2018 The U.S. Food and Drug Administration has approved immune checkpoint inhibitors and chimeric antigen receptor T cells (CAR-T cells) as immunotherapy strategies for cancer. These therapies cause a wide variety of adverse events, which mimic other disease st ... Full text Link to item Cite

Effectiveness and Safety of Rivaroxaban in Patients With Cancer-Associated Venous Thrombosis.

Conference J Natl Compr Canc Netw · May 2018 Background: Although not designated as guideline-recommended first-line anticoagulation therapy, patients are receiving rivaroxaban for the treatment and secondary prevention of cancer-associated venous thrombosis (CAT). We sought to estimate the cumulativ ... Full text Link to item Cite

American Society of Clinical Oncology Statement: Biosimilars in Oncology.

Journal Article J Clin Oncol · April 20, 2018 As many biosimilars come to market in the next several years, their use in oncology will play an important role in the future care of patients with cancer. ASCO is committed to providing education and guidance to the oncology community on the use of biosim ... Full text Link to item Cite

Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer.

Journal Article Thromb Res · April 2018 BACKGROUND: Venous thromboembolism (VTE) represents a leading cause of morbidity and mortality among patients with cancer. METHODS: Hospitalization data reported on adult cancer patients at US medical centers between 1995 and 2012 were analyzed. Cancer dia ... Full text Link to item Cite

Analysis of Factors Associated With In-hospital Mortality in Lung Cancer Chemotherapy Patients With Neutropenia.

Conference Clin Lung Cancer · March 2018 Lung cancer, compared with other solid tumors, is associated with high mortality rates from febrile neutropenia. The risk factors associated with in-hospital mortality were identified and compared for patients with lung cancer and patients with other solid ... Full text Link to item Cite

Characterizing Potentially Preventable Cancer- and Chronic Disease-Related Emergency Department Use in the Year After Treatment Initiation: A Regional Study.

Journal Article J Oncol Pract · March 2018 PURPOSE: As new quality metrics and interventions for potentially preventable emergency department (ED) visits are implemented, we sought to compare methods for evaluating the prevalence and costs of potentially preventable ED visits that were related to c ... Full text Link to item Cite

Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update.

Journal Article Ann Surg Oncol · February 2018 PURPOSE: To update the American Society of Clinical Oncology (ASCO)-Society of Surgical Oncology (SSO) guideline for sentinel lymph node (SLN) biopsy in melanoma. METHODS: An ASCO-SSO panel was formed, and a systematic review of the literature was conducte ... Full text Link to item Cite

Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update.

Journal Article J Clin Oncol · February 1, 2018 Purpose To update the American Society of Clinical Oncology (ASCO)-Society of Surgical Oncology (SSO) guideline for sentinel lymph node (SLN) biopsy in melanoma. Methods An ASCO-SSO panel was formed, and a systematic review of the literature was conducted ... Full text Link to item Cite

Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK).

Journal Article Oncologist · February 2018 BACKGROUND: Patients with lung cancer are known to be at increased risk for venous thromboembolism (VTE). Venous thromboembolism is associated with increased risk for early mortality. However, there have been no studies performing a comprehensive assessmen ... Full text Link to item Cite

Clinical prediction rules for mortality in patients with pulmonary embolism and cancer to guide outpatient management: a meta-analysis.

Journal Article J Thromb Haemost · February 2018 UNLABELLED: Essentials Clinical prediction rules (CPRs) can stratify patients with pulmonary embolism (PE) and cancer. A meta-analysis was done to assess prognostic accuracy in CPRs for mortality in these patients. Eight studies evaluating ten CPRs were in ... Full text Link to item Cite

Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States.

Journal Article BMC Cancer · January 6, 2018 BACKGROUND: Bone metastases commonly occur in conjunction with solid tumors, and are associated with serious bone complications. Population-based estimates of bone metastasis incidence are limited, often based on autopsy data, and may not reflect current t ... Full text Link to item Cite

A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.

Journal Article Support Care Cancer · January 2018 PURPOSE: Filgrastim (NEUPOGEN®) is the originator recombinant human granulocyte colony-stimulating factor widely used for preventing neutropenia-related infections and mobilizing hematopoietic stem cells. This report presents findings of a systematic liter ... Full text Link to item Cite

Rationale, Opportunities, and Reality of Biosimilar Medications REPLY

Journal Article NEW ENGLAND JOURNAL OF MEDICINE · 2018 Cite

Integrative omics to detect bacteremia in patients with febrile neutropenia.

Journal Article PLoS One · 2018 BACKGROUND: Cancer chemotherapy-associated febrile neutropenia (FN) is a common condition that is deadly when bacteremia is present. Detection of bacteremia depends on culture, which takes days, and no accurate predictive tools applicable to the initial ev ... Full text Link to item Cite

Effectiveness and Safety of Rivaroxaban in Patients With Cancer-Associated Venous Thrombosis

Journal Article JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK · 2018 Full text Cite

Patient-reported outcomes in acute myeloid leukemia: Where are we now?

Journal Article Blood Rev · January 2018 Outcomes for acute myeloid leukemia remain poor, and treatment decisions must consider not just quantity, but also quality of life (QOL). We conducted a systematic review of studies in patients with acute myeloid leukemia or high-risk myelodysplastic syndr ... Full text Link to item Cite

Hematopoietic growth factors

Chapter · January 1, 2018 Cite

Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Journal Article J Natl Compr Canc Netw · December 2017 Myeloid growth factors (MGFs) are given as supportive care to patients receiving myelosuppressive chemotherapy to reduce the incidence of neutropenia. This selection from the NCCN Guidelines for MGFs focuses on the evaluation of regimen- and patient-specif ... Full text Link to item Cite

A Patient Risk Model of Chemotherapy-Induced Febrile Neutropenia: Lessons Learned From the ANC Study Group.

Journal Article J Natl Compr Canc Netw · December 2017 Neutropenia and its complications, including febrile neutropenia (FN), represent major toxicities associated with cancer chemotherapy, resulting in considerable morbidity, mortality, and costs. The myeloid growth factors such as granulocyte colony-stimulat ... Full text Link to item Cite

Chemotherapy Use at the End of Life in Uganda.

Journal Article J Glob Oncol · December 2017 Purpose Avoiding chemotherapy during the last 30 days of life has become a goal of cancer care in the United States and Europe, yet end-of-life chemotherapy administration remains a common practice worldwide. The purpose of this study was to determine the ... Full text Link to item Cite

How do clinics perform across multiple end of life metrics?

Conference Journal of Clinical Oncology · November 1, 2017 86 Background: National bodies have proposed a number of metrics to measure quality of care at the end of life (EOL). MACRA legislation allows clinics to select the metrics they report to CMS. The self-selection of reported metri ... Full text Cite

Polypharmacy and out-of-pocket medication costs in the last month of life among commercially insured patients with advanced cancer: Insights from linking a regional cancer registry and insurance claims.

Conference Journal of Clinical Oncology · November 1, 2017 79 Background: Polypharmacy, defined as the concurrent use of multiple medications, may expose patients to drug-drug interactions and excessive medication costs. Patients with advanced cancer may benefit from medication discontin ... Full text Cite

Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.

Journal Article Thromb Haemost · November 1, 2017 Venous thromboembolism (VTE) is a frequent complication of cancer associated with morbidity, mortality, increased hospitalizations and higher health care costs. Cancer patients at increased risk for VTE can be identified using a validated risk assessment s ... Full text Link to item Cite

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update.

Journal Article J Clin Oncol · October 1, 2017 Purpose To update the ASCO guideline for antiemetics in oncology. Methods ASCO convened an Expert Panel and conducted a systematic review of the medical literature for the period of November 2009 to June 2016. Results Forty-one publications were included i ... Full text Link to item Cite

Clinical predictors of early mortality in colorectal cancer patients undergoing chemotherapy: Results from a global prospective cohort study

Journal Article JNCI Cancer Spectrum · September 1, 2017 Background:Early mortality is a major problem in colorectal cancer (CRC). We have shown that Khorana Score is predictive of early mortality in other cancers. Here, we evaluated the value of this score and other prognostic variables in predicting early mort ... Full text Cite

The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review.

Journal Article Support Care Cancer · August 2017 PURPOSE: Granulocyte colony-stimulating factors (G-CSF) are commonly used in clinical practice to prevent febrile neutropenia (FN). US and EU prescribing information and treatment guidelines from the NCCN, ASCO, and EORTC specify that pegfilgrastim, a long ... Full text Link to item Cite

Impact of the elimination of cost sharing for mammographic breast cancer screening among rural US women: A natural experiment.

Journal Article Cancer · July 1, 2017 BACKGROUND: Rural US women experience disparities in breast cancer screening and outcomes. In 2006, a national rural health insurance provider, the National Rural Electric Cooperative Association (NRECA), eliminated out-of-pocket costs for screening mammog ... Full text Link to item Cite

A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study.

Journal Article J Comp Eff Res · July 2017 Colony stimulating factors (CSF) are widely prescribed to avoid febrile neutropenia (FN) among cancer patients receiving chemotherapy, but studies show their use is often not consistent with practice guidelines. In addition, there is limited high quality e ... Full text Link to item Cite

Abstract 2767: Consistency of standing orders for primary prophylactic CSF within a national network of community oncology practices: SWOG intergroup trial S1415CD

Conference Cancer Research · July 1, 2017 AbstractBACKGROUNDAmong the 400,000 individuals undergoing chemotherapy for breast, colorectal and lung cancer in the US, many are at risk of febrile neutropenia (FN). Prophy ... Full text Cite

Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology.

Journal Article JAMA Oncol · July 1, 2017 This study compares reports from 2 next-generation sequencing tests to determine the level of concordance between platforms. ... Full text Link to item Cite

Untapped Potential of Observational Research to Inform Clinical Decision Making: American Society of Clinical Oncology Research Statement.

Journal Article J Clin Oncol · June 1, 2017 ASCO believes that high-quality observational studies can advance evidence-based practice for cancer care and are complementary to randomized controlled trials (RCTs). Observational studies can generate hypotheses by evaluating novel exposures or biomarker ... Full text Link to item Cite

Costs, Trends, and Related Factors in Treating Lung Cancer Patients in 67 Hospitals in Guangxi, China.

Journal Article Cancer Invest · May 28, 2017 Lung cancer is a common disease with high mortality in China. Recent economic advances have led to improved medical capabilities, while costs associated with treating this disease have increased. Such change contributes to a commonly held belief that healt ... Full text Link to item Cite

Systematic reviews and meta-analyses in geriatric oncology.

Conference Journal of Clinical Oncology · May 20, 2017 e21517 Background: Cancer incidence for most malignancies increases with age with the majority diagnosed after age 65. Aging is also associated with an increasing number of major comorbidities and greater risk and consequences of ... Full text Cite

Neutropenia related hospitalization risk in lung cancer patients with chemotherapy.

Conference Journal of Clinical Oncology · May 20, 2017 e18290 Background: We sought to describe outcomes following granulocyte-colony stimulating factor (G-CSF) prophylaxis in patients with lung cancer receiving chemotherapy regimens with low to intermediate risk for inducing neutrop ... Full text Cite

Predictors of advanced imaging use during breast cancer surveillance.

Conference Journal of Clinical Oncology · May 20, 2017 e18337 Background: Our objectives were to determine advanced imaging use (whole body imaging with bone scan, CT, or PET-CT and breast MRI) during breast cancer surveillance, and to identify drivers of potential imaging overuse as ... Full text Cite

Patterns in provider types and cost of surveillance testing in early-stage breast cancer patients: A regional study.

Conference Journal of Clinical Oncology · May 20, 2017 6582 Background: Although ASCO Choosing Wisely guidelines recommend against routine surveillance testing or imaging for asymptomatic individuals with early-stage breast cancer (ESBC) treated with curative intent, they are frequen ... Full text Cite

The role of chronic disease in the costs of potentially preventable emergency department use during treatment: A regional study.

Conference Journal of Clinical Oncology · May 20, 2017 6505 Background: The Centers for Medicare and Medicaid Services (CMS) released a quality metric for potentially preventable chemotherapy-associated emergency department (ED) use, effective in 2020. This metric excludes diagnoses ... Full text Cite

Predicting neutropenia risk in patients with cancer using electronic data.

Journal Article J Am Med Inform Assoc · April 1, 2017 OBJECTIVES: Clinical guidelines recommending the use of myeloid growth factors are largely based on the prescribed chemotherapy regimen. The guidelines suggest that oncologists consider patient-specific characteristics when prescribing granulocyte-colony s ... Full text Link to item Cite

Reply to L. Del Mastro and A. Prat.

Journal Article J Clin Oncol · April 1, 2017 Full text Link to item Cite

Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.

Journal Article Pharmacoeconomics · April 2017 OBJECTIVE: The objective of this study was to evaluate the cost effectiveness of no prophylaxis, primary prophylaxis (PP), or secondary prophylaxis (SP) with granulocyte colony-stimulating factors (G-CSFs), i.e., pegfilgrastim, lipegfilgrastim, filgrastim ... Full text Link to item Cite

Development of cancer care episodes to measure costs for breast, colorectal, and non-small cell lung cancer.

Conference Journal of Clinical Oncology · March 10, 2017 29 Background: Cancer care costs are rising, creating concerns about affordability. As a result, delivery systems are creating alternative payment structures to lower costs while maintaining or improving quality. As cancer care d ... Full text Cite

Out of system (OOS) costs for oncology clinics treating patients with breast, colorectal, and non-small cell lung cancer in Washington state.

Conference Journal of Clinical Oncology · March 10, 2017 5 Background: As payers move from fee-for-service to episode-based reimbursement, there is a need for oncology providers to accurately measure in- and out-of-system resource use and cost for patients under their care. Medicare as ... Full text Cite

Patient engagement on claims-registry reports of cost and quality.

Conference Journal of Clinical Oncology · March 10, 2017 159 Background: Moving cancer care towards a value framework requires patients, providers, and payers to weigh cost, quality, and outcomes in decision-making. Many efforts are underway to help providers and payers make value deci ... Full text Cite

Clinic level variation in emergency department and inpatient utilization in a community setting.

Conference Journal of Clinical Oncology · March 10, 2017 226 Background: Early studies of the oncology medical home suggest that intensive outpatient care (e.g. 24-hour phone triage, same-day infusion) reduces emergency department (ED) and inpatient (IP) use during cancer treatment. Li ... Full text Cite

Costs of potentially preventable emergency department use during cancer treatment: A regional study.

Conference Journal of Clinical Oncology · March 10, 2017 2 Background: There is growing recognition that many emergency department (ED) visits during cancer treatment may be related to poorly controlled disease or treatment-related symptoms and could be prevented. An RCT using the Symp ... Full text Cite

Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial.

Conference Thromb Res · March 2017 BACKGROUND: Ambulatory cancer patients at high-risk for venous thromboembolism (VTE) can be identified using a validated risk score (Khorana score). We evaluated the benefit of outpatient thromboprophylaxis with dalteparin in high-risk patients in a multic ... Full text Link to item Cite

Association of Risk Factors, Mortality, and Care Costs of Adults With Acute Myeloid Leukemia With Admission to the Intensive Care Unit.

Journal Article JAMA Oncol · March 1, 2017 IMPORTANCE: Adults with acute myeloid leukemia (AML) commonly require support in the intensive care unit (ICU), but risk factors for admission to the ICU and adverse outcomes remain poorly defined. OBJECTIVE: To examine risk factors, mortality, length of s ... Full text Link to item Cite

Abstract P2-16-01: Relationship between overall survival and surrogate measures in patients with metastatic breast cancer treated with chemotherapy

Conference Cancer Research · February 15, 2017 AbstractBackground: While metastatic breast cancer (MBC) is considered an incurable disease, nearly one-fifth of patients live longer than five years following diagnosis. In an effort to identify novel agent ... Full text Cite

Patterns of surveillance testing in commercially insured patients with breast cancer across provider types: A regional study.

Conference Journal of Clinical Oncology · February 10, 2017 4 Background: Oncologists, primary care physicians (PCPs), and other clinicians provide care for breast cancer patients following active treatment. Clinical practice guidelines are largely consistent in recommended number of clin ... Full text Cite

Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Journal Article J Clin Oncol · February 10, 2017 Purpose To provide current recommendations on the use of sentinel node biopsy (SNB) for patients with early-stage breast cancer. Methods PubMed and the Cochrane Library were searched for randomized controlled trials, systematic reviews, meta-analyses, and ... Full text Link to item Cite

Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models.

Journal Article Expert Rev Pharmacoecon Outcomes Res · February 2017 We reviewed the evolution of the methods used in cost-effectiveness analyses of granulocyte colony-stimulating factors (G-CSFs) in the primary and secondary prevention of febrile neutropenia (FN) in patients receiving myelosuppressive cancer chemotherapy. ... Full text Link to item Cite

Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.

Journal Article Support Care Cancer · February 2017 INTRODUCTION: Evidence suggests that many cancer chemotherapy patients who are candidates for colony-stimulating factor (CSF) prophylaxis do not receive it or receive it inconsistent with guidelines, and that such patients have a higher risk of febrile neu ... Full text Link to item Cite

Thromboembolic events (TE) among patients with metastatic pancreatic ductal adenocarcinoma (mPDA) after chemotherapy (Chemo).

Conference Journal of Clinical Oncology · February 1, 2017 280 Background: Clinical trials suggest that patients with mPDA are at high risk of TE from both disease and treatment. TE rates and anticoagulant use among mPDA patients after first line chemo were investigated. Methods: Medicar ... Full text Cite

Risk of infection among patients with non-metastatic solid tumors or non-Hodgkin's lymphoma receiving myelosuppressive chemotherapy and antimicrobial prophylaxis in US clinical practice.

Journal Article J Oncol Pharm Pract · January 2017 Purpose Guidelines generally do not recommend oral antimicrobials for prophylaxis against chemotherapy-related infections in patients with solid tumors. Evidence on antimicrobial prophylaxis use, and associated chemotherapy-related infection risk, in US cl ... Full text Link to item Cite

Participant attitudes toward an intensive trial of multiple biopsies, multidimensional molecular analysis, and reporting of results in metastatic triple-negative breast cancer

Journal Article JCO Precision Oncology · January 1, 2017 Purpose Multidimensional molecular analysis oftumortissue intensively over space andtime can provide insight into how cancers evolve and escape treatment. Attitudes of participants in such trials have not been assessed. We explored patient views regarding ... Full text Cite

Global Prospective Cohort Study of Factors Associated with Venous Thromboembolism in Patients with Lung Cancer Receiving Cancer Therapy

Conference Blood · December 2, 2016 AbstractBACKGROUND: Patients with lung cancer are known to be at increased risk for venous thromboembolism (VTE). However, there have been few studies of risk factors for VTE in lung cancer patients undergoi ... Full text Cite

Predictors of Venous Thmromboembolism in Colorectal Cancer: Results from a Global Prospective Study

Conference Blood · December 2, 2016 AbstractBACKGROUNDVenous thromboembolism (VTE) is an important complication among patients with colorectal cancer but its prevalence and predictors are incompletely understoo ... Full text Cite

Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer

Journal Article Journal of Clinical Oncology · November 10, 2016 Purpose To describe outcomes after granulocyte colony-stimulating factor (G-CSF) prophylaxis in patients with breast cancer who received chemotherapy regimens with low-to-intermediate risk of induction of neutrope ... Full text Cite

Health care utilization and costs at end of life among patients with leukemia or lymphoma in a regional cancer registry-insurance claims linked database.

Conference Journal of Clinical Oncology · October 9, 2016 184 Background: End-of-life (EOL) care for persons with hematologic malignancies is variable and often involves high-intensity services at death approaches, which may not reflect patient or family preferences. We characterized he ... Full text Cite

Innovations in American Society of Clinical Oncology Practice Guideline Development.

Journal Article J Clin Oncol · September 10, 2016 Since the beginning of its guidelines program in 1993, ASCO has continually sought ways to produce a greater number of guidelines while maintaining its commitment to using the rigorous development methods that minimize the biases that threaten the validity ... Full text Link to item Cite

Generating and evaluating evidence of the clinical utility of molecular diagnostic tests in oncology.

Journal Article Genet Med · August 2016 PURPOSE: Enthusiasm for molecular diagnostic (MDx) testing in oncology is constrained by the gaps in required evidence regarding its impact on patient outcomes (clinical utility (CU)). This effectiveness guidance document proposes recommendations for the d ... Full text Link to item Cite

Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.

Journal Article J Clin Oncol · July 10, 2016 PURPOSE: A Cancer Care Ontario (CCO) guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer including adjuvant targeted therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancers was identified ... Full text Link to item Cite

A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality.

Journal Article Oncologist · July 2016 BACKGROUND: Retrospective studies have suggested an association between cancer-associated venous thromboembolism (VTE) and patient survival. We evaluated a previously validated VTE Clinical Risk Score in also predicting early mortality and cancer progressi ... Full text Link to item Cite

Biomarker Tests for Molecularly Targeted Therapies: Laying the Foundation and Fulfilling the Dream.

Journal Article J Clin Oncol · June 10, 2016 Precision medicine focuses on the management of individual patients on the basis of biomarkers and other distinguishing characteristics, with the overarching objective of improving clinical outcomes. The rapid proliferation of biomarker tests and targeted ... Full text Link to item Cite

End of life services for cancer patients: A population-based evaluation.

Conference Journal of Clinical Oncology · May 20, 2016 Full text Cite

Incidence of bone metastases in U.S. patients with solid tumors.

Conference Journal of Clinical Oncology · May 20, 2016 Full text Cite

American Cancer Society Head and Neck Cancer Survivorship Care Guideline.

Journal Article CA Cancer J Clin · May 2016 Answer questions and earn CME/CNE The American Cancer Society Head and Neck Cancer Survivorship Care Guideline was developed to assist primary care clinicians and other health practitioners with the care of head and neck cancer survivors, including monitor ... Full text Link to item Cite

Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol.

Journal Article BMJ Open · April 29, 2016 INTRODUCTION: Parenteral anticoagulants may improve outcomes in patients with cancer by reducing risk of venous thromboembolic disease and through a direct antitumour effect. Study-level systematic reviews indicate a reduction in venous thromboembolism and ... Full text Link to item Cite

Chemotherapy costs associated with receipt of the adoption of oncotype DX in early-stage breast cancer within the SEER-Medicare population.

Conference Journal of Clinical Oncology · March 1, 2016 32 Background: The Oncotype DX (ODX) multigene assay has been previously suggested to result in an overall reduction in the use of adjuvant chemotherapy and associated costs for women with early stage, estrogen receptor (ER)-posi ... Full text Cite

Regional engagement to define, report, and use quality metrics to improve palliative care in oncology.

Conference Journal of Clinical Oncology · March 1, 2016 282 Background: Palliative care in oncology encompasses a wide array of care, and optimal performance metrics remain uncertain. To address this issue we held a regional meeting that included patient advocates, clinicians, private ... Full text Cite

HICOR IQ: Developing a regional oncology metric reporting platform.

Conference Journal of Clinical Oncology · March 1, 2016 165 Background: The Hutchinson Institute for Cancer Outcomes Research (HICOR) has adopted a multi-stakeholder approach to identify and prioritize metrics to characterize oncology care in the Western Washington. In March 2015, HIC ... Full text Cite

Measuring adherence to a Choosing Wisely recommendation in a regional oncology clinic.

Conference Journal of Clinical Oncology · March 1, 2016 196 Background: Natural language processing (NLP) has the potential to significantly ease the burden of manual abstraction of unstructured electronic text when measuring adherence to national guidelines. We incorporated NLP into ... Full text Cite

Value in cancer care: Regional initiative to improve care through data reporting and interventions.

Conference Journal of Clinical Oncology · March 1, 2016 34 Background: In the context of many initiatives aimed at measuring quality and value in cancer care, the Hutchinson Institute for Cancer Outcomes Research (HICOR), partnered with community members to launch a regional, stakehol ... Full text Cite

Regional initiative to use data transparency to improve cancer care.

Conference Journal of Clinical Oncology · March 1, 2016 39 Background: In the context of many initiatives aimed at measuring quality and value in cancer care, the Hutchinson Institute for Cancer Outcomes Research (HICOR) has adopted a multi-stakeholder approach to characterize oncolog ... Full text Cite

American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.

Journal Article J Clin Oncol · February 20, 2016 The purpose of the American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline is to provide recommendations to assist primary care and other clinicians in the care of female adult survivors of breast cancer. A s ... Full text Link to item Cite

Abstract P5-13-07: An investigator-initiated registry trial of simple oral therapy for low risk breast cancer

Conference Cancer Research · February 15, 2016 AbstractBackground: Across multiple studies performed in several countries with widely instituted screening mammography programs at different intervals between exams, up to 19% of breast cancer identified is ... Full text Cite

Reply to M.G. McNamara et al and T.H. Oo.

Journal Article J Clin Oncol · February 10, 2016 Full text Link to item Cite

Antiemetics: American Society of Clinical Oncology Focused Guideline Update.

Journal Article J Clin Oncol · February 1, 2016 PURPOSE: To update a key recommendation of the American Society of Clinical Oncology antiemetic guideline. This update addresses the use of the oral combination of netupitant (a neurokinin 1 [NK1] receptor antagonist) and palonosetron (a 5-hydroxytryptamin ... Full text Link to item Cite

Changing patterns of chemotherapy relative dose intensity and supportive care for aggressive B-cell non-Hodgkin lymphoma.

Conference Leuk Lymphoma · February 2016 Maintaining high relative dose intensity (RDI) is associated with improved outcomes, especially in patients with aggressive B-cell non-Hodgkin lymphoma (NHL). To evaluate changes in practice, we examined RDI, chemotherapy treatment patterns, dose delays an ... Full text Link to item Cite

The Quality of Survival (QoS): A concept framework to assist communication and decision making about cancer care.

Conference Journal of Clinical Oncology · January 20, 2016 78 Background: The past decade has seen the development of transitional, novel cancer therapies that lengthen survival, yet data regarding the quality of that survival are limited or unavailable. Improving patient (pt)/healthcare ... Full text Cite

Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma.

Journal Article Expert Opin Drug Saf · 2016 INTRODUCTION: Myelosuppression induced by cancer chemotherapy is associated with considerable morbidity and mortality. Febrile neutropenia (FN) represents an oncologic emergency requiring immediate evaluation and treatment. Resulting chemotherapy dose redu ... Full text Link to item Cite

American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.

Journal Article CA Cancer J Clin · 2016 Answer questions and earn CME/CNE The purpose of the American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline is to provide recommendations to assist primary care and other clinicians in the care of female adu ... Full text Link to item Cite

Issues on the Use of White Blood Cell Growth Factors in Oncology Practice.

Journal Article Am Soc Clin Oncol Educ Book · 2016 Appropriate use of myeloid growth factors may reduce the risk of neutropenic complications including febrile neutropenia (FN) in patients receiving cancer chemotherapy. The recently updated American Society of Clinical Oncology (ASCO) Guidelines on the Use ... Full text Link to item Cite

Cost of Hospitalization in Patients with Cancer and Febrile Neutropenia and Impact of Comorbid Conditions

Conference Blood · December 3, 2015 Background: Febrile neutropenia (FN) remains a serious complication of cancer chemotherapy often leading to hospitalization and an increased risk of mortality and cost.Methods: Data on hospitalizations between 2004 ... Full text Cite

Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.

Journal Article JAMA Oncol · November 2015 IMPORTANCE: Guidelines recommend consideration of chemotherapy for most patients with early-stage, estrogen receptor-positive, invasive breast cancer in the absence of additional prognostic information. The 21-gene recurrence score (RS) assay has been show ... Full text Link to item Cite

Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices.

Journal Article J Natl Compr Canc Netw · November 2015 BACKGROUND: A wide variety of myelosuppressive chemotherapy regimens are used for the treatment of cancer in clinical practice. Neutropenic complications, such as febrile neutropenia, are among the most common side effects of chemotherapy, and they often n ... Full text Link to item Cite

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.

Journal Article J Clin Oncol · October 1, 2015 PURPOSE: To update the 2006 American Society of Clinical Oncology guideline on the use of hematopoietic colony-stimulating factors (CSFs). METHODS: The American Society of Clinical Oncology convened an Update Committee and conducted a systematic review of ... Full text Link to item Cite

Breast cancer screening utilization and understanding of current guidelines among rural U.S. women with private insurance.

Journal Article Breast Cancer Res Treat · October 2015 Women living in rural areas of the U.S. face disparities in screening mammography and breast cancer outcomes. We sought to evaluate utilization of mammography, awareness of screening guidelines, and attitudes towards screening among rural insured U.S. wome ... Full text Link to item Cite

Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?

Journal Article Cancer Med · August 2015 This study evaluated the correlation between the risk of febrile neutropenia (FN) estimated by physicians and the risk of severe neutropenia or FN predicted by a validated multivariate model in patients with nonmyeloid malignancies receiving chemotherapy. ... Full text Link to item Cite

Importance of Risk Factors for Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified as High-Risk in Guidelines for Myeloid Growth Factor Use.

Journal Article J Natl Compr Canc Netw · August 2015 BACKGROUND: Clinical practice guidelines recommend prophylaxis in patients with cancer receiving a colony-stimulating factor (CSF) when the risk of febrile neutropenia (FN) is high (>20%). For patients receiving chemotherapy regimens not documented as high ... Full text Link to item Cite

The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy.

Journal Article Ann Oncol · July 2015 BACKGROUND: Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) is associated with higher chemotherapy relative dose intensity, which may lead to improved outcomes; however, the association between G-CSF primary prophylaxis and overall s ... Full text Link to item Cite

Baseline Estimates of Adherence to American Society of Clinical Oncology/American Board of Internal Medicine Choosing Wisely Initiative Among Patients With Cancer Enrolled With a Large Regional Commercial Health Insurer.

Journal Article J Oncol Pract · July 2015 PURPOSE: The American Society of Clinical Oncology (ASCO)/American Board of Internal Medicine (ABIM) Choosing Wisely (CW) measures aim to reduce the use of interventions that lack evidence of benefit in cancer care. The study presented here characterized a ... Full text Link to item Cite

Resource utilization for chemotherapy-induced nausea and vomiting events in patients with solid tumors treated with antiemetic regimens

Journal Article American Health and Drug Benefits · July 1, 2015 BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) can lead to increased emergency department visits and hospitalizations, which may contribute to increased cost of care. Antiemetic agents, such as neurokinin-1 (NK1) receptor antagonists and 5-hyd ... Cite

Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.

Journal Article JAMA Oncol · May 2015 IMPORTANCE: In 2006, the Centers for Medicare & Medicaid Services approved coverage for the use of the 21-gene recurrence score (RS) assay in women with early-stage, estrogen receptor-positive, node-negative breast cancers to help guide recommendations for ... Full text Link to item Cite

Abstract P6-10-01: Risk of chemotherapy-induced febrile neutropenia (FN) in patients (pts) with non-metastatic breast cancer (BC) and documented risk factors for FN

Conference Cancer Research · May 1, 2015 AbstractBackground: Clinical practice guidelines recommend primary prophylactic colony-stimulating factor (CSF) for pts with cancer receiving myelosuppressive chemotherapy when their risk of FN is high (≥20% ... Full text Cite

When is good, good enough? Methodological pragmatism for sustainable guideline development.

Journal Article Implement Sci · March 6, 2015 BACKGROUND: Continuous escalation in methodological and procedural rigor for evidence-based processes in guideline development is associated with increasing costs and production delays that threaten sustainability. While health research methodologists are ... Full text Link to item Cite

Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.

Journal Article J Clin Oncol · February 20, 2015 PURPOSE: To provide current recommendations about the prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer. METHODS: PubMed and the Cochrane Library were searched for randomized controlled trials, systematic reviews, meta-analy ... Full text Link to item Cite

Evidence synthesis and guideline development in genomic medicine: current status and future prospects.

Journal Article Genet Med · January 2015 PURPOSE: With the accelerated implementation of genomic medicine, health-care providers will depend heavily on professional guidelines and recommendations. Because genomics affects many diseases across the life span, no single professional group covers the ... Full text Link to item Cite

Management of chemotherapy-induced neutropenia: measuring quality, cost, and value.

Journal Article J Natl Compr Canc Netw · January 2015 Treatment-associated neutropenia continues to represent the most common dose-limiting toxicity of cancer chemotherapy. It often leads to fever and infection, prompting hospitalization and occasionally resulting in serious morbidity, and even mortality, des ... Full text Link to item Cite

The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study.

Journal Article Springerplus · 2015 BACKGROUND: Febrile neutropenia (FN) is a major dose-limiting toxicity of cancer chemotherapy resulting in considerable morbidity, mortality, and cost. This study evaluated the time course of neutropenic events and patterns of supportive care interventions ... Full text Link to item Cite

Evolving Healthcare Quality in Top Tertiary General Hospitals in China during the China Healthcare Reform (2010-2012) from the Perspective of Inpatient Mortality.

Journal Article PLoS One · 2015 Healthcare reforms (HR) initiated by many countries impacts on healthcare systems worldwide. Being one of fast developing countries, China launched HR in 2009. Better understanding of its impact is helpful for China and others in further pursuit of HR. Her ... Full text Link to item Cite

Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors.

Journal Article J Oncol Pract · January 2015 PURPOSE: Although studies have evaluated the risk and consequences of febrile neutropenia (FN) among patients receiving cancer chemotherapy in US clinical practice, none have focused on a broad group of patients with metastatic disease. METHODS: A retrospe ... Full text Link to item Cite

Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens.

Journal Article Support Care Cancer · December 2014 PURPOSE: Considerable evidence exists concerning the risk of febrile neutropenia (FN) associated with well-established, older chemotherapy regimens. Little is known, however, about the risks associated with many regimens that were introduced in the past de ... Full text Link to item Cite

Reply to I.A. Voutsadakis et al and A. Goyal et al.

Journal Article J Clin Oncol · December 1, 2014 Full text Link to item Cite

Biosimilars: a cure to the U.S. health care cost conundrum?

Journal Article Blood Rev · November 2014 As the cost of healthcare continues to rise and patents on biologics near expiration, biosimilars are gaining visibility as a mechanism for cost reduction. Yet, the introduction of biosimilars into the U.S. market will be complex, due to the related comple ... Full text Link to item Cite

Colony-stimulating factors for chemotherapy-induced febrile neutropenia.

Journal Article Cochrane Database Syst Rev · October 30, 2014 BACKGROUND: Febrile neutropenia is a frequent adverse event experienced by people with cancer who are undergoing chemotherapy, and is a potentially life-threatening situation. The current treatment is supportive care plus antibiotics. Colony-stimulating fa ... Full text Link to item Cite

Regional initiative to define, collect, and report value metrics in cancer care.

Conference Journal of Clinical Oncology · October 20, 2014 25 Background: In the context of numerous national initiatives aimed at measuring quality and value in cancer care, the Hutchinson Institute for Cancer Outcomes Research, in partnership with local healthcare delivery organization ... Full text Cite

Reply to L.k. Griffeth et al and J.E. Battley et al.

Journal Article J Clin Oncol · September 1, 2014 Full text Link to item Cite

Importance of comparative effectiveness research to the future of healthcare evaluation and delivery.

Journal Article J Comp Eff Res · September 2014 Gary H Lyman speaks to Laura Dormer, Commissioning Editor: Gary H Lyman is a practicing medical oncologist and is nationally and internationally recognized for his leadership in comparative effectiveness, health services and outcomes research. He is a Full ... Full text Link to item Cite

Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation.

Journal Article J Clin Oncol · June 10, 2014 PURPOSE: This guideline presents screening, assessment, and treatment approaches for the management of adult cancer survivors who are experiencing symptoms of fatigue after completion of primary treatment. METHODS: A systematic search of clinical practice ... Full text Link to item Cite

Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review.

Journal Article Crit Rev Oncol Hematol · June 2014 Neutropenia with fever (febrile neutropenia [FN]) is a serious consequence of myelosuppressive chemotherapy that usually results in hospitalization and the need for intravenous antibiotics. FN may result in dose reductions, delays, or even discontinuation ... Full text Link to item Cite

Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.

Journal Article Gynecol Oncol · June 2014 OBJECTIVE: Evaluate the cost-effectiveness of primary prophylaxis (PP) or secondary prophylaxis (SP) with pegfilgrastim, filgrastim (6-day and 11-day), or no prophylaxis to reduce the risk of febrile neutropenia (FN) in patients with recurrent ovarian canc ... Full text Link to item Cite

Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.

Journal Article J Oncol Pharm Pract · June 2014 Featured Publication OBJECTIVE: To examine the incidence, treatment, and consequences of febrile neutropenia across inpatient and outpatient care settings. METHODS: Data were obtained from Humedica's National Electronic Health Record-Derived Longitudinal Patient-Level Database ... Full text Link to item Cite

Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure.

Journal Article Ann Intern Med · May 20, 2014 BACKGROUND: Childhood cancer survivors treated with anthracyclines are at high risk for asymptomatic left ventricular dysfunction (ALVD), subsequent heart failure, and death. The consensus-based Children's Oncology Group (COG) Long-Term Follow-up Guideline ... Full text Link to item Cite

A national survey of breast cancer screening in rural America.

Conference Journal of Clinical Oncology · May 20, 2014 Full text Cite

Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline.

Journal Article J Clin Oncol · May 10, 2014 PURPOSE: The Society of Surgical Oncology (SSO)/American Society for Radiation Oncology (ASTRO) guideline on surgical margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer was considered for endorsemen ... Full text Link to item Cite

Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update.

Journal Article J Clin Oncol · May 1, 2014 PURPOSE: To provide evidence-based recommendations to practicing oncologists, surgeons, and radiation therapy clinicians to update the 2005 clinical practice guideline on the use of sentinel node biopsy (SNB) for patients with early-stage breast cancer. ME ... Full text Link to item Cite

Guidelines for treatment and prevention of venous thromboembolism among patients with cancer.

Journal Article Thromb Res · May 2014 The association between cancer and thrombosis has been recognized for more than 150 years. Not only are patients with cancer at a substantially increased risk of developing venous thromboembolism (VTE), the link between several coagulation factors and tumo ... Full text Link to item Cite

Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study.

Journal Article Cancer Med · April 2014 Neutropenic complications remain an important dose-limiting toxicity of cancer chemotherapy-associated with considerable morbidity, mortality, and cost. Risk of the initial neutropenic event is greatest during the first cycle. The purpose of this study was ... Full text Link to item Cite

An exponential growth in incidence of thyroid cancer: trends and impact of CT imaging.

Journal Article AJNR Am J Neuroradiol · April 2014 Featured Publication BACKGROUND AND PURPOSE: Workup of incidental thyroid nodules detected on CT imaging could be contributing to the increased diagnosis of small thyroid cancers. The purpose of this study was to evaluate recent trends in the incidence of thyroid cancer, and t ... Full text Link to item Cite

Imagine a world without cancer.

Journal Article BMC Cancer · March 14, 2014 BACKGROUND: Since the "War on Cancer" was declared in 1971, the United States alone has expended some $300 billion on research, with a heavy focus on the role of genomics in anticancer therapy. Voluminous data have been collected and analyzed. However, in ... Full text Link to item Cite

Predictors of early mortality in colorectal cancer patients undergoing chemotherapy: Results from a global prospective cohort study.

Conference Journal of Clinical Oncology · January 20, 2014 532 Background: Early mortality is a major problem in colorectal cancer and our understanding of risk factors and predictors is incomplete. A venous thromboembolism (VTE) Risk Score, comprising primary site, baseline hemoglobin, ... Full text Cite

Predictors of clinically significant bleeding in colorectal cancer: Results from a global prospective cohort study.

Conference Journal of Clinical Oncology · January 20, 2014 558 Background: Bleeding is an important complication among patients with colorectal cancer but its prevalence and predictors are incompletely understood. We evaluated data from a global prospective cohort study to define the inc ... Full text Cite

Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.

Journal Article J Med Econ · January 2014 OBJECTIVE: Evaluate the cost-effectiveness of primary vs secondary prophylaxis (PP vs SP) with pegfilgrastim to reduce the risk of febrile neutropenia (FN) in Non-Hodgkin's Lymphoma (NHL) patients receiving myelosuppressive chemotherapy from a US payer per ... Full text Link to item Cite

Abstract P3-15-05: Risk and consequences of neutropenic complications with adjuvant use of trastuzumab and chemotherapy in women with metastatic breast cancer

Conference Cancer Research · December 15, 2013 AbstractBackground: Between 20-30% of women with metastatic breast cancer (MBC) have tumors that overexpress human epidermal growth factor receptor-2, and many receive adjuvant trastuzumab and chemotherapy. ... Full text Cite

Abstract P3-12-07: Dose delays, dose reductions, and relative dose intensity in early stage breast cancer patients receiving (neo)adjuvant chemotherapy in community oncology practices

Conference Cancer Research · December 15, 2013 AbstractBackground: Neutropenic complications, such as febrile neutropenia (FN), often necessitate delays or reductions in doses of myelosuppressive chemotherapy. The resulting reduced relative dose intensit ... Full text Cite

Abstract P3-15-08: A multicenter observational study to investigate the relationship between physician-assessed febrile neutropenia (FN) risk and prediction model FN or SN (severe neutropenia) risk in patients with breast cancer

Conference Cancer Research · December 15, 2013 AbstractBackground: A prediction model was previously developed to estimate the risk of SN or FN during the first cycle of chemotherapy, taking into account both the myelotoxicity of the chemotherapy regimen ... Full text Cite

Reply to T.H. Oo.

Journal Article J Clin Oncol · December 1, 2013 Full text Link to item Cite

Risk Score For Venous Thromboembolism (VTE) In Ambulatory Patients: Impact Of Cancer Type and Risk Score On VTE Incidence, Early Mortality and Progression-Free Survival

Conference Blood · November 15, 2013 AbstractBackgroundWhile ambulatory patients receiving cancer chemotherapy are at increased risk for venous thromboembolism (VTE), curr ... Full text Cite

Risk and Consequences of Neutropenic Complications Among Patients with Metastatic Solid Tumors Receiving Myelosuppressive Chemotherapy

Conference Blood · November 15, 2013 AbstractBackgroundWhile several studies have evaluated the risk and consequences of febrile neutropenia (FN) among patients receiving ... Full text Cite

Risk of Infection Among Patients with Non-Metastatic Solid Tumors or Non-Hodgkin’s Lymphoma Receiving Myelosuppressive Chemotherapy and Antimicrobial Prophylaxis in US Clinical Practice

Conference Blood · November 15, 2013 AbstractBackgroundClinical practice guidelines recommend oral antimicrobials (AMB)—principally, the fluoroquinolones—for prophylaxis a ... Full text Cite

Appropriate chemotherapy dosing in obese patients with cancer.

Journal Article Nat Rev Clin Oncol · November 2013 Featured Publication Full text Link to item Cite

Counting the costs of cancer care.

Journal Article Lancet Oncol · November 2013 Featured Publication Full text Link to item Cite

Pharmacogenetic testing in the face of unclear clinical efficacy: lessons from cytochrome P450 2D6 for tamoxifen.

Journal Article Cancer · October 15, 2013 Featured Publication BACKGROUND: This study evaluated self-reported knowledge, practice, and attitudes toward commercially available cytochrome P450 2D6 (CYP2D6) pharmacogenomic testing for patients on tamoxifen for breast cancer (CYPT) among US oncologists while evidence for ... Full text Link to item Cite

The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials.

Journal Article Ann Oncol · October 2013 Featured Publication BACKGROUND: The granulocyte colony-stimulating factor (G-CSF) is utilized to reduce neutropenic complications in patients receiving cancer chemotherapy. This study represents a systematic review and evidence summary of the impact of G-CSF support on chemot ... Full text Link to item Cite

Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer.

Journal Article Crit Rev Oncol Hematol · October 2013 Featured Publication The burden of venous thromboembolism (VTE) is high in patients with cancer, particularly those with metastatic disease and those receiving chemotherapy. The use of heparin and heparin derivatives should be considered for primary prevention of VTE in hospit ... Full text Link to item Cite

Risk factors for in-hospital mortality and prolonged length of stay in older patients with solid tumor malignancies.

Journal Article J Geriatr Oncol · October 2013 OBJECTIVE: Hospitalized adult patients with cancer and with major comorbidities have higher mortality rates and longer duration of hospitalization. There is limited understanding of risk factors that contribute to prolonged hospitalization and mortality in ... Full text Link to item Cite

Will biosimilars gain momentum?

Journal Article J Natl Compr Canc Netw · October 1, 2013 Featured Publication Biosimilars, also known as follow-on biologics, continue to be an area of great interest in oncology because of the potential cost savings and improved access related to their use, yet significant confusion remains regarding their introduction in the Unite ... Full text Link to item Cite

Myeloid growth factors.

Journal Article J Natl Compr Canc Netw · October 1, 2013 Featured Publication Febrile neutropenia, a common side effect of myelosuppressive chemotherapy in patients with cancer, can result in prolonged hospitalization and broad-spectrum antibiotic use, often prompting treatment delays or dose reductions of drug regimens. Prophylacti ... Full text Link to item Cite

National survey of breast cancer screening in rural America.

Conference Journal of Clinical Oncology · September 10, 2013 13 Background: Screening mammography leads to early detection of breast cancer and improved survival. We conducted a survey of predominantly rural U.S. women who receive health insurance through the National Rural Electric Cooper ... Full text Cite

Incidental thyroid nodules on CT: evaluation of 2 risk-categorization methods for work-up of nodules.

Journal Article AJNR Am J Neuroradiol · September 2013 Featured Publication BACKGROUND AND PURPOSE: Thyroid nodules are common incidental findings on CT, but there are no clear guidelines regarding their further diagnostic work-up. This study compares the performance of 2 risk-categorization methods of selecting CT-detected incide ... Full text Link to item Cite

Chemotherapy dosing in overweight and obese patients with cancer.

Journal Article Nat Rev Clin Oncol · August 2013 Featured Publication Retrospective and prospective preclinical and clinical data have demonstrated an association between chemotherapy dose intensity and both clinical efficacy and toxicity. The optimum tolerable and effective dose and schedule of chemotherapeutic agents is ba ... Full text Link to item Cite

Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects.

Journal Article J Natl Cancer Inst · July 3, 2013 Featured Publication A major promise of genomic research is information that can transform health care and public health through earlier diagnosis, more effective prevention and treatment of disease, and avoidance of drug side effects. Although there is interest in the early a ... Full text Link to item Cite

Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.

Journal Article J Clin Oncol · June 10, 2013 Featured Publication PURPOSE: To provide recommendations about prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer. Prophylaxis in the outpatient, inpatient, and perioperative settings was considered, as were treatment and use of anticoagulation a ... Full text Link to item Cite

Comparative effectiveness research in oncology.

Journal Article Oncologist · June 2013 Featured Publication Although randomized controlled trials represent the gold standard for comparative effective research (CER), a number of additional methods are available when randomized controlled trials are lacking or inconclusive because of the limitations of such trials ... Full text Link to item Cite

A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.

Journal Article Breast Cancer Res Treat · June 2013 Featured Publication Early-stage breast cancer (ESBC) is commonly treated with myelosuppressive chemotherapy, and maintaining full-dose chemotherapy on the planned schedule is associated with improved patient outcome. Retrospective analysis of patients with ESBC treated from 1 ... Full text Link to item Cite

Prevalence and impact of correlative science in breast cancer phase II trials.

Journal Article Breast Cancer Res Treat · June 2013 Featured Publication Correlative science (CS) can potentially augment clinical trial results by identifying biomarkers of response and resistance to a novel intervention. We evaluated recently published breast cancer phase II trials (BP2T) to determine prevalence, characterist ... Full text Link to item Cite

Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer.

Journal Article Gynecol Oncol · April 2013 Featured Publication OBJECTIVE: There is limited information concerning the role of relative dose intensity (RDI) on clinical outcomes in solid tumors. The objectives of our study were to evaluate the prognostic significance of RDI and predictors of reduced RDI in women with n ... Full text Link to item Cite

Multidisciplinary care of patients with early-stage breast cancer.

Journal Article Surg Oncol Clin N Am · April 2013 Featured Publication There is a compelling need for close coordination and integration of multiple specialties in the management of patients with early-stage breast cancer. Optimal patient care and outcomes depend on the sequential and often simultaneous participation and dial ... Full text Link to item Cite

Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer.

Journal Article Genet Med · March 2013 Featured Publication PURPOSE: New evidence is available regarding the utility of the 21-gene recurrence score assay in guiding chemotherapy use for node-negative, estrogen receptor-positive breast cancer. We applied this evidence in a decision-analytic model to re-evaluate the ... Full text Link to item Cite

Update on the role of epothilones in metastatic breast cancer

Journal Article Current Breast Cancer Reports · March 1, 2013 Featured Publication The role of epothilones in the treatment of locally advanced and metastatic breast cancer remains unclear. While the pivotal studies for ixabepilone were published between 2005 and 2010, and the agent received approval in 2007 from the U.S. Food and Drug A ... Full text Cite

Short-term costs associated with primary prophylactic G-CSF use during chemotherapy.

Journal Article Am J Manag Care · February 2013 Featured Publication BACKGROUND: Chemotherapy is vital for breast cancer treatment, but early-onset toxicities like neutropenia hinder its administration. Neutropenia also increases costs due to hospitalizations and aggressive systemic antibiotic administration. Primary prophy ... Link to item Cite

Thrombosis and cancer: emerging data for the practicing oncologist.

Journal Article Am Soc Clin Oncol Educ Book · 2013 Featured Publication The American Society of Clinical Oncology (ASCO) recently updated clinical practice guidelines on the treatment and prevention of venous thromboembolism (VTE) in patients with cancer. Although several new studies have been reported, many questions remain a ... Full text Link to item Cite

Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis.

Journal Article Oncologist · 2013 UNLABELLED: The occurrence of malignant disease increases the risk for venous thromboembolism (VTE). Here we evaluate the risk for VTE in a large unselected cohort of patients with cancer receiving chemotherapy. METHODS: The United States IMPACT health car ... Full text Link to item Cite

Abstract P2-10-03: A cross-platform comparison of genomic signatures and OncotypeDx score to discover potential prognostic/predictive genes and pathways

Journal Article Cancer Research · December 15, 2012 AbstractBackground: Microarray assessment of breast cancer demonstrates disease subsets among the major breast cancer biologic categories (ER, PR, HER-2) with likely additional prognostic and treatment (pred ... Full text Cite

Abstract P3-06-07: Ki67 as a Predictive Marker of Response to Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer (ESBC): A Systematic Review and Evidence Summary

Journal Article Cancer Research · December 15, 2012 AbstractBackground: Immunohistochemical (IHC) assessment of the proportion of cells staining for the KI67 nuclear antigen is being increasing utilized in the management of patients with early-stage breast ca ... Full text Cite

Abstract P1-15-04: The relationship of relative dose intensity and supportive care to febrile neutropenia rates in patients with early stage breast cancer receiving chemotherapy: a prospective cohort study of chemotherapy-associated toxicity

Conference Cancer Research · December 15, 2012 AbstractBackground: Febrile neutropenia (FN) represents a major dose-limiting toxicity of cancer chemotherapy resulting in considerable morbidity, mortality, and cost. Patients have the highest risk of the i ... Full text Cite

Comparative effectiveness research in oncology: an overview.

Journal Article J Clin Oncol · December 1, 2012 Featured Publication Full text Link to item Cite

A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.

Journal Article Value Health · December 2012 Featured Publication OBJECTIVES: Uncertainty exists regarding appropriate and affordable use of adjuvant chemotherapy in stage II colon cancer (T3, proficient DNA mismatch repair). This study aimed to estimate the effectiveness and costs from a US societal perspective of a mul ... Full text Link to item Cite

Reply to P.K.L. Chin et al, P. Chambers et al, and J.H. Beumer et al

Journal Article Journal of Clinical Oncology · November 1, 2012 Full text Cite

Economics of the recombinant human granulocyte colony-stimulating factors

Journal Article Milestones in Drug Therapy · October 8, 2012 Featured Publication Full text Cite

Making genuine progress against metastatic breast cancer.

Journal Article J Clin Oncol · October 1, 2012 Featured Publication Full text Link to item Cite

Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline.

Journal Article Ann Surg Oncol · October 2012 Featured Publication PURPOSE: The American Society of Clinical Oncology (ASCO) and Society of Surgical Oncology (SSO) sought to provide an evidence-based guideline on the use of lymphatic mapping and sentinel lymph node (SLN) biopsy in staging patients with newly diagnosed mel ... Full text Link to item Cite

RISK OF MAJOR BLEEDING IN CANCER PATIENTS RECEIVING CHEMOTHERAPY

Conference ANNALS OF ONCOLOGY · September 1, 2012 Link to item Cite

American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology.

Journal Article J Clin Oncol · September 1, 2012 Featured Publication The American Society of Clinical Oncology (ASCO) guidelines program employs a systematic review-based methodology to produce evidence-based guidelines. This is consistent with the stance of the Institute of Medicine on guideline development, which is that ... Full text Link to item Cite

Costs associated with febrile neutropenia in the US.

Journal Article Pharmacoeconomics · September 1, 2012 Featured Publication BACKGROUND AND OBJECTIVE: Febrile neutropenia (FN) is a potentially life-threatening condition that may develop in cancer patients treated with myelosuppressive chemotherapy and result in considerable costs. This study was designed to estimate US healthcar ... Full text Link to item Cite

Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline.

Journal Article J Clin Oncol · August 10, 2012 Featured Publication PURPOSE: The American Society of Clinical Oncology (ASCO) and Society of Surgical Oncology (SSO) sought to provide an evidence-based guideline on the use of lymphatic mapping and sentinel lymph node (SLN) biopsy in staging patients with newly diagnosed mel ... Full text Link to item Cite

Preventing VTE in Outpatients With Cancer.

Journal Article Chest · July 2012 Featured Publication Full text Link to item Cite

Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score.

Journal Article Cancer · July 1, 2012 Featured Publication BACKGROUND: Tools are lacking to assess the individual risk of severe toxicity from chemotherapy. Such tools would be especially useful for older patients, who vary considerably in terms of health status and functional reserve. METHODS: The authors conduct ... Full text Link to item Cite

Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research.

Journal Article Genet Med · July 2012 Featured Publication The clinical utility is uncertain for many cancer genomic applications. Comparative effectiveness research (CER) can provide evidence to clarify this uncertainty. The aim of this study was to identify approaches to help stakeholders make evidence-based dec ... Full text Link to item Cite

Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer.

Journal Article Gynecol Oncol · June 2012 Featured Publication OBJECTIVE: To identify factors that increase the risk of neutropenic events in women with advanced ovarian carcinoma receiving initial chemotherapy. METHODS: Multi-center retrospective study of women with FIGO stage III-IV epithelial ovarian cancer treated ... Full text Link to item Cite

Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.

Journal Article Pharmacoeconomics · June 1, 2012 Featured Publication BACKGROUND: The pharmacoeconomics of the myeloid growth factors (MGFs) is an important topic that has received substantial attention in recent years. The use of the MGFs as primary prophylaxis to prevent febrile neutropenia (FN) has grown considerably over ... Full text Link to item Cite

Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice.

Journal Article Breast Cancer Res Treat · May 2012 Featured Publication Chemotherapy is widely used to treat early stage breast cancer (ESBC). Reductions and delays in dose administered--e.g., due to advanced age or febrile neutropenia (FN)--are generally believed to increase risk of disease progression and reduce survival. Li ... Full text Link to item Cite

Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.

Journal Article J Clin Oncol · May 1, 2012 Featured Publication PURPOSE: To provide recommendations for appropriate cytotoxic chemotherapy dosing for obese adult patients with cancer. METHODS: The American Society of Clinical Oncology convened a Panel of experts in medical and gynecologic oncology, clinical pharmacolog ... Full text Link to item Cite

Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer.

Journal Article Crit Rev Oncol Hematol · March 2012 Featured Publication Randomized controlled trials (RCTs) have suggested a potential advantage of dose-dense chemotherapy in improving disease-free and overall survival in patients with certain malignancies. This systematic review summarizes the literature on the efficacy of do ... Full text Link to item Cite

Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.

Journal Article Pharmacoeconomics · February 1, 2012 Featured Publication BACKGROUND: Granulocyte-colony stimulating factor (G-CSF) reduces the risk of severe neutropenia associated with chemotherapy, but its cost implications following chemotherapy are unknown. OBJECTIVE: Our objective was to examine associations between G-CSF ... Full text Link to item Cite

The incidence of venous thromboembolism in cancer patients: a real-world analysis.

Journal Article Clin Adv Hematol Oncol · January 2012 Featured Publication Link to item Cite

Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer.

Journal Article Chemotherapy · 2012 Featured Publication BACKGROUND: The burden of chemotherapy-induced neutropenic complications (CINC) in women with metastatic breast cancer (MBC) is largely unknown and may differ across cancer populations due to variation in the characteristics of patients, their disease and ... Full text Link to item Cite

P3-14-04: Assessment of Genomic Prognostic Signatures as Predictors of Response to Neoadjuvant Chemotherapy in Patients with Early Stage Breast Cancer.

Journal Article Cancer Research · December 15, 2011 AbstractBackground: Based on results from randomized clinical trials, adjuvant and neoadjuvant chemotherapy (NCT) strategies in early stage breast cancer patients (ESBC) achieve comparable long term results. ... Full text Cite

P1-11-07: Impact of Reduction in Cost-Sharing on Screening Mammography Utilization among Rural U.S. Women.

Conference Cancer Research · December 15, 2011 AbstractBackground: Early detection of breast cancer through mammography screening leads to earlier stage at diagnosis and improved survival. For reasons that are poorly understood, in recent years the rate ... Full text Cite

P5-13-17: Multigene Signature Assays in Patients with Early-Stage Breast Cancer (ESBC) Receiving Neoadjuvant Chemotherapy: An NCI-Funded Systematic Review and Evidence Summary of Predictive Performance.

Conference Cancer Research · December 15, 2011 AbstractBackground: A comprehensive literature search and evidence synthesis of multigene signatures predictive of response to systemic chemotherapy in patients with breast cancer was initiated as a part of ... Full text Cite

P5-18-11: Incidence of Chemotherapy Dose Reductions and Dose Delays, and Reduced Chemotherapy Dose Intensity in Early Stage Breast Cancer.

Conference Cancer Research · December 15, 2011 AbstractBackground: Chemotherapy is widely used to treat early stage breast cancer (ESBC). Dose reductions and dose delays–e.g., due to advanced age or severe/febrile neutropenia–are generally believed to in ... Full text Cite

P5-20-03: Personalizing Supportive Care: A Clinical Prediction Model for Neutropenic Complications in Patients with Early-Stage Breast Cancer (ESBC) Receiving Intermediate Risk Chemotherapy.

Conference Cancer Research · December 15, 2011 AbstractBackground: Neutropenic complications including severe and febrile neutropenia (FN) represent major dose-limiting toxicities of cancer chemotherapy. A general risk model for neutropenic complications ... Full text Cite

Hematopoietic growth factors

Chapter · December 7, 2011 Cite

Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients.

Journal Article Breast Cancer Res Treat · November 2011 Featured Publication Effective systemic therapy is vital for successful breast cancer treatment, but early onset toxicities like neutropenia hinder systemic therapy administration, especially in the elderly. Primary prophylactic use of granulocyte-colony stimulating factors (G ... Full text Link to item Cite

Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Journal Article J Clin Oncol · November 1, 2011 Featured Publication PURPOSE: To update the American Society of Clinical Oncology (ASCO) guideline for antiemetics in oncology. METHODS: A systematic review of the medical literature was completed to inform this update. MEDLINE, the Cochrane Collaboration Library, and meeting ... Full text Link to item Cite

Antiemetics: american society of clinical oncology clinical practice guideline update.

Journal Article J Oncol Pract · November 2011 Featured Publication ASCO's update to its antiemetics guideline now includes an evaluation of evidence on complementary antiemetic therapy. ... Full text Link to item Cite

Comparison of demographic characteristics, surgical resection patterns, and survival outcomes for veterans and nonveterans with non-small cell lung cancer in the Pacific Northwest.

Journal Article J Thorac Oncol · October 2011 Featured Publication INTRODUCTION: Lung cancer is a leading cause of death in the United States and among veterans. This study compares patterns of diagnosis, treatment, and survival for veterans diagnosed with non-small cell lung cancer (NSCLC) using a recently established ca ... Full text Link to item Cite

NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.

Journal Article J Natl Compr Canc Netw · September 2011 Featured Publication Biologics are essential to oncology care. As patents for older biologics begin to expire, the United States is developing an abbreviated regulatory process for the approval of similar biologics (biosimilars), which raises important considerations for the s ... Full text Link to item Cite

Sentinel node biopsy for head and neck melanoma: a systematic review.

Journal Article Otolaryngol Head Neck Surg · September 2011 Featured Publication OBJECTIVE: This systematic review was conducted to examine the test performance of sentinel node biopsy in head and neck melanoma, including the identification rate and false-negative rate. DATA SOURCES: PubMed, EMBASE, ASCO, and SSO database searches were ... Full text Link to item Cite

Reply to S. Hapani et al

Journal Article Journal of Clinical Oncology · September 1, 2011 Full text Cite

Myeloid growth factors.

Journal Article J Natl Compr Canc Netw · August 1, 2011 Featured Publication Full text Link to item Cite

Biosimilars: are they ready for primetime in the United States?

Journal Article J Natl Compr Canc Netw · August 1, 2011 Featured Publication The introduction of alternative versions of biologic products, also known as biosimilars, into the United States market has been gaining increasing visibility as patents for many agents are nearing expiration. Unlike generics, which are regulated under the ... Full text Link to item Cite

Long-term outcomes of myeloid growth factor treatment.

Journal Article J Natl Compr Canc Netw · August 1, 2011 Featured Publication Myeloid growth factors are used to reduce myelotoxicity and the risk of infection after cancer chemotherapy and in patients with chronic neutropenia. This article addresses the long-term benefits and risks associated with granulocyte colony-stimulating fac ... Full text Link to item Cite

Systematic review of 99mTc human serum albumin and 99mTc sulfur colloid studies of sentinel lymph node biopsy of cutaneous melanoma of the head and neck

Conference Laryngoscope · July 11, 2011 Featured Publication Introduction: Sentinel lymph node biopsy (SLNB) of head and neck melanoma presents a technical challenge due to the multiplicity of basins and variable lymph node drainage. Radiotracer size and particulate nature determines speed of lymphatic drainage into ... Full text Cite

Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy.

Journal Article Med Care · July 2011 Featured Publication OBJECTIVE: Chemotherapy is vital for breast cancer management, but early-onset toxicities like neutropenia hinder its administration, especially in the elderly. Primary prophylactic (PP) use of granulocyte-colony stimulating factors (G-CSF) helps prevent n ... Full text Link to item Cite

Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer.

Journal Article Breast Cancer Res Treat · June 2011 Featured Publication Chemotherapy is vital for breast cancer management, but early onset toxicities like neutropenia hinder its administration. Primary prophylactic (PP) use of colony- stimulating factors (CSF) helps prevent neutropenia and ensures successful chemotherapy comp ... Full text Link to item Cite

Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.

Journal Article J Clin Oncol · May 1, 2011 Featured Publication PURPOSE: Thromboembolism is a major source of morbidity and mortality in patients with cancer. The contribution of anti-vascular endothelial growth factor therapy to these events remains controversial. PATIENTS AND METHODS: Individual patient data were ava ... Full text Link to item Cite

Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy.

Journal Article Cancer · May 1, 2011 Featured Publication BACKGROUND: A prospective cohort study was undertaken to develop and validate a risk model for neutropenic complications in cancer patients receiving chemotherapy. METHODS: The study population consisted of 3760 patients with common solid tumors or maligna ... Full text Link to item Cite

Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis.

Journal Article J Clin Oncol · April 10, 2011 Featured Publication PURPOSE: To perform a meta-analysis of all published studies of sentinel lymph node (SLN) biopsy for staging patients with melanoma. METHODS: Published literature in all languages between 1990 and 2009 was critically appraised. Primary outcomes evaluated i ... Full text Link to item Cite

Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis.

Journal Article Cancer · April 1, 2011 Featured Publication Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in patients with cancer. The risk of VTE varies over the natural history of cancer, with the highest risk occurring during hospitalization and after disease recurrence. Patient ... Full text Link to item Cite

Use of a multigene prognostic assay for selection of adjuvant chemotherapy in patients with stage II colon cancer: Impact on quality-adjusted life expectancy and costs.

Conference Journal of Clinical Oncology · February 1, 2011 491 Background: Uncertainty exists regarding the use of adjuvant therapy in patients with stage II colon cancer. To assist decision making, we compared quality-adjusted life expectancy and costs associated with using a multigene ... Full text Cite

Breast cancer screening with mammography.

Journal Article Curr Oncol Rep · February 2011 Featured Publication There has been a great deal of controversy regarding the change in breast cancer screening recommendations released by the US Preventive Services Task Force in November 2009. Despite limited new data, the Task Force changed their previous recommendations d ... Full text Link to item Cite

Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.

Journal Article Cancer Treat Res · 2011 Featured Publication Chemotherapy-induced neutropenia and its complications are major dose-limiting toxicities of cancer chemotherapy. The myeloid growth factors have been shown to reduce the risk of neutropenic events across malignancies, regimens, and associated risk categor ... Full text Link to item Cite

The myeloid growth factors.

Journal Article Cancer Treat Res · 2011 Featured Publication Full text Link to item Cite

Introduction to the hematopoietic growth factors.

Journal Article Cancer Treat Res · 2011 Featured Publication Full text Link to item Cite

The economics of the hematopoietic growth factors.

Journal Article Cancer Treat Res · 2011 Featured Publication Full text Link to item Cite

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

Journal Article Eur J Cancer · January 2011 Featured Publication Chemotherapy-induced neutropenia is a major risk factor for infection-related morbidity and mortality and also a significant dose-limiting toxicity in cancer treatment. Patients developing severe (grade 3/4) or febrile neutropenia (FN) during chemotherapy ... Full text Link to item Cite

A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia.

Journal Article Curr Opin Hematol · January 2011 Featured Publication PURPOSE OF REVIEW: Clinical practice guidelines for the prevention of febrile neutropenia in patients receiving cancer chemotherapy utilizing the myeloid growth factors have been developed by several major international professional organizations. This rev ... Full text Link to item Cite

Cancer Treatment and Research: Preface

Journal Article Cancer Treatment and Research · January 1, 2011 Full text Cite

Response

Journal Article Journal of the National Cancer Institute · December 21, 2010 Full text Cite

Reply to N. Lathia et al

Journal Article Journal of Clinical Oncology · December 20, 2010 Full text Cite

Abstract PD06-09: Sentinel Node Biopsy Versus Axillary Lymph Node Dissection in Early-Stage Breast Cancer: A Meta-Analysis of Randomized Controlled Trials

Conference Cancer Research · December 15, 2010 AbstractBackground: Lymphatic mapping with sentinel node biopsy (SNB) has become a widely used technology for reducing morbidity associated with breast cancer staging despite limited data from randomized con ... Full text Cite

Abstract P5-10-01: Overall Survival in Breast Cancer Patients in Randomized Controlled Trials Comparing Primary G-CSF Chemotherapy Support to Control

Conference Cancer Research · December 15, 2010 AbstractBackground Randomized controlled trials (RCTs) have demonstrated that granulocyte colony-stimulating factor (G-CSF) is capable of reducing the risk of neutropenic complications including febrile neut ... Full text Cite

Abstract P1-09-01: Impact of Granulocyte-Colony Stimulating Factor (G-CSF) Use on Medical Costs after Initial Chemotherapy in Early-Stage Breast Cancer (ESBC)

Conference Cancer Research · December 15, 2010 AbstractBackground: G-CSF minimizes severe neutropenia risk associated with chemotherapy, but its cost implications following chemotherapy are unknown.Objective: To examine t ... Full text Cite

Availability of experimental therapy outside oncology randomized clinical trials in the United States.

Journal Article J Clin Oncol · December 1, 2010 Featured Publication PURPOSE: Investigational cancer therapies may be available outside trials as "off-protocol therapy" (OPRx), with implications for patient safety, trial accrual, and access to care. We conducted a literature-based analysis of recent randomized trials to eva ... Full text Link to item Cite

Risk of mortality in patients with cancer who experience febrile neutropenia.

Journal Article Cancer · December 1, 2010 Featured Publication BACKGROUND: Febrile neutropenia (FN) is a serious and potentially life-threatening condition that may develop in patients with cancer who receive myelosuppressive chemotherapy. The risk of mortality from FN is not well characterized in current clinical pra ... Full text Link to item Cite

A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer.

Journal Article Cancer Invest · November 2010 Featured Publication Among the 77 infiltrating breast carcinomas, we found that progesterone receptor (PR) expression was inversely associated with recurrence score (RS, p < .0001). RS is also significantly associated with tubule formation, mitosis, and luminal B subtype. The ... Full text Link to item Cite

Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery.

Journal Article J Hematol Oncol · August 19, 2010 Featured Publication BACKGROUND: In newly diagnosed patients with Hodgkin lymphoma (HL) the effect of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD)-related neutropenia on chemotherapy delivery is poorly documented. The aim of this analysis was to assess the impact ... Full text Open Access Link to item Cite

Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy.

Journal Article Thromb Res · August 2010 Featured Publication BACKGROUND: Leukocytosis has been associated with thrombosis and mortality in cancer patients. We explored the association of leukocytosis with venous thromboembolism (VTE) and early mortality in cancer patients initiating chemotherapy. METHODS: Data from ... Full text Link to item Cite

Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review.

Journal Article J Clin Oncol · June 10, 2010 Featured Publication PURPOSE: To evaluate the risk of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and overall mortality in patients receiving chemotherapy with or without granulocyte colony-stimulating factor (G-CSF), a systematic review of randomized contro ... Full text Link to item Cite

Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer.

Journal Article Breast Cancer Res Treat · June 2010 Featured Publication There are few studies of model-based survival projections using early empirical results for estimating long-term survival. Utilizing Early Breast Cancer Trialists' Collaborative Group (EBCTCG) data, a Markov model was generated to compare empirical results ... Full text Link to item Cite

Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy.

Journal Article Crit Rev Oncol Hematol · June 2010 Featured Publication We investigated the incidences of febrile neutropenia (FN) and related complications in elderly (> or =65 years) breast cancer patients receiving chemotherapy supported by pegfilgrastim primary prophylaxis (PP; n=150) or current practice (CP) neutropenia m ... Full text Link to item Cite

How we treat febrile neutropenia in patients receiving cancer chemotherapy.

Journal Article J Oncol Pract · May 2010 Featured Publication Although improved supportive care has reduced mortality associated with febrile neutropenia, it continues to cause chemotherapy limitations, morbidity, mortality, and cost among patients with cancer. ... Full text Link to item Cite

Themyeloid growth factors in older adults with cancer

Chapter · January 1, 2010 Introduction Myelosuppression represents the major dose-limiting toxicity of cancer chemotherapy regimens, particularly in older cancer patients. In addition, aging is associated with a progressive decline in the functional reserve of the bone marrow as we ... Full text Cite

Breast cancer screening: science, society and common sense.

Journal Article Cancer Invest · January 2010 Featured Publication Full text Link to item Cite

Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer.

Journal Article Cancer · December 15, 2009 Featured Publication Venous thromboembolism (VTE) is a frequent complication of cancer and cancer treatment and is associated with multiple clinical consequences, including recurrent VTE, bleeding, and an increase in the risk of death. Although the risks associated with VTE ha ... Full text Link to item Cite

Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy.

Journal Article Cancer · November 15, 2009 Featured Publication BACKGROUND: This prospective study evaluated patient and treatment characteristics that contributed to hematologic toxicity in older breast cancer patients treated with curative intent in the community setting. METHODS: Data were collected on 1224 patients ... Full text Link to item Cite

Isolated tumor cells in breast cancer.

Journal Article N Engl J Med · November 12, 2009 Featured Publication Full text Link to item Cite

NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis.

Journal Article J Natl Compr Canc Netw · November 2009 Featured Publication Full text Link to item Cite

Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action.

Journal Article J Clin Oncol · October 10, 2009 Featured Publication PURPOSE: Venous thromboembolism (VTE) is an increasingly frequent complication of cancer and its treatments, and is associated with worsened mortality and morbidity in patients with cancer. DESIGN: The Italian Association of Medical Oncology, the National ... Full text Link to item Cite

Cancer, clots and consensus: new understanding of an old problem.

Journal Article J Clin Oncol · October 10, 2009 Featured Publication Full text Link to item Cite

Prevention of venous thromboembolism in the non-surgical patient with cancer

Journal Article Clinical Advances in Hematology and Oncology · October 1, 2009 Cite

3005 Risk of mortality in patients with cancer experiencing febrile neutropenia

Conference European Journal of Cancer Supplements · September 2009 Full text Cite

The road to romiplostim approval and beyond.

Journal Article Oncology (Williston Park) · July 2009 Featured Publication Link to item Cite

Preventing venous thromboembolism in cancer patients: can we do better?

Journal Article J Oncol Pract · July 2009 Featured Publication Full text Link to item Cite

The road to romiplostim approval and beyond.

Journal Article Oncology (Williston Park, N.Y.) · July 1, 2009 Featured Publication Cite

Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors.

Journal Article Cancer · June 15, 2009 Featured Publication BACKGROUND: Phase 3 clinical trials performed primarily outside the US demonstrate that intravesical instillation of chemotherapy immediately after transurethral resection of the bladder (TURB) decreases cancer recurrence rates. The authors sought to deter ... Full text Link to item Cite

Cancer and thrombosis: back to the future renewed interest in an old problem.

Journal Article Cancer Invest · June 2009 Featured Publication Cancer patients are at increased risk for thromboembolic complications due to the release of procoagulants, compression or invasion of blood vessels and the reduced mobility associated with cancer and cancer treatment. This has led to recommendations for t ... Full text Link to item Cite

Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States.

Journal Article Clin Ther · May 2009 Featured Publication BACKGROUND: Prophylaxis with granulocyte colony-stimulating factor reduces the risk for febrile neutropenia (FN) in patients receiving myelosuppressive chemotherapy. OBJECTIVE: We estimated the incremental cost-effectiveness of primary prophylaxis (startin ... Full text Link to item Cite

Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.

Journal Article Eur J Cancer · March 2009 Featured Publication Granulocyte colony-stimulating factors (G-CSFs) reduce febrile neutropaenia (FN) incidence but may be used inconsistently in current practice (CP). This study compared the efficacy of pegfilgrastim primary prophylaxis (PPP) with CP neutropaenia management ... Full text Link to item Cite

Longwall roof control through a fundamental understanding of shield–strata interaction

Journal Article International Journal of Rock Mechanics and Mining Sciences · February 2009 Full text Cite

Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.

Journal Article Curr Med Res Opin · February 2009 Featured Publication OBJECTIVES: Prophylaxis with granulocyte-colony stimulating factor (G-CSF) reduces the risk of febrile neutropenia (FN) in patients receiving myelosuppressive chemotherapy. Randomized clinical trials have shown that pegfilgrastim, a 2nd-generation G-CSF, i ... Full text Link to item Cite

Impact of chemotherapy dose intensity on cancer patient outcomes.

Journal Article J Natl Compr Canc Netw · January 2009 Featured Publication Chemotherapy dose intensity represents unit dose of chemotherapy administered per unit time. Dose intensity can be increased or decreased through altering dose administered, time interval of administration, or both. Evidence supporting the importance of de ... Full text Link to item Cite

Myeloid growth factors.

Journal Article J Natl Compr Canc Netw · January 2009 Featured Publication Full text Link to item Cite

Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy.

Journal Article Value Health · 2009 Featured Publication OBJECTIVE: Prophylaxis with granulocyte colony-stimulating factor (G-CSF) reduces the risk of febrile neutropenia (FN) in patients receiving myelosuppressive chemotherapy. We estimated the incremental cost-effectiveness of G-CSF pegfilgrastim primary (star ... Full text Link to item Cite

Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group.

Journal Article J Clin Oncol · December 10, 2008 Featured Publication PURPOSE: There is considerable variation in the use of HLA-matched related bone marrow transplantation (BMT) for the treatment of pediatric patients with newly diagnosed acute myeloid leukemia (AML). Some oncologists have argued that BMT should be offered ... Full text Link to item Cite

Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer.

Journal Article Arch Intern Med · November 24, 2008 Featured Publication BACKGROUND: Anemia is frequent in patients with cancer, but there are concerns regarding treatment with erythropoiesis-stimulating agents. Blood transfusions are commonly used as an alternative, but with little data regarding outcomes. METHODS: In a retros ... Full text Link to item Cite

Variation in the cost of medications for the treatment of colorectal cancer.

Journal Article Am J Manag Care · November 2008 Featured Publication OBJECTIVE: To evaluate the economic burden of colorectal cancer (CRC) treatment on the healthcare system as treatment costs have risen 340-fold during the past 5 years. STUDY DESIGN: Nationwide registry. METHODS: Patients with CRC (N = 421) were selected f ... Link to item Cite

Myelodysplastic syndromes.

Journal Article J Natl Compr Canc Netw · October 2008 Featured Publication Link to item Cite

In reply

Journal Article Journal of Clinical Oncology · September 15, 2008 Full text Cite

Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose.

Journal Article Int J Radiat Oncol Biol Phys · September 1, 2008 Featured Publication PURPOSE: Subsequent malignant neoplasms (SMNs) are a dominant cause of morbidity and mortality in children treated for Hodgkin's disease (HD). We evaluated select demographic and therapeutic factors associated with SMNs, specifically gender and radiation d ... Full text Link to item Cite

ASCO Clinical Practice Guidelines: Past, Present and Future.

Journal Article J Oncol Pract · September 2008 Featured Publication Full text Link to item Cite

Journal of oncology practice in transition.

Journal Article J Oncol Pract · September 2008 Full text Link to item Cite

American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges.

Journal Article J Clin Oncol · August 20, 2008 Featured Publication The American Society of Clinical Oncology (ASCO) published its first clinical practice guideline, which focused on the use of hematopoietic colony-stimulating factors, in 1994. Since then, ASCO has published 24 additional guidelines or technology assessmen ... Full text Link to item Cite

Development and validation of a predictive model for chemotherapy-associated thrombosis.

Journal Article Blood · May 15, 2008 Featured Publication Risk of venous thromboembolism (VTE) is elevated in cancer, but individual risk factors cannot identify a sufficiently high-risk group of outpatients for thromboprophylaxis. We developed a simple model for predicting chemotherapy-associated VTE using basel ... Full text Link to item Cite

Optimal cancer care across the spectrum of life and disease.

Journal Article Am J Manag Care · May 2008 Featured Publication Link to item Cite

Undertreatment of cancer patients with chemotherapy is a global concern.

Journal Article J Oncol Pract · May 2008 Featured Publication Full text Link to item Cite

Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.

Journal Article JAMA · April 2, 2008 Featured Publication CONTEXT: Gene expression profiling may be useful for prognostic and therapeutic strategies in breast carcinoma. OBJECTIVES: To demonstrate the value in integrating genomic information with clinical and pathological risk factors, to refine prognosis, and to ... Full text Link to item Cite

Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.

Journal Article Hum Pathol · March 2008 Featured Publication Androgen receptor has been implicated in the pathogenesis of breast carcinoma. In this study, we explored the potential role of androgen receptor in breast cancer by analyzing its expression using immunohistochemistry and its relationship with tumor progre ... Full text Link to item Cite

Recommendations on the use of 18F-FDG PET in oncology.

Journal Article J Nucl Med · March 2008 Featured Publication UNLABELLED: The rationale was to develop recommendations on the use of (18)F-FDG PET in breast, colorectal, esophageal, head and neck, lung, pancreatic, and thyroid cancer; lymphoma, melanoma, and sarcoma; and unknown primary tumor. Outcomes of interest in ... Full text Link to item Cite

Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice.

Journal Article J Natl Compr Canc Netw · February 2008 Featured Publication This study was undertaken to describe the relationship between the occurrence and timing of neutropenic events and chemotherapy treatment in a community-based population of patients with cancer. The study included 2962 patients with breast, lung, colorecta ... Full text Link to item Cite

Cancer supportive care: Advances in therapeutic strategies

Book · January 1, 2008 Written with a broader perspective and knowledge, Cancer Supportive Care: Advances in Therapeutic Strategies presents state-of-the-art management options for the full range of symptoms, toxicities, and complications experienced by cancer patients. In addit ... Cite

Preface

Book · January 1, 2008 Cite

Neutropenia and its complications

Chapter · January 1, 2008 Neutrophils form the first line of host defense from infections by bacterial and fungal pathogens. Whenever there is any break in the integrity of a body surface, it is the capacity to generate an acute inflammatory response with rapid accumulation of neut ... Cite

Risk prediction of chemotherapy-associated toxicity in patients receiving cancer chemotherapy

Chapter · January 1, 2008 Prognostic or risk models evaluate the association between an outcome (dependent variable)-such as disease, response, and survival-and one or more predictive or prognostic factors (independent variables). Such models are used for a number of purposes, incl ... Cite

Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy.

Journal Article Value Health · 2008 Featured Publication OBJECTIVES: Neutropenia and its complications, including febrile neutropenia (FN), are a common side effect of cancer chemotherapy. Results of clinical trials showed that prophylactic use of granulocyte colony-stimulating factors (G-CSF) is effective in pr ... Full text Link to item Cite

Estimating net benefits and harms of screening mammography in women age 40 to 49 years.

Journal Article Ann Intern Med · December 18, 2007 Featured Publication Full text Link to item Cite

American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.

Journal Article J Clin Oncol · December 1, 2007 Featured Publication PURPOSE: To develop guideline recommendations for the use of anticoagulation in the prevention and treatment of venous thromboembolism (VTE) in patients with cancer. METHODS: A comprehensive systematic review of the medical literature on the prevention and ... Full text Link to item Cite

Cost-Effectiveness of Primary Prophylaxis with Pegfilgrastim Versus Filgrastim in Non-Hodgkin’s Lymphoma Patients Receiving CHOP-21.

Conference Blood · November 16, 2007 AbstractProphylaxis with granulocyte colony-stimulating factors (G-CSFs) starting in the first and continuing in subsequent chemotherapy cycles when the risk of febrile neutropenia (FN) is ≥20% is recommende ... Full text Cite

Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients.

Journal Article Cancer · November 15, 2007 Featured Publication BACKGROUND: Venous thromboembolism (VTE) contributes to morbidity and mortality in cancer patients and is a frequent complication of anticancer therapy. In the current study, the frequency, risk factors, and trends associated with VTE were examined among h ... Full text Link to item Cite

Agents under investigation for the treatment and prevention of neutropenia.

Journal Article Expert Opin Investig Drugs · November 2007 Featured Publication Neutropenia, and most notably febrile neutropenia, represents a significant complication following chemotherapy administration. Present agents used for the treatment of neutropenia include G-CSF, GM-CSF and G-CSF conjugated to polyethylene glycol (PEG) as ... Full text Link to item Cite

ASCO Clinical Practice Guidelines and Beyond.

Journal Article J Oncol Pract · November 2007 Featured Publication Full text Link to item Cite

Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.

Journal Article Cancer · October 1, 2007 Featured Publication BACKGROUND: This prospective study was undertaken to evaluate patient and treatment characteristics that contribute to hematologic toxicity in older cancer patients. METHODS: A nationwide study of 115 community oncology practices was conducted between 2002 ... Full text Link to item Cite

Advances in Cancer Investigation

Journal Article Cancer Investigation · October 1, 2007 Full text Cite

Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials.

Journal Article Curr Med Res Opin · September 2007 Featured Publication BACKGROUND AND OBJECTIVE: While head-to-head clinical trials demonstrate pegfilgrastim to be as efficacious as filgrastim in reducing chemotherapy-induced neutropenia, these studies lacked the statistical power to demonstrate better outcomes with one thera ... Full text Link to item Cite

A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications.

Journal Article Cancer · September 1, 2007 Featured Publication BACKGROUND: Preclinical evidence suggests that anticoagulants, in particular the low-molecular-weight heparins (LMWH), exert an antitumor effect, whereas clinical trials have reported conflicting results. The authors conducted a comprehensive, systematic r ... Full text Link to item Cite

Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.

Journal Article J Clin Oncol · July 20, 2007 Featured Publication PURPOSE: Randomized controlled trials (RCTs) of prophylactic granulocyte colony-stimulating factors (G-CSF) have demonstrated a significant reduction in febrile neutropenia (FN) after systemic chemotherapy. Several RCTs have been published recently that in ... Full text Link to item Cite

Granulocyte colony-stimulating factors: finding the right indication.

Journal Article Curr Opin Oncol · July 2007 Featured Publication PURPOSE OF REVIEW: Neutropenic complications including febrile neutropenia represent major dose-limiting toxicities of cancer chemotherapy. Recommendations for the use of recombinant myeloid growth factors to reduce the risk of neutropenic complications an ... Full text Link to item Cite

Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens.

Journal Article J Clin Oncol · June 20, 2007 Featured Publication PURPOSE: Breast cancer outcomes are worse among black women and women of lower socioeconomic status. The purpose of this study was to investigate racial and social differences in selection of breast cancer adjuvant chemotherapy regimens. METHODS: Detailed ... Full text Link to item Cite

In reply [4]

Journal Article Journal of Clinical Oncology · June 1, 2007 Full text Cite

The moving target of cancer care costs

Journal Article ONCOLOGY · June 1, 2007 Featured Publication Cite

Economics of cancer care.

Journal Article J Oncol Pract · May 2007 Featured Publication Full text Link to item Cite

The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients.

Journal Article Transfusion · April 2007 Featured Publication BACKGROUND: The scientific method requires that only experiments actually and correctly performed be used to draw conclusions. The intention-to-treat principle requires that all patients, even those not or improperly treated, be included. In clinical trial ... Full text Link to item Cite

Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.

Journal Article Cancer · March 15, 2007 Featured Publication BACKGROUND: The prognostic accuracy for distant recurrence-free survival using a 21-gene reverse-transcriptase polymerase chain reaction (RT-PCR) assay underwent validation in 668 lymph node-negative, estrogen receptor-positive women with early-stage breas ... Full text Link to item Cite

Ductal carcinoma in situ: a review of recent advances.

Journal Article Curr Opin Obstet Gynecol · February 2007 Featured Publication PURPOSE OF REVIEW: This review summarizes recent findings on ductal carcinoma in situ of the breast and their impact on prognosis and management of the disease. RECENT FINDINGS: Great advances have been made in our understanding of ductal carcinoma in situ ... Full text Link to item Cite

Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.

Journal Article J Natl Compr Canc Netw · February 2007 Featured Publication Three different practice guidelines for the myeloid growth factors were recently published by major professional organizations. A comprehensive review and comparison of the guidelines using a priori structured content criteria and a previously validated qu ... Full text Link to item Cite

Myeloid growth factors. Clinical practice guidelines in oncology.

Journal Article J Natl Compr Canc Netw · February 2007 Featured Publication Full text Link to item Cite

Preface

Journal Article Breast Cancer: Translational Therapeutic Strategies · January 29, 2007 Cite

Breast Cancer: Translational Therapeutic Strategies

Book · January 29, 2007 Considering the impact of translational breakthroughs on the early detection, diagnosis, prevention, and treatment of breast cancer, this all-encompassing guide collects cutting-edge research on the most promising strategies and agents likely to impact the ... Cite

Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy.

Journal Article J Clin Oncol · January 20, 2007 Featured Publication PURPOSE: The purpose of this study was to investigate the relationship between socioeconomic status (SES) and the use of intentionally reduced doses of chemotherapy in the adjuvant treatment of breast cancer. PATIENTS AND METHODS: Patients with breast canc ... Full text Link to item Cite

Improving Outcomes with Prophylactic Anticoagulation in Patients with Cancer: Lessons from the American Society of Clinical Oncology Guidelines

Chapter · January 1, 2007 Risk of Venous Thromboembolism in Cancer Patients The risk of venous thromboembolism (VTE) is substantially increased in cancer patients, most notably those with cancers of gastrointestinal origin (1-3). Risk factors for VTE in cancer patients also include ... Full text Cite

Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.

Journal Article Pharmacoeconomics · 2007 Featured Publication BACKGROUND: The prophylactic use of granulocyte colony-stimulating factors (G-CSFs) reduces the severity and duration of neutropenia and reduces the incidence of febrile neutropenia after cancer chemotherapy. However, the use of G-CSFs, particularly filgra ... Full text Link to item Cite

Screening mammography at 40-49 years: regret or no regret?

Journal Article Lancet · December 9, 2006 Featured Publication Full text Link to item Cite

Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.

Journal Article Breast Cancer Res Treat · December 2006 Featured Publication BACKGROUND: This retrospective study was undertaken to define risk factors for reductions in dose intensity of adjuvant chemotherapy in women with early stage breast cancer (ESBC). METHODS: A nationwide survey of 190 community oncology practices was conduc ... Full text Link to item Cite

Chemotherapy dose intensity and quality cancer care.

Journal Article Oncology (Williston Park) · December 2006 Featured Publication Myelosuppression continues to represent the major dose-limiting toxicity of cancer chemotherapy. Neutropenia and its complications, including febrile neutropenia, occur most often early in the course of treatment but are often underreported in clinical tri ... Link to item Cite

Gene expression profile assays as predictors of recurrence-free survival in early-stage breast cancer: a metaanalysis.

Journal Article Clin Breast Cancer · December 2006 Featured Publication BACKGROUND: Several investigators have reported efforts to define gene expression signatures based on prediction of survival in early-stage breast cancer. The analysis reported here reviews test performance characteristics of reported gene expression signa ... Full text Link to item Cite

O11 Hematologic toxicity in older cancer patients undergoing systemic chemotherapy

Conference Critical Reviews in Oncology/Hematology · November 2006 Full text Cite

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.

Journal Article Eur J Cancer · October 2006 Featured Publication Chemotherapy-induced neutropenia is not only a major risk factor for infection-related morbidity and mortality, but is also a significant dose-limiting toxicity in cancer treatment. Patients developing severe (grade 3/4) or febrile neutropenia (FN) during ... Full text Link to item Cite

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Journal Article J Clin Oncol · July 1, 2006 Featured Publication PURPOSE: To update the 2000 American Society of Clinical Oncology guideline on the use of hematopoietic colony-stimulating factors (CSF). UPDATE METHODOLOGY: The Update Committee completed a review and analysis of pertinent data published from 1999 through ... Full text Link to item Cite

Benefits of early intervention with erythropoiesis- stimulating proteins in chemotherapy-induced anemia.

Journal Article Oncology (Williston Park) · July 2006 Featured Publication Anemia is common in patients treated with chemotherapy for both solid and hematologic malignancies, contributing to fatigue and diminished quality of life and exposing them to the inherent risks of red blood cell transfusions. Erythropoiesis-stimulating pr ... Link to item Cite

Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials.

Journal Article Cancer Treat Rev · June 2006 Featured Publication BACKGROUND: The colony-stimulating factors (CSFs) are widely utilized to prevent neutropenic complications in both adults and children, but randomized controlled trials in the pediatric setting have reported varied results. A systematic review of the liter ... Full text Link to item Cite

Venous thromboembolism in patients with diffuse large B-cell lymphoma.

Journal Article Leuk Lymphoma · June 2006 Featured Publication We conducted a retrospective record review to determine the frequency of venous thromboembolism (VTE) in patients with diffuse large B-cell lymphoma (DLBCL). All records from 1990 to 2001 of patients with the diagnosis of DLBCL at a tertiary care hospital ... Full text Link to item Cite

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.

Journal Article Cancer · May 15, 2006 Featured Publication BACKGROUND: Hospitalization for febrile neutropenia (FN) in cancer patients is associated with considerable morbidity, mortality, and cost. The study was undertaken to better define mortality, length of stay (LOS), cost, and risk factors associated with mo ... Full text Link to item Cite

Examining the benefits of early erythropoietic intervention in patients with chemotherapy-induced anemia

Journal Article American Journal of Oncology Review · April 1, 2006 Featured Publication Cite

Thromboembolism in hospitalized neutropenic cancer patients.

Journal Article J Clin Oncol · January 20, 2006 Featured Publication PURPOSE: Cancer is associated with thrombosis, but the frequency of thromboembolism in hospitalized cancer patients receiving current chemotherapy regimens is not known. We investigated venous and arterial thromboembolism and associated outcomes in hospita ... Full text Link to item Cite

Randomized clinical trials for hematopoietic stem cell transplantation: lessons to be learned from the European experience.

Journal Article Bone Marrow Transplant · January 2006 Featured Publication We evaluated the number and characteristics of randomized controlled trials (RCTs) addressing hematopoietic stem cell transplantation (HSCT) for patients with hematological malignancies, comparing the productivity of US and Europe. A MEDLINE search was con ... Full text Link to item Cite

Burden of pancreatic cancer and disease progression: economic analysis in the US.

Journal Article Oncology · 2006 Featured Publication OBJECTIVES: The few studies that have estimated the costs of pancreatic cancer were limited by small sample sizes, geography or patient age range. Using a large nationwide claims database, this study examines the cost of pancreatic cancer beginning with in ... Full text Link to item Cite

Risks and consequences of chemotherapy-induced neutropenia.

Journal Article Clin Cornerstone · 2006 Neutropenia represents a major dose-limiting toxicity of chemotherapy and is associated with an increased risk of infection, impaired patient quality of life, and interference with the delivery of full-dose chemotherapy. These complications increase not on ... Full text Link to item Cite

Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis.

Journal Article Cancer · January 1, 2006 Featured Publication BACKGROUND: Lymphatic mapping with sentinel lymph node biopsy has the potential for reducing the morbidity associated with breast carcinoma staging. It has become a widely used technology despite limited data from controlled clinical trials. METHODS: A sys ... Full text Link to item Cite

Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review.

Journal Article Cancer · January 1, 2006 Featured Publication BACKGROUND: In recent years there has been an increasing debate regarding the benefits of initiating erythropoietic treatment in patients with cancer when anemia is still relatively mild. To address this, a systematic review of studies was conducted that a ... Full text Link to item Cite

Introduction

Journal Article Clinical Cornerstone · January 1, 2006 Full text Cite

Variation in the cost of treatment for colorectal cancer.

Conference JOURNAL OF CLINICAL ONCOLOGY · 2006 Cite

Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study.

Journal Article Cancer · December 15, 2005 Featured Publication BACKGROUND: The incidence of venous thromboembolism (VTE) is increased in cancer, but little information is available about risk factors in cancer patients on chemotherapy. METHODS: We analyzed data from a prospective, multicenter observational study to de ... Full text Link to item Cite

The challenge of systematic reviews of diagnostic and staging studies in cancer.

Journal Article Cancer Treat Rev · December 2005 Featured Publication PURPOSE: Most diagnostic and staging studies focus on test performance characteristics while others may address long term clinical outcomes such as disease-free or overall survival, quality of life or cost. However, controversy remains as to which outcomes ... Full text Link to item Cite

Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action.

Journal Article Expert Opin Biol Ther · December 2005 Granulocyte colony-stimulating factors such as filgrastim (Neupogen, Amgen, Inc.) and pegfilgrastim (Neulasta, Amgen, Inc.) are frequently used in clinical practice for the prevention of chemotherapy-induced neutropenia and its potentially life-threatening ... Full text Link to item Cite

In reply [2]

Journal Article Journal of Clinical Oncology · December 1, 2005 Full text Cite

Length of stay and mortality associated with febrile neutropenia among children with cancer.

Journal Article J Clin Oncol · November 1, 2005 Featured Publication PURPOSE: The aim of this study was to evaluate risk factors for longer length of stay (los) and mortality among hospitalized children with cancer who have febrile neutropenia. METHODS: This study involved analysis of longitudinal data from the University H ... Full text Link to item Cite

American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer.

Journal Article J Clin Oncol · October 20, 2005 Featured Publication PURPOSE: To develop a guideline for the use of sentinel node biopsy (SNB) in early stage breast cancer. METHODS: An American Society of Clinical Oncology (ASCO) Expert Panel conducted a systematic review of the literature available through February 2004 on ... Full text Link to item Cite

Time is money for both the healthy and the sick.

Journal Article Med Care · July 2005 Featured Publication Full text Link to item Cite

Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence.

Journal Article J Natl Compr Canc Netw · July 2005 Featured Publication The prophylactic use of myeloid growth factors reduces the risk of chemotherapy-induced neutropenia and its complications, including febrile neutropenia and infection-related mortality. Perhaps most importantly, the prophylactic use of colony-stimulating f ... Full text Link to item Cite

Myeloid growth factors clinical practice guidelines in oncology.

Journal Article J Natl Compr Canc Netw · July 2005 Featured Publication Full text Link to item Cite

Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials.

Journal Article J Clin Oncol · June 20, 2005 Featured Publication PURPOSE: Current treatment for febrile neutropenia (FN) includes hospitalization for evaluation, empiric broad-spectrum antibiotics, and other supportive care. Clinical trials have reported conflicting results when studying whether the colony-stimulating f ... Full text Link to item Cite

Undertreatment of obese women receiving breast cancer chemotherapy.

Journal Article Arch Intern Med · June 13, 2005 Featured Publication BACKGROUND: Systematic undertreatment of breast cancer in overweight and obese women may contribute to the poorer prognosis in these women. The objective of this study was to investigate treatment patterns in overweight and obese women undergoing breast ca ... Full text Link to item Cite

Use of re-randomized data in meta-analysis.

Journal Article BMC Med Res Methodol · May 10, 2005 BACKGROUND: Outcomes collected in randomized clinical trials are observations of random variables that should be independent and identically distributed. However, in some trials, the patients are randomized more than once thus violating both of these assum ... Full text Link to item Cite

Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.

Journal Article Am J Manag Care · May 2005 Featured Publication OBJECTIVE: To appraise the economics of a recurrence score (RS), based on an assay that predicts distant recurrence-free survival in lymph-node-negative (LN-), estrogen-receptor-positive (ER+) patients with early-stage breast cancer receiving tamoxifen. ST ... Link to item Cite

The strengths and limitations of meta-analyses based on aggregate data.

Journal Article BMC Med Res Methodol · April 25, 2005 BACKGROUND: Properly performed systematic reviews and meta-analyses are thought by many to represent among the highest level of evidence addressing important clinical issues. Few would disagree that meta-analyses based on individual patient data (IPD) offe ... Full text Link to item Cite

A primer in prognostic and predictive models: development and validation of neutropenia risk models.

Journal Article Support Cancer Ther · April 1, 2005 Featured Publication Prognostic or risk models can be used to identify risk factors that are associated with the outcome of interest or to accurately predict response to therapy. Increasingly, such models are playing a role in clinical oncology when selecting patients for more ... Full text Link to item Cite

Economic analysis of prophylactic pegfilgrastim in cancer patients receiving chemotherapy

Journal Article Journal of Supportive Oncology · March 1, 2005 Cite

The economic burden of anemia in cancer patients receiving chemotherapy.

Journal Article Value Health · 2005 BACKGROUND: Anemia is one of the most common hematologic complications of cancer and cytotoxic treatment. The economic burden associated with anemia in patients with malignancy has not yet been extensively studied. METHODS: Patients receiving chemotherapy ... Full text Link to item Cite

Hemopoiesis and aging.

Journal Article Cancer Treat Res · 2005 Full text Link to item Cite

Risk models for predicting chemotherapy-induced neutropenia.

Journal Article Oncologist · 2005 Neutropenia and its complications, including febrile neutropenia, are major dose-limiting toxicities of systemic cancer chemotherapy. A number of studies have attempted to identify risk factors for neutropenia and its consequences to develop predictive mod ... Full text Link to item Cite

Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.

Journal Article Value Health · 2005 Featured Publication OBJECTIVES: Febrile neutropenia (FN) in patients with cancer treated with chemotherapy has traditionally been managed with inpatient broad-spectrum antibiotics until the infection and neutropenia have resolved. A newer strategy is outpatient oral or intrav ... Full text Link to item Cite

The impact of anaemia and its treatment on employee disability and medical costs.

Journal Article Pharmacoeconomics · 2005 OBJECTIVE: Anaemia is a common haematological complication of cancer and cytotoxic treatment. The incremental economic burden associated with medical care and short-term disability of anaemia in patients with malignancy and receiving chemotherapy has not b ... Full text Link to item Cite

Moving beyond febrile neutropenia.

Journal Article Support Cancer Ther · January 1, 2005 Full text Link to item Cite

The colony-stimulating factors: use to prevent and treat neutropenia and its complications.

Journal Article Expert Opin Biol Ther · December 2004 The colony-stimulating factors (CSFs) represent the only biological response modifiers used in clinical practice to treat or prevent neutropenia. These pleiotropic cytokines are available in clinical practice as granulocyte CSF (G-CSF), granulocyte-macroph ... Full text Link to item Cite

Economic Analysis of Prophylactic Pegfilgrastim in Cancer Patients Receiving Chemotherapy.

Conference Blood · November 16, 2004 AbstractIntroduction: Neutropenia and its complications are major dose-limiting toxicities of systemic cancer chemotherapy. Febrile neutropenia (FN) generally prompts immediate hospitalization for evaluation ... Full text Cite

Prophylactic Colony-Stimulating Factors in Pediatric Patients Receiving Myelosuppressive Chemotherapy: A Meta-Analysis of Randomized Controlled Trials.

Conference Blood · November 16, 2004 AbstractBackground: The colony-stimulating factors (CSFs) are widely utilized to prevent neutropenic complications in both adults and children, but randomized controlled trials in the pediatric setting have ... Full text Cite

Hematopoietic Stem Cell Transplantation Phase III Clinical Trials for Patients with Hematological Malignancies in the US: Lessons To Be Learned from the European Experience.

Conference Blood · November 16, 2004 Introduction: Evidence-based medicine defines standard therapies primarily from Phase III randomized controlled trials (RCT), when available. In this report we examined trends in ther number and characteristics of phase III RCT addressing the manag ... Full text Cite

Assessment of Clinical Outcomes Following Erythropoietic Intervention at a Hemoglobin Concentration above 10 g/dL: A Comprehensive Review of Recent Literature.

Conference Blood · November 16, 2004 AbstractCurrent practice guidelines for the management of chemotherapy-induced anemia (CIA) recommend initiating erythropoietic intervention at hemoglobin (Hb) ≤ 10 g/dL (American Society of Hematology [ASH] ... Full text Cite

First Cycle Risk of Severe and Febrile Neutropenia in Cancer Patients Receiving Systemic Chemotherapy: Results from a Prospective Nationwide Study.

Conference Blood · November 16, 2004 AbstractIntroduction: Myelosuppression represents the major dose-limiting toxicity of cancer chemotherapy. This prospective, nationwide study was undertaken to better define risk of neutropenia and its compl ... Full text Cite

Validation of a Risk Model for Hospitalized Adult Cancer Patients with Febrile Neutropenia.

Conference Blood · November 16, 2004 AbstractIntroduction: Febrile neutropenia (FN) represents the most common dose-limiting toxicity associated with systemic chemotherapy and is associated with considerable morbidity and mortality. The majorit ... Full text Cite

Thromboembolism in Hospitalized Neutropenic Cancer Patients.

Conference Blood · November 16, 2004 AbstractBackground: Cancer is associated with thrombosis, but the frequency of thromboembolism in hospitalized cancer patients receiving contemporary chemotherapy regimens is not known. We investigated the f ... Full text Cite

Gene Expression Profile Signatures to Predict Survival in Diffuse Large B-Cell Lymphoma: A Meta-Analysis of Early Results.

Conference Blood · November 16, 2004 AbstractBackground: Diffuse large B-cell lymphoma (DLBCL) represents the most common lymphoma in adults. Although responsive to chemotherapy, less than half of patients are currently cured. In an effort to b ... Full text Cite

Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.

Journal Article J Clin Oncol · November 1, 2004 PURPOSE: To assess the incidence of and risk factors for reduced relative dose-intensity (RDI) in patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). METHODS: A nationwide survey was conducted of 567 oncology practices with data ... Full text Link to item Cite

Benefits of GM-CSF Versus Placebo or G-CSF in Reducing Chemotherapy-Induced Complications: A Systematic Review of the Literature.

Journal Article Support Cancer Ther · October 1, 2004 Unlike granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF) is not approved for reducing the incidence or duration of chemotherapy-induced febrile neutropenia. However, some studies have been conducted in ... Full text Link to item Cite

Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches.

Journal Article Support Care Cancer · August 2004 Despite advances in the treatment of many side effects associated with chemotherapy, alopecia remains an issue that is difficult to resolve. Chemotherapy-induced alopecia (CIA) is a condition that can have profound psychosocial and quality-of-life conseque ... Full text Link to item Cite

A Southwest Oncology Group Randomized Phase II Study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer.

Journal Article Breast Cancer Res Treat · May 2004 PURPOSE: To evaluate whether the high complete response (CR) rates for the combination of doxorubicin and paclitaxel in metastatic breast cancer observed in two European studies could be replicated in a multi-institutional cooperative group trial. PATIENTS ... Full text Link to item Cite

The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia.

Journal Article Crit Rev Oncol Hematol · May 2004 Healthcare costs continue to rise with hospitalization representing the single largest component of direct medical costs associated with cancer care. Neutropenia and its complications including febrile neutropenia remain the major dose-limiting toxicity as ... Full text Link to item Cite

Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy.

Journal Article Pharmacotherapy · April 2004 STUDY OBJECTIVES: Previous studies have used direct hospital costs to determine the threshold at which the cost of prophylactic use of colony-stimulating factor (CSF) is offset by savings from the lower risk of hospitalization for febrile neutropenia. By c ... Full text Link to item Cite

Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.

Journal Article Cancer · January 15, 2004 Cytotoxic chemotherapy suppresses the hematopoietic system, impairing host protective mechanisms and limiting the doses of chemotherapy that can be tolerated. Neutropenia, the most serious hematologic toxicity, is associated with the risk of life-threateni ... Full text Link to item Cite

Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries.

Journal Article Am J Med · January 1, 2004 PURPOSE: To assess physician use of erythropoietin in cancer patients before publication of the American Society of Clinical Oncology/American Society of Hematology guidelines. METHODS: Questionnaires about erythropoietin use in practice and 12 hypothetica ... Full text Link to item Cite

Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.

Journal Article J Clin Oncol · December 15, 2003 PURPOSE: This retrospective study was undertaken to assess practice patterns in adjuvant chemotherapy for early-stage breast cancer (ESBC) and to define the incidence and predictive factors of reduced relative dose-intensity (RDI). PATIENTS AND METHODS: A ... Full text Link to item Cite

Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy.

Journal Article Leuk Lymphoma · December 2003 We sought to identify risk factors associated with the time to febrile neutropenia in patients with intermediate-grade, non-Hodgkin's lymphoma (NHL) who were receiving treatment with CHOP chemotherapy. Data were collected from 12 community and academic onc ... Full text Link to item Cite

Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.

Journal Article Cancer · December 1, 2003 BACKGROUND: Hospitalization for chemotherapy-induced febrile neutropenia is associated with substantial cost and may negatively impact clinical outcome due to associated dose attenuation. METHODS: Medical records of 1355 patients with intermediate-grade no ... Full text Link to item Cite

Introduction. Neutropenia risk models in oncology.

Journal Article Oncology (Williston Park) · November 2003 Link to item Cite

Risk assessment in oncology clinical practice. From risk factors to risk models.

Journal Article Oncology (Williston Park) · November 2003 Myelosuppression and neutropenia represent the major dose-limiting toxicity of cancer chemotherapy. Chemotherapy-induced neutropenia may be accompanied by fever, presumably due to life-threatening infection, which generally requires hospitalization for eva ... Link to item Cite

Cost effectiveness of myeloid growth factors in cancer chemotherapy.

Journal Article Curr Hematol Rep · November 2003 Healthcare costs continue to rise and hospitalization represents the single largest component of direct medical costs associated with cancer care. Neutropenia and its complications, including febrile neutropenia (FN), remain the major dose-limiting toxicit ... Link to item Cite

Delivering optimal adjuvant chemotherapy in primary breast cancer: The role of rHuG-CSF

Journal Article European Journal of Cancer, Supplement · November 1, 2003 Most patients with operable breast cancer now receive postoperative medical treatment in the form of adjuvant chemotherapy, hormone manipulation or both. These additional interventions have led to a significant improvement in disease-free survival and over ... Full text Cite

Epidemiology of febrile neutropenia.

Journal Article Support Cancer Ther · October 1, 2003 Febrile neutropenia (FN) continues to represent a major cause of morbidity, mortality, and cost in patients receiving cancer chemotherapy. The reported rates of FN vary considerably among studies depending on the treatment regimen, delivered dose intensity ... Full text Link to item Cite

The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: an observational study.

Journal Article BMC Nurs · September 19, 2003 BACKGROUND: Quality of life may be affected by daily injections of supportive hematopoietic growth factor medication, which is frequently required by patients with cancer undergoing chemotherapy. The objective of the study was to identify areas where long- ... Full text Link to item Cite

The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: An observational study

Journal Article BMC Nursing · September 19, 2003 Background: Quality of life may be affected by daily injections of supportive hematopoietic growth factor medication, which is frequently required by patients with cancer undergoing chemotherapy. The objective of the study was to identify areas where long- ... Full text Cite

Survival after HLA-identical allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: meta-analysis of randomized controlled trials.

Journal Article Bone Marrow Transplant · August 2003 The impact of peripheral blood stem cell transplantation (PBSCT) on survival relative to bone marrow transplantation (BMT) remains poorly defined. Several randomized controlled trials (RCTs) comparing HLA-matched related PBSC- and BMT for patients with hem ... Full text Link to item Cite

Balancing the benefits and costs of colony-stimulating factors: a current perspective.

Journal Article Semin Oncol · August 2003 Neutropenia is the most common dose-limiting toxicity associated with cancer chemotherapy. Neutropenic complications, including febrile neutropenia, occur in a substantial proportion of patients with chemotherapy-induced neutropenia. Although neutropenia a ... Full text Link to item Cite

Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials.

Journal Article J Natl Compr Canc Netw · July 2003 Delivery of cancer chemotherapy is often limited by myelotoxicity, primarily neutropenia. As part of an effort to create a model to predict the risk of chemotherapy-induced neutropenia, we reviewed the reports of randomized clinical trials with more than 5 ... Full text Link to item Cite

Evidence-based oncology in cancer treatment reviews.

Journal Article Cancer Treat Rev · February 2003 Full text Link to item Cite

Colony stimulating factors for chemotherapy induced febrile neutropenia.

Journal Article Cochrane Database Syst Rev · 2003 BACKGROUND: Febrile neutropenia is a frequent event for cancer patients undergoing chemotherapy and it is potentially a life threatening situation. The current treatment is supportive care plus antibiotics. Colony stimulating factors (CSF) are cytokines th ... Full text Link to item Cite

Evidence-based use of colony-stimulating factors in elderly cancer patients.

Journal Article Cancer Control · 2003 BACKGROUND: Neutropenia and its complications represent the major dose-limiting toxicity of cancer chemotherapy, especially in the elderly. Hematopoietic growth factors have been shown to reduce the severity and duration of febrile neutropenia (FN) and to ... Full text Link to item Cite

Balancing the benefits and costs of colony-stimulating factors: A current perspective

Journal Article Seminars in Oncology · 2003 Neutropenia is the most common dose-limiting toxicity associated with cancer chemotherapy. Neutropenic complications, including febrile neutropenia, occur in a substantial proportion of patients with chemotherapy-induced neutropenia. Although neutropenia a ... Cite

G-CSF as prophylaxis of febrile neutropenia in SCLC.

Journal Article Expert Opin Pharmacother · September 2002 OBJECTIVES: In 1991, small cell lung cancer (SCLC) was reported as the first tumour type where colony stimulating factor (CSF) support was clinically effective. We reviewed 13 health services research studies that addressed CSF use as supportive care for S ... Full text Link to item Cite

Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients.

Journal Article Curr Opin Hematol · May 2002 Health care costs continue to rise, and hospitalization represents the single largest component of direct medical costs associated with cancer care. Neutropenia and its complications including febrile neutropenia (FN) remain the major dose-limiting toxicit ... Full text Link to item Cite

Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis.

Journal Article Am J Med · April 1, 2002 PURPOSE: Several studies have evaluated the efficacy of the recombinant colony-stimulating factors in reducing the severity and duration of neutropenia and the risk of infection associated with dose-intensive cancer chemotherapy. We performed a meta-analys ... Full text Link to item Cite

Filgrastim in patients with neutropenia: potential effects on quality of life.

Journal Article Drugs · 2002 Treatment- and disease-related neutropenia are associated with a number of negative clinical effects such as febrile neutropenia, documented infection, hospitalisation for infection-related morbidity, infection-related mortality, and decreased ability to a ... Full text Link to item Cite

Evaluation and appraisal of randomized controlled trials in myeloma.

Journal Article Ann Oncol · November 2001 PURPOSE: To critically appraise therapeutic innovations tested in randomized controlled trials (RCTs) in multiple myeloma from 1966-1998. DESIGN: We performed a comprehensive search to identify published RCTs in multiple myeloma. Quality dimensions of the ... Full text Link to item Cite

Economic analysis of randomized, controlled trials.

Journal Article Curr Oncol Rep · September 2001 To facilitate the comparison of different treatment strategies, measures have been developed that bring together clinical, quality-of-life, and economic outcomes into summary measures such as the quality-adjusted life year, cost-effectiveness, and cost-uti ... Full text Link to item Cite

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

Journal Article J Clin Oncol · August 15, 2001 PURPOSE: The American Joint Committee on Cancer (AJCC) recently proposed major revisions of the tumor-node-metastases (TNM) categories and stage groupings for cutaneous melanoma. Thirteen cancer centers and cancer cooperative groups contributed staging and ... Full text Link to item Cite

Hematopoietic growth factors in the older cancer patient.

Journal Article Curr Opin Hematol · May 2001 Aging is associated with a progressive decline in the functional reserve of multiple organ systems, which may lead to enhanced susceptibility to stress such as that caused by cancer chemotherapy. Myelodepression is the most common and the most commonly fat ... Full text Link to item Cite

The effects of postinjection massage on the sensitivity of lymphatic mapping in breast cancer.

Journal Article J Am Coll Surg · January 2001 BACKGROUND: The technique of lymphatic mapping and sentinel lymph node (SLN) biopsy is rapidly becoming the preferred method of staging the axilla of the breast cancer patient. This report describes the impact of postinjection massage on the sensitivity of ... Full text Link to item Cite

Understanding economic analyses

Journal Article Evidence-based Oncology · January 1, 2001 Full text Cite

Use of colony-stimulating factors in the elderly cancer patient

Journal Article Oncology Spectrums · January 1, 2001 Cancer is, in large part, a disease of aging. The progressive decline with age in the functional reserve of specific organs including bone marrow may limit the ability of elderly cancer patients to tolerate treatment. Myelosuppression with neutropenia rema ... Cite

Industry-sponsored research

Journal Article The Lancet · December 2000 Full text Cite

The uncertainty principle and industry-sponsored research.

Journal Article Lancet · August 19, 2000 BACKGROUND: Reporting of pharmaceutical-industry-sponsored randomised clinical trials often result in biased findings, either due to selective reporting of studies with non-equivalent arms or publication of low-quality papers, wherein unfavourable results ... Full text Link to item Cite

Quality of life after adjuvant chemotherapy for breast cancer.

Journal Article Breast Cancer Res Treat · July 2000 PURPOSE: To evaluate the quality of life of breast cancer patients previously treated with adjuvant chemotherapy. METHOD: Registry data were used to recruit a sample of breast cancer patients (N = 61; mean age = 51.6 years) with no current evidence of dise ... Full text Link to item Cite

A predictive model for neutropenia associated with cancer chemotherapy.

Journal Article Pharmacotherapy · July 2000 Studies of primary prophylaxis of febrile neutropenia (FN) with recombinant human granulocyte colony-stimulating factor (rHu-G-CSF, filgrastim) administered to all patients starting their initial course of chemotherapy have demonstrated clinical effectiven ... Full text Link to item Cite

Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma.

Journal Article Ann Surg · June 2000 OBJECTIVE: To determine the clinical significance of a molecular assay based on the reverse transcriptase polymerase chain reaction (RT-PCR) for the presence of micrometastatic melanoma cells in sentinel lymph nodes (SLNs). SUMMARY BACKGROUND DATA: Routine ... Full text Link to item Cite

Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer.

Journal Article J Pain Symptom Manage · June 2000 Hot flashes are among the most commonly reported symptoms among women who have completed treatment for breast cancer. Relatively little is known, however, about hot flashes among women while they are undergoing breast cancer treatment. The present study in ... Full text Link to item Cite

Evidentiary challenges to evidence-based medicine.

Journal Article J Eval Clin Pract · May 2000 The evidence-based medicine (EBM) movement has exerted a strong influence on contemporary medicine. It has been used to define the hierarchy of knowledge in clinical medicine by classifying clinical findings according to the perceived relevance and validit ... Full text Link to item Cite

A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care.

Journal Article Eur J Cancer · April 2000 Studies of primary prophylaxis of febrile neutropenia with recombinant granulocyte colony-stimulating factor (r-metHuG-CSF, filgrastim), administered to all patients starting with the initial course of chemotherapy, have demonstrated an economic advantage ... Full text Link to item Cite

What threshold for adjuvant therapy in older breast cancer patients?

Journal Article J Clin Oncol · April 2000 PURPOSE: To consider the question of when to prescribe adjuvant treatment for elderly breast cancer patients, particularly when comorbidities are present. Knowledge of the threshold relapse risks above which adjuvant treatment is worth prescribing would en ... Full text Link to item Cite

Quality of life after coronary angioplasty or continued medical treatment for angina: three-year follow-up in the RITA-2 trial. Randomized Intervention Treatment of Angina.

Journal Article J Am Coll Cardiol · March 15, 2000 OBJECTIVES: We sought to evaluate the impact of percutaneous transluminal coronary angioplasty (PTCA) and medical treatment on self-perceived quality of life among patients with angina. BACKGROUND: The second Randomized Intervention Treatment of Angina tri ... Full text Link to item Cite

Linking evidence-based medicine therapeutic summary measures to clinical decision analysis.

Journal Article MedGenMed · January 13, 2000 OBJECTIVE: Evidence-based medicine (EBM) seeks to improve clinical practice by evaluating the quality of clinical evidence and ensuring that only the "best" evidence from clinical research is used in the management of individual patients. EBM has contribut ... Link to item Cite

Talking about treatment.

Journal Article Ann Intern Med · January 4, 2000 Full text Link to item Cite

Talking about treatment.

Journal Article Ann Intern Med · January 4, 2000 Full text Link to item Cite

Lymphatic mapping and sentinel lymph node biopsy in patients with breast cancer.

Journal Article Annu Rev Med · 2000 The standard of care for the evaluation of axillary nodal involvement remains complete lymph node dissection. Lymphatic mapping and sentinel lymph node (SLN) biopsy are changing this long-held paradigm; indeed, several leading institutions already reserve ... Full text Link to item Cite

Hemopoietic reserve in the older cancer patient: clinical and economic considerations.

Journal Article Cancer Control · 2000 BACKGROUND: Older individuals are at increased risk for myelosuppression, the most common complication of cytotoxic chemotherapy. Causes include reduction in hemopoietic stem cell reserve, increased prevalence of chronic diseases, and increased prevalence ... Full text Link to item Cite

A predictive model for neutropenia associated with cancer chemotherapy

Journal Article Pharmacotherapy · 2000 Studies of primary prophylaxis of febrile neutropenia (FN) with recombinant human granulocyte colony-stimulating factor (rHu-G-CSF, filgrastim) administered to all patients starting their initial course of chemotherapy have demonstrated clinical effectiven ... Cite

Understanding treatment benefits and harms

Journal Article Evidence-based Oncology · January 1, 2000 Full text Cite

Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates.

Journal Article J Pain Symptom Manage · October 1999 This study investigated the characteristics, course, and correlates of fatigue in women receiving adjuvant chemotherapy for breast cancer. Fifty-four patients were assessed before the start of chemotherapy and during the first three treatment cycles. An ag ... Full text Link to item Cite

Lymphatic Mapping and Sentinel Lymph Node Biopsy.

Journal Article Breast J · September 1999 The status of the regional nodal basin remains the most important prognostic indicator of survival. The current standard of care for the management of invasive breast cancer is the complete removal of the tumor, with documentation of negative margins by ei ... Full text Link to item Cite

Cutaneous lymphatic drainage in patients with grossly involved nodal basins.

Journal Article Ann Surg Oncol · June 1999 BACKGROUND: The development of lymphatic mapping techniques has facilitated the identification of the sentinel lymph node (SLN), the first node in the regional basin into which cutaneous lymphatics flow from a particular skin area. Previous studies have sh ... Full text Link to item Cite

Update of the economic analyses of the use of the colony-stimulating factors.

Journal Article Curr Opin Hematol · May 1999 The colony-stimulating factors have been used effectively in a variety of clinical settings to prevent febrile neutropenia and to assist patients receiving dose-intensive chemotherapy with or without stem cell support. Several studies have confirmed the cl ... Full text Link to item Cite

The effects of NSAIDs on breast cancer prognostic factors.

Journal Article Oncol Rep · 1999 There are several risk factors involved in the pathogenesis of breast cancer. The role of non-steroidal anti-inflammatory drugs (NSAIDs) in the development of breast cancer has not been fully clarified. In order to investigate the impact of NSAIDs ingestio ... Link to item Cite

The economics of febrile neutropenia: implications for the use of colony-stimulating factors.

Journal Article Eur J Cancer · November 1998 The occurrence of fever and neutropenia following cancer chemotherapy generally prompts hospitalisation for evaluation and treatment. Colony-stimulating factors (CSFs) have been shown to reduce the risk of febrile neutropenia (FN) and the need for hospital ... Full text Link to item Cite

Molecular staging of malignant melanoma: correlation with clinical outcome.

Journal Article JAMA · October 28, 1998 CONTEXT: For most solid tumors, the metastatic status of regional lymph nodes is the strongest predictor of relapse and survival. However, routine pathological examination of lymph nodes may underestimate the number of patients with melanoma who have nodal ... Full text Link to item Cite

Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer.

Journal Article Ann Surg Oncol · September 1998 BACKGROUND: Controversies over the frequency and intensity of the follow-up care of breast cancer patients exist. Some physicians have adopted an intensive approach to follow-up care that consists of frequent laboratory tests and routine imaging studies, i ... Full text Link to item Cite

Economic impact of granulopoiesis stimulating agents on the management of febrile neutropenia.

Journal Article Curr Opin Oncol · July 1998 The granulopoiesis-stimulating agents (GSAs) have been effectively utilized in a variety of fashions to treat or prevent febrile neutropenia or to assist patients receiving dose-intensive chemotherapy with or without stem cell support. The high cost of the ... Full text Link to item Cite

Efficacy of hyperthermic isolated limb perfusion for extremity-confined recurrent melanoma.

Journal Article Ann Surg Oncol · June 1998 BACKGROUND: Recurrent melanoma of the extremity has been treated by local excision, systemic chemotherapy, amputation, or a combination of these approaches. Hyperthermic isolated limb perfusion (HILP) provides a method of limb preservation through isolatio ... Full text Link to item Cite

Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer.

Journal Article Ann Surg · May 1998 OBJECTIVE: To define preliminary guidelines for the use of lymphatic mapping techniques in patients with breast cancer. SUMMARY BACKGROUND DATA: Lymphatic mapping techniques have the potential of changing the standard of surgical care of patients with brea ... Full text Link to item Cite

Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer.

Journal Article J Clin Oncol · May 1998 PURPOSE: Clinical reports suggest that many breast cancer patients experience persistent fatigue as a long-term side effect of adjuvant chemotherapy treatment. To investigate this issue further, we examined the characteristics and correlates of fatigue in ... Full text Link to item Cite

Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory.

Journal Article Qual Life Res · May 1998 Although fatigue is one of the most common and debilitating symptoms experienced by cancer patients, it has received little systematic attention. This situation is due in large part to the lack of adequate instruments to measure fatigue. The primary aim of ... Full text Link to item Cite

Comorbidity and functional status are independent in older cancer patients.

Journal Article J Clin Oncol · April 1998 PURPOSE: Comorbidity is a frequent and often therapeutically limiting problem in older cancer patients. However, to date, there is no standard measure of the comorbidity burden available for these patients. We tested the performance of two comorbidity scal ... Full text Link to item Cite

Methodological challenges in the evaluation of prognostic factors in breast cancer.

Journal Article Breast Cancer Res Treat · 1998 Many studies are carried out in an effort to find factors that help explain the large unexplained variation in prognosis of breast cancer patients. The principles of good study design and analysis are less well appreciated for prognostic factor studies tha ... Full text Link to item Cite

Estimated blood loss in group O as compared to non-group O radical prostatectomy patients

Journal Article Hematology · January 1, 1998 Background and objectives: Blood group O individuals have been shown to have lower levels of von Willebrand factor (vWF). It is not known if these differences are associated with an increased bleeding risk. We retrospectively assessed estimated blood loss ... Full text Cite

Cytologic evaluation of lumpectomy margins in patients with ductal carcinoma in situ: clinical outcome.

Journal Article Ann Surg Oncol · December 1997 BACKGROUND: Breast conservation therapy is controversial for ductal carcinoma in situ (DCIS) due to recently reported high recurrence rates. We believe that cytologic evaluation of lumpectomy margins improves efficiency and leads to a lower recurrence rate ... Full text Link to item Cite

A Primer for Evaluating Clinical Trials.

Journal Article Cancer Control · October 1997 BACKGROUND: Evidence-based medicine demands the use of information from clinical trials to direct medical care. Knowledge of the principles of trial design and conduct is important to assess the validity of results. METHODS: The authors review the key prin ... Full text Link to item Cite

Sentinel lymph node biopsy in melanoma of the head and neck.

Journal Article Plast Reconstr Surg · September 1997 BACKGROUND: The sentinel lymph node is the first node or nodes to drain a cutaneous melanoma. Sentinel lymph node biopsy is performed to determine whether regional metastases are present. The authors' experience with the new technique of sentinel lymph nod ... Full text Link to item Cite

Menopausal Status and the Impact of Early Recurrence on Breast Cancer Survival.

Journal Article Cancer Control · July 1997 BACKGROUND: Breast cancer represents the leading form of invasive cancer among American women, killing nearly 50,000 annually. Several prognostic factors that are associated with survival include age, race, menopausal status, and the stage of disease at pr ... Full text Link to item Cite

Weight gain associated with adjuvant tamoxifen therapy in stage I and II breast cancer: fact or artifact?

Journal Article Breast Cancer Res Treat · June 1997 There is a perception that tamoxifen causes weight gain in breast cancer patients. The purpose of this research study was to determine if weight gain is associated with tamoxifen therapy and to observe the impact of weight gain on recurrence and survival. ... Full text Link to item Cite

The Role of Selective Lymphadenectomy in Breast Cancer.

Journal Article Cancer Control · May 1997 BACKGROUND: Axillary node dissection is considered a standard staging procedure in patients with breast cancer. The procedure is associated with significant morbidity and provides pathologists with many lymph nodes to evaluate. METHODS: A total of 174 wome ... Full text Link to item Cite

Investment in new technology research can save future health care dollars.

Journal Article J Fla Med Assoc · March 1997 OBJECTIVE: To perform a cost analysis of the emerging technology of lymphatic mapping for patients with malignant melanoma. DESIGN: A retrospective, computer-aided chart and financial cost and charge review of consecutive patients with the diagnosis of mel ... Link to item Cite

Cancer in the elderly. Epidemiologic and clinical implications.

Journal Article Clin Geriatr Med · February 1997 Cancer is a major problem for the older population. The incidence of most malignancies increases with age, with cancer being the second most common cause of death in persons older than 65. With the decline in deaths related to cardiovascular diseases, canc ... Link to item Cite

Bilaterality and recurrence rates for lobular breast cancer: considerations for treatment.

Journal Article Ann Surg Oncol · 1997 BACKGROUND: The purpose of this study was to evaluate the tumor biology with respect to bilaterality and recurrence rates for bilateral infiltrating lobular (IL) breast carcinoma in comparison with other histological types. METHODS: A prospectively accrued ... Full text Link to item Cite

Importance of race on breast cancer survival.

Journal Article Ann Surg Oncol · January 1997 Featured Publication BACKGROUND: Breast cancer survival has been shown to be significantly less among black women than white women. The reason for this difference in survival is unclear. METHODS: Data were obtained retrospectively on 439 women seen between 1985 and 1993 based ... Full text Link to item Cite

Lymphatic mapping and sentinel node biopsy in the patient with breast cancer.

Journal Article JAMA · December 11, 1996 Featured Publication OBJECTIVES: To identify the sentinel lymph node(s) (SLN[s]) (the first node[s] draining the primary tumor in the regional lymphatic basin) in patients with invasive breast cancer and to test the hypothesis that the histologic characteristics of the SLN pre ... Link to item Cite

Evaluation of new putative tumor markers for melanoma.

Journal Article Ann Surg Oncol · November 1996 Featured Publication BACKGROUND: The early diagnosis of recurrent melanoma can contribute to better outcome if the disease can be surgically resected or if the metastases are responsive to systemic therapies. Lipid-associated sialic acid (LASA-P) and the S-100 protein (S-100) ... Full text Link to item Cite

Use of G-CSF to Sustain Dose Intensity in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Pilot Study.

Journal Article Cancer Control · November 1996 Featured Publication BACKGROUND: Adjuvant chemotherapy for breast cancer is frequently accompanied by neutropenia requiring dose reduction or treatment delay that can potentially compromise therapeutic effectiveness. Recombinant granulocyte-colony stimulating factor (G-CSF) re ... Link to item Cite

Optimal duration of adjuvant tamoxifen treatment in elderly breast cancer patients: Influence of age, comorbidities, and various effectiveness hypotheses on life-expectancy and cost

Journal Article Breast Disease · November 1, 1996 Featured Publication The aim of this study was to explore the effects of the duration of adjuvant tamoxifen on life-expectancy of elderly patients with breast cancer and to study the cost-effectiveness of prolonging tamoxifen treatment. Our data sources were the medical litera ... Cite

Age and the Risk of Breast Cancer Recurrence.

Journal Article Cancer Control · October 1996 Featured Publication BACKGROUND: Various parameters assist in the definition of prognosis and in the choice of therapy for breast cancer. This study evaluates the effects of prognostic factors on disease outcome in elderly women. METHODS: A retrospective cohort analysis was pe ... Link to item Cite

Patients' attitudes regarding out-of-hospital blood transfusion.

Journal Article Transfusion · February 1996 Featured Publication BACKGROUND: While the administration of blood transfusions outside of the hospital has become more prevalent, little is known about patients' attitudes regarding this practice. STUDY DESIGN AND METHODS: Twenty-nine adult patients who regularly received blo ... Full text Link to item Cite

Management of cancer in the aged.

Journal Article Compr Ther · February 1996 Featured Publication Link to item Cite

Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma.

Journal Article Ann Surg · February 1996 Featured Publication BACKGROUND: The sentinel lymph node (SLN), the first node draining the primary tumor site, has been shown to reflect the histologic features of the remainder of the lymphatic basin in patients with melanoma. Intraoperative localization of the SLN, first pr ... Full text Link to item Cite

The tumor biology of melanoma nodal metastases.

Journal Article Am Surg · January 1996 Featured Publication Approximately 20 per cent of melanomas greater than 0.76 mm in thickness will metastasize to the regional lymph nodes if treated with wide local excision alone (WLE). Elective lymph node dissection (ELND) is associated with significant morbidity, which inc ... Link to item Cite

The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly.

Journal Article Cancer · November 1, 1995 Featured Publication BACKGROUND: Studies indicate that the incidence of primary malignant brain tumors in the elderly is increasing, but this may reflect increased case ascertainment due to the introduction of computed tomography (CT) scanning. In addition, tumor histology was ... Full text Link to item Cite

A cost analysis of hematopoietic colony-stimulating factors.

Journal Article Oncology (Williston Park) · November 1995 Featured Publication The administration of hematopoietic colony-stimulating factors (CSFs) to reduce the severity and duration of neutropenia associated with systemic chemotherapy has become widespread, although the appropriate use of these agents has not yet been fully define ... Link to item Cite

Timing of weight gain and breast cancer risk.

Journal Article Cancer · July 15, 1995 Featured Publication BACKGROUND: Obesity and body-fat distribution have been associated with the incidence of breast and endometrial cancers. It may be critical to determine if the timing of weight gain during periods of hormonal change, such as menarche, pregnancy, or menopau ... Full text Link to item Cite

Increasing Incidence of Primary Brain Tumors in the Elderly in Florida.

Journal Article Cancer Control · July 1995 Featured Publication Based on data from the Florida Cancer Data System for the periods from 1981 through 1984 and 1986 through 1989, the incidence of primary malignant brain tumors in those aged 65 years or older rose steadily. The incidence of primary brain tumors in elderly ... Link to item Cite

The identification and mapping of melanoma regional nodal metastases: minimally invasive surgery for the diagnosis of nodal metastases.

Journal Article Am Surg · February 1995 Featured Publication The most controversial part of melanoma surgical care involves the role of elective lymph node dissection (ELND). Whereas proponents cite retrospective studies demonstrating the ability to control regional metastases and more accurate staging, opponents ci ... Link to item Cite

Non‐Operative Observation of Mammographic Abnormalities: Medical Legal Implications

Journal Article The Breast Journal · January 1, 1995 Featured Publication Abstract: Delay in breast cancer diagnosis continues to account for the highest percentage of medical malpractice cases. Two papers were reviewed concerning palpation and mammo‐graphic thresholds of detection and prognostic factor analysis for breast cance ... Full text Cite

A cost analysis of hematopoietic colony-stimulating factors

Journal Article ONCOLOGY · 1995 Featured Publication The administration of hematopoietic colony-stimulating factors (CSFs) to reduce the severity and duration of neutropenia associated with systemic chemotherapy has become widespread, although the appropriate use of these agents has not yet been fully define ... Cite

The orderly progression of melanoma nodal metastases.

Journal Article Ann Surg · December 1994 Featured Publication OBJECTIVE: The aim of this study was to determine the order of melanoma nodal metastases. SUMMARY BACKGROUND DATA: Most solid tumors are thought to demonstrate a random nodal metastatic pattern. The incidence of skip nodal metastases precluded the use of s ... Full text Link to item Cite

Age as a prognostic factor in the malignant melanoma population.

Journal Article Ann Surg Oncol · November 1994 Featured Publication BACKGROUND: The incidence of malignant melanoma is increasing faster than any other cancer, and the state of Florida has one of the highest incidence of melanoma in the United States. This increased incidence is thought to be due to the intense sunlight ex ... Full text Link to item Cite

Management of chemotherapy in a pregnancy complicated by a large neuroblastoma.

Journal Article Obstet Gynecol · October 1994 Featured Publication BACKGROUND: The English literature contains infrequent reports of neuroendocrine carcinoma during pregnancy. The chemotherapy for this type of malignancy can cause severe nausea and neutropenia. We used recently developed modalities to ameliorate these sid ... Link to item Cite

The effect of changing disease risk on clinical reasoning.

Journal Article J Gen Intern Med · September 1994 Featured Publication OBJECTIVE: To assess the ability of health care professionals to evaluate the effect of clinical test results in different settings. DESIGN: Subjects were presented with a series of generic clinical scenarios in which information about the test performance ... Full text Link to item Cite

Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group.

Journal Article Journal of Clinical Oncology · August 1994 PURPOSE In 1984, the Department of Veterans Affairs Cooperative Studies Program began a trial in which patients with resectable squamous cell carcinoma of the larynx were randomized to receive standard surgery fol ... Full text Cite

The effect of weight-loss on estimated breast-cancer risk and sex-hormone levels.

Journal Article Oncol Rep · May 1994 Featured Publication The effect of weight loss on estimated breast cancer risk, sex hormone binding globulin (SHBG), total and free estradiol levels was evaluated. Increasing weight loss reduced upper body fat distribution progressively. Women with a family history of breast c ... Full text Link to item Cite

High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma.

Journal Article Blood · April 1, 1994 Featured Publication Interleukin-6 (IL-6) is a multifunctional cytokine postulated to play a central role as a growth factor for multiple myeloma (MM). We evaluated the spontaneous secretion of IL-6 in supernatants of Ficoll-Hypaque--enriched bone marrow (BM) cultures from 35 ... Link to item Cite

Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer

Journal Article Clinical Infectious Diseases · January 1, 1994 Featured Publication Patients with small-cell lung cancer were enrolled in a multicenter, randomized, double-blind, placebo-controlled trial of recombinant methionyl G-CSF to study the incidence of infection as manifested by fever with neutropenia (absolute neutrophil count,<1 ... Full text Cite

Management of chemotherapy in a pregnancy complicated by a large neuroblastoma

Journal Article Obstetrics and Gynecology · 1994 Featured Publication Background: The English literature contains infrequent reports of neuroendocrine carcinoma during pregnancy. The chemotherapy for this type of malignancy can cause severe nausea and neutropenia. We used recently developed modalities to ameliorate these sid ... Cite

Trimethoprim-sulfamethoxazole prophylaxis in granulocytopenic patients with acute leukemia: evaluation of serum antibiotic levels in a randomized, double-blind, placebo-controlled Department of Veterans Affairs Cooperative Study.

Journal Article Clin Infect Dis · September 1993 Featured Publication Despite widespread use of trimethoprim-sulfamethoxazole (TMP-SMZ) for prophylaxis in neutropenic patients, questions remain regarding its efficacy, toxicity, the risk of selection of resistant isolates, and the relation of its activity to selective decolon ... Full text Link to item Cite

Response

Journal Article Journal of the National Cancer Institute · August 4, 1993 Full text Cite

Cost-effectiveness of white cell-reduction filters in treatment of adult acute myelogenous leukemia.

Journal Article Transfusion · August 1993 The objective of this study was to compare the cost and cost-effectiveness of three transfusion strategies in the treatment of acute myelogenous leukemia: 1) the use of unfiltered pooled platelets until alloimmunization developed and of crossmatch-compatib ... Full text Link to item Cite

Variation in body fat distribution and breast cancer risk in the families of patients with breast cancer and control families.

Journal Article Cancer · May 1, 1993 BACKGROUND: The pattern of body fat distribution in women has been correlated with the risk of developing breast and endometrial cancer. The authors determined whether body fat distribution varied between first-degree relatives of patients with breast canc ... Full text Link to item Cite

Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy.

Journal Article J Natl Cancer Inst · March 17, 1993 BACKGROUND: Hematopoietic growth factors (HGFs) have been shown to reduce the incidence of neutropenia and fever in patients receiving cancer chemotherapy. PURPOSE: This cost analysis was designed to determine the conditions in which use of HGFs in patient ... Full text Link to item Cite

The medical legal implications of following mammographic breast masses.

Journal Article Am Surg · February 1993 Delay in breast cancer diagnosis continues to account for the highest percentage of medical malpractice cases in the United States. A retrospective, computer-aided study was undertaken to investigate a number of parameters used in making medical-legal deci ... Link to item Cite

Overestimation of test effects in clinical judgment.

Journal Article J Cancer Educ · 1993 The purpose of this study was to assess the ability of health care professionals to evaluate the effect of test results on disease risk. Fifty health care professionals, including 29 physicians and 21 nonphysicians, associated with a university hospital we ... Full text Link to item Cite

The anatomy of missed breast cancers.

Journal Article Surg Oncol · 1993 Missed breast cancer continues to account for the highest percentage of medical malpractice cases in the United States. A retrospective, computer-aided study was performed to investigate the mechanisms of missed breast carcinomas, missed either by mammogra ... Full text Link to item Cite

Environmental tobacco smoke and lung cancer risk in nonsmoking women.

Journal Article J Natl Cancer Inst · September 16, 1992 BACKGROUND: Exposure to environmental tobacco smoke (passive smoking) has been suggested to be a cause of lung cancer, although early epidemiologic studies have produced inconsistent results. PURPOSE: We conducted an epidemiologic case-control study to ass ... Full text Link to item Cite

Risk factors for cancer.

Journal Article Prim Care · September 1992 It is no longer reasonable to divide cancers into those that are genetic in origin and those that are environmental in origin. With rare exception, carcinogenesis involves environmental factors that directly or indirectly exert a change in the cell's genom ... Link to item Cite

A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.

Journal Article J Clin Oncol · February 1992 PURPOSE: To determine whether combination chemotherapy is superior to single agents for recurrent/metastatic head and neck cancer, we compared the efficacy and toxicity of cisplatin (CP) and fluorouracil (5-FU), alone and in combination in a phase III tria ... Full text Link to item Cite

Concentrated albumin infusion as an aid to postoperative recovery after pelvic exenteration.

Journal Article Gynecol Oncol · December 1991 Twenty-eight patients underwent pelvic exenterations for gynecologic malignancies between June 1986 and June 1989. The postoperative fluid and electrolytes were managed by one of two regimens. One group of 10 patients was given concentrated 25% albumin inf ... Full text Link to item Cite

Breast cancer of the older woman: an annotated review.

Journal Article J Am Geriatr Soc · November 1991 Full text Link to item Cite

Upper-body fat distribution and endometrial cancer risk.

Journal Article JAMA · October 2, 1991 STUDY OBJECTIVE: --To determine if body fat distribution affected endometrial cancer risk. DESIGN: --Case-control study. SETTING: --This study was carried out at the H. Lee Moffitt Cancer Center at the University of South Florida, Tampa, where all patients ... Link to item Cite

Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.

Journal Article N Engl J Med · July 18, 1991 BACKGROUND: Neutropenia and infection are major dose-limiting side effects of chemotherapy. Previous studies have suggested that recombinant methionyl granulocyte colony-stimulating factor (G-CSF) can reduce chemotherapy-related neutropenia in patients wit ... Full text Link to item Cite

Estimate of breast cancer risk reduction with weight loss.

Journal Article Cancer · May 15, 1991 Upper body fat localization has been associated with an increased risk of cancer. This study demonstrated that 64.2% of 124 women with at least a 4.5-kg weight loss decreased their upper body fat localization, as measured by a reduction in their suprailiac ... Full text Link to item Cite

Obesity, body fat distribution, and sex hormones in breast cancer patients.

Journal Article Cancer · April 15, 1991 This study addresses the relationship between female sex hormones, obesity, body fat distribution, and breast cancer. Increasing obesity correlated with a progressive fall in sex hormone-binding globulin (SHBG) level and an increase in testosterone level. ... Full text Link to item Cite

Obesity and body fat distribution and breast cancer prognosis.

Journal Article Cancer · January 15, 1991 This study addresses the effect of obesity and body fat distribution on axillary lymph node involvement, tumor size, and estrogen receptor (ER) level in breast cancer patients. Anthropometric measurements were prospectively obtained on 248 consecutively an ... Full text Link to item Cite

The effect of duration of intervention and locus of control on dietary change.

Journal Article Am J Prev Med · 1991 Scientific evidence supports a relationship between diet and the incidence of cancer. This finding has resulted in dietary recommendations that have been disseminated to the public. To reduce actual cancer incidence, these recommendations must lead to diet ... Link to item Cite

A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer.

Journal Article Cancer · January 1, 1991 In a randomized multi-center study, 83 patients with small cell lung cancer were randomly assigned to treatment with cisplatin 100 mg/m2 intravenously (IV) day 1 and etoposide 120 mg/m2 IV days 1, 2, and 3 or cisplatin 100 mg/m2 IV day 1 and etoposide 120 ... Full text Link to item Cite

A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer

Journal Article Cancer · 1991 In a randomized multi-center study, 83 patients with small cell lung cancer were randomly assigned to treatment with cisplatin 100 mg/m2 intravenously (IV) day 1 and etoposide 120 mg/m2 IV days 1, 2, and 3 or cisplatin 100 mg/m2 IV day 1 and etoposide 120 ... Cite

Extra-medullary relapse of acute myeloid leukemia at phlebotomy and bone marrow sites

Journal Article Hematology Reviews and Communications · December 1, 1990 Acute myelogenous leukemia can have many sites of extramedullary involvement, including bone, soft tissues, kidneys, lung, gastrointestinal tract, ovary, and skin. Skin involvement usually occurs with no specific favored sites. However, we present a patien ... Cite

Serum cholesterol reduction with tamoxifen.

Journal Article Breast Cancer Res Treat · November 1990 The serum cholesterol levels of 123 consecutively and newly diagnosed women with Stage I and II breast cancer taking tamoxifen were compared with a control group of 81 consecutively newly diagnosed women with Stage I and II breast cancer who were not takin ... Full text Link to item Cite

Human factor IXLincoln Park: a molecular characterization.

Journal Article Mol Cell Probes · October 1990 Using genomic DNA prepared from peripheral blood samples of a patient with factor IX deficiency, all eight exons as well as sequences around the splice junctions and putative promoter region of human factor IX DNA have been subjected to polymerase chain re ... Full text Link to item Cite

Tuboovarian abscess in postmenopausal women.

Journal Article J Reprod Med · May 1990 A retrospective review was done on all patients at Tampa General Hospital with a surgically confirmed tuboovarian abscess between March 31, 1983, and April 30, 1988. Patients were grouped according to their menopausal status. Sixty-three were identified. F ... Link to item Cite

Abdominal pain and a pelvic mass.

Journal Article Hosp Pract (Off Ed) · April 30, 1990 Link to item Cite

Abdominal obesity and breast cancer risk.

Journal Article Ann Intern Med · February 1, 1990 STUDY OBJECTIVE: To determine if body fat distribution affects breast cancer risk. DESIGN: Prospective case-control study. PATIENTS: The anthropometric measurements of 216 consecutively and newly diagnosed women with invasive carcinoma of the breast were c ... Full text Link to item Cite

INDIVIDUALIZED TREATMENT OF THE OLDER CANCER-PATIENT - A DECISION-ANALYSIS

Conference JOURNAL OF THE AMERICAN GERIATRICS SOCIETY · 1990 Cite

The value of current nutrition information.

Journal Article Prev Med · January 1990 To prevent or delay the occurrence of chronic diseases, scientific bodies from the cardiologic and oncologic disciplines have made recommendations regarding the daily dietary intake of certain macro- and micronutrients. This study assessed the knowledge of ... Full text Link to item Cite

Abdominal pain and a pelvic mass

Journal Article Hospital Practice · 1990 Cite

Cloning and characterization of the 5' end (exon 1) of the gene encoding human factor X.

Journal Article Gene · December 14, 1989 Human blood-coagulation factor X (hBCFX) is a serine protease zymogen which participates in the middle phase of blood coagulation. Recently, we and others have reported the cDNA sequences. At present, partial hBCFX gene structure is available. In this pape ... Full text Link to item Cite

Treatment of recurrent and metastatic endometrial cancer with cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate.

Journal Article Gynecol Oncol · October 1989 The combination of cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate was used to treat 15 patients with recurrent and metastatic endometrial cancer. Four patients had a complete response and one patient had a partial response, yielding a tota ... Full text Link to item Cite

A new objective measurement of esophageal lumen patency.

Journal Article Am J Gastroenterol · October 1989 This study was performed to develop a system to measure dysphagia in an objective fashion, test its correlation with subjective estimates of dysphagia, and encourage the use of a standardized measure of esophageal stenosis. Thirty-five patients with mechan ... Link to item Cite

Wound hematoma: prophylaxis with topical thrombin.

Journal Article South Med J · May 1989 We studied 123 patients having elective exploratory laparotomy through a midline vertical incision for gynecologic disease; patients were randomized to receive wound irrigation with either saline or topical thrombin before closure of the incision. Seven pa ... Link to item Cite

Impetiginous lesions in recurrent AML.

Journal Article Hosp Pract (Off Ed) · March 30, 1989 Link to item Cite

Anti-c-myc DNA increases differentiation and decreases colony formation by HL-60 cells.

Journal Article In Vitro Cell Dev Biol · March 1989 The proto-oncogene c-myc, whose gene product has a role in replication, is overexpressed in the human promyelocytic leukemia HL-60 cell line. Treatment of HL-60 cells with an antisense oligodeoxyribonucleotide complementary to the start codon and the next ... Full text Link to item Cite

ANTI-C-MYC DNA INCREASES DIFFERENTIATION AND DECREASES COLONY FORMATION BY HL-60 CELLS

Journal Article IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY · 1989 Cite

Anti-c-myc DNA increases differentiation and decreases colony formation by HL-60 cells

Journal Article In Vitro Cellular and Developmental Biology - Animal · 1989 Cite

Impetiginous lesions in recurrent AML

Journal Article Hospital Practice · 1989 Cite

Lung cancer in Florida. Risks associated with residence in the central Florida phosphate mining region.

Journal Article Am J Epidemiol · July 1988 A case-control study that included 25,398 cases of lung cancer among Florida residents, first diagnosed in 1981-1983, was conducted to determine if residence in the central Florida phosphate mining region was associated with an increased risk of lung cance ... Full text Link to item Cite

Clinical assessment of beta blockade.

Journal Article Clin Cardiol · May 1988 This study was undertaken to assess a clinical measurement (leg squats) in order to determine the adequacy of beta-adrenergic blockade (AdBB) utilizing the symptom-limited exercise test heart rate of less than 120 beats/min as the standard. Seventy subject ... Full text Link to item Cite

Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA.

Journal Article Proc Natl Acad Sci U S A · February 1988 The human promyelocytic leukemia cell line HL-60 overexpresses the c-myc protooncogene. A calculated secondary structure for c-myc mRNA placed the initiation codon in a bulge of a weakly base-paired region. Treatment of HL-60 cells with 5' d(AACGTTGAGGGGCA ... Full text Link to item Cite

BODY-FAT DISTRIBUTION AND BREAST-CANCER RISK

Conference BREAST CANCER RESEARCH AND TREATMENT · 1988 Cite

LYSIS OF AUTOLOGOUS MONOCYTES BY LYMPHOKINE-ACTIVATED KILLER (LAK) CELLS FROM CANCER-PATIENTS

Conference PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · 1988 Cite

Treatment of recurrent and metastatic cervical cancer with cis-platin, doxorubicin, and cyclophosphamide.

Journal Article Gynecol Oncol · January 1988 The combination of cisplatin, doxorubicin, and cyclophosphamide was used to treat 28 patients with recurrent and metastatic cervical cancer. Five patients had a complete response and one patient had a partial response, yielding a total response rate of 21% ... Full text Link to item Cite

Cigarette smoking and the risk of female reproductive cancer.

Journal Article Am J Obstet Gynecol · July 1987 An epidemiologic study was conducted to evaluate the relationship between cigarette smoking and the risk of breast, endometrial, and ovarian cancers. Results indicated a clear reduction of risk for endometrial cancer among women aged 50 years and older who ... Full text Link to item Cite

Major morbidity after pelvic exenteration: a seven-year experience.

Journal Article Obstet Gynecol · April 1987 Thirty-eight patients underwent pelvic exenteration at the University of South Florida during the last seven years. The majority of the operations were performed for recurrent carcinoma of the cervix, and the operative mortality was 5.3%. Twenty-one patien ... Link to item Cite

Continuous-infusion diaziquone in acute myeloid leukemia: a Southeastern Cancer Study Group trial.

Journal Article Cancer Treat Rep · March 1987 Diaziquone (AZQ) is a synthetic quinone with considerable activity against L1210 leukemia and potent myelosuppressive activity in man. To test the efficacy and toxicity of AZQ administered by continuous infusion, a phase II multi-institutional trial was un ... Link to item Cite

Clinical study evaluating efficacy of praziquantel in clonorchiasis.

Journal Article Antimicrob Agents Chemother · February 1987 In 74 patients with clonorchiasis, the efficacy and safety of praziquantel was evaluated in a two-phase study: a double-blind, randomized controlled trial of praziquantel versus placebo (42 patients) and an open study (32 patients). All but one of the pati ... Full text Link to item Cite

A NEW OBJECTIVE MEASUREMENT OF THE SEVERITY OF DYSPHAGIA

Conference GASTROINTESTINAL ENDOSCOPY · 1987 Cite

VARIATIONS IN LUNG-CANCER CELL TYPE AMONG WOMEN

Conference PREVENTIVE MEDICINE · 1987 Cite

Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report of the head and neck contracts program

Journal Article Cancer · 1987 To determine the efficacy of adjuvant chemotherapy in patients with advanced head and neck squamous carcinoma, the National Cancer Institute initiated a multi-institutional, prospective randomized trial termed the Head and Neck Contracts Program. Between 1 ... Full text Cite

Leukemia and groundwater contamination.

Journal Article JAMA · November 21, 1986 Link to item Cite

Cardiovascular effects and safety of dental anesthesia and dental interventions in patients with recent uncomplicated myocardial infarction.

Journal Article Arch Intern Med · November 1986 To determine the cardiovascular effects and safety of dental anesthesia and dental interventions in patients within three weeks of uncomplicated acute myocardial infarction, 40 patients were studied. Twenty patients, group 1, underwent injectable local den ... Link to item Cite

Peritoneal cytology and invasive carcinoma of the cervix.

Journal Article Gynecol Oncol · July 1986 One hundred thirty-nine patients with invasive carcinoma of the cervix underwent laparotomy at the University of South Florida between February 1980 and November 1983. One hundred nineteen had laparotomy prior to treatment and 20 after treatment for recurr ... Full text Link to item Cite

Digitalis use in a retirement community.

Journal Article J Am Geriatr Soc · July 1986 Complex medical problems of older patients demand that particular care be taken with their use of digitalis. Although accounting for more than 5% of the top ten prescribed drugs in the United States, studies have suggested that digitalis use might be disco ... Full text Link to item Cite

Eosinophils in corneas removed by penetrating keratoplasty.

Journal Article Br J Ophthalmol · May 1986 One hundred consecutively submitted corneas removed by penetrating keratoplasty were studied histologically to determine the frequency in which eosinophils are found. In 20 corneas eosinophils occurred in densities ranging from 0.2 to more than 50 per high ... Full text Link to item Cite

Leukemia and Radium Groundwater Contamination-Reply

Journal Article JAMA: The Journal of the American Medical Association · February 21, 1986 Full text Cite

Phase II evaluation of cisplatin, bleomycin, and vindesine in advanced squamous cell carcinoma of the esophagus: a Southeastern Cancer Study Group Trial.

Journal Article Cancer Treat Rep · February 1986 Adults with advanced, measurable, squamous cell carcinoma of the esophagus were treated with a combination of cisplatin, bleomycin, and vindesine. Of 27 evaluable patients, seven (29%) had partial response, all occurring within the first two cycles of ther ... Link to item Cite

CIGARETTE-ATTRIBUTABLE RISK FOR CANCER IN WOMEN

Conference PREVENTIVE MEDICINE · 1986 Cite

EXPOSURE TO LOW-LEVELS OF IONIZING-RADIATION AND LUNG-CANCER RISK IN FLORIDA

Conference AMERICAN JOURNAL OF EPIDEMIOLOGY · 1986 Cite

Impact of smoking and smokeless tobacco on the risk of cancer of the head and neck.

Journal Article Head Neck Surg · 1986 A case-control epidemiologic study was conducted to determine the relationship between quantities and types of tobacco and the risk of cancers of individual sites within the head and neck. Substantial variations were found to exist in the tobacco-associate ... Full text Link to item Cite

Association of leukemia with radium groundwater contamination.

Journal Article JAMA · August 2, 1985 Radiation exposure, including the ingestion of radium, has been causally associated with leukemia in man. Groundwater samples from 27 counties on or near Florida phosphate lands were found to exceed 5 pCi/L total radium in 12.4% of measurements. The incide ... Link to item Cite

Factors affecting the incidence of infectious morbidity after radical hysterectomy.

Journal Article Am J Obstet Gynecol · August 1, 1985 A double-blind, placebo-controlled trial was performed to assess the value of cefoxitin for prophylaxis against postoperative infection following radical hysterectomy. Infectious morbidity was observed in 35% of 43 patients in the control group and 23% of ... Full text Link to item Cite

Factors affecting the incidence of infectious morbidity after radical hysterectomy

Journal Article American Journal of Obstetrics and Gynecology · 1985 A double-blind, placebo-controlled trial was performed to assess the value of cefoxitin for prophylaxis against postoperative infection following radical hysterectomy. Infectious morbidity was observed in 35% of 43 patients in the control group and 23% of ... Cite

LEUKEMIA ASSOCIATED WITH RADIUM GROUNDWATER CONTAMINATION

Conference PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · 1985 Cite

Leukemia associated with radium groundwater contamination

Journal Article Proceedings of the American Association for Cancer Research · January 1, 1985 Cite

Sudden death in cancer patients receiving lithium.

Journal Article J Clin Oncol · November 1984 Lithium carbonate may attenuate the incidence and severity of infection associated with cancer chemotherapy but does not appear to improve patient survival. Of 100 patients with small-cell lung cancer receiving an identical regimen of cyclophosphamide, dox ... Full text Link to item Cite

High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study.

Journal Article Am J Clin Oncol · August 1984 Amsacrine (AMSA) has been shown to be an effective therapeutic agent in the treatment of adult acute nonlymphocytic leukemia (ANLL). The Eastern Cooperative Oncology Group studied the efficacy and toxicity of high-dose amsacrine (200 mg/m2/day for 5 days) ... Full text Link to item Cite

Lithium carbonate in patients with small cell lung cancer receiving combination chemotherapy.

Journal Article Am J Med · June 1981 Lithium administration has been shown to attenuate the leukopenia associated with systemic chemotherapy. The results of a randomized trial of lithium in 45 patients with small cell lung cancer who received combination chemotherapy and radiation therapy are ... Full text Link to item Cite

INTENSIVE COMBINATION CHEMOTHERAPY AND RADIOTHERAPY FOR SMALL CELL BRONCHOGENIC-CARCINOMA (SCBC)

Conference PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · 1981 Cite

EARLY DEATH IN PATIENTS WITH ELECTROCARDIOGRAPHIC (ECG) ABNORMALITIES RECEIVING LITHIUM-CARBONATE (LC)

Conference PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · 1981 Cite

SERUM LITHIUM LEVEL AND THE ATTENUATION OF CHEMOTHERAPY MYELOSUPPRESSION

Conference PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · 1981 Cite

SEQUENTIAL METHOTREXATE (MTX) AND 5-FLUOROURACIL (5FU) IN ADENOCARCINOMA OF THE COLON AND RECTUM

Conference PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · 1981 Cite

Intensive combination chemotherapy and radiotherapy for small cell bronchogenic carcinoma (SCBC)

Journal Article Proceedings of the American Association for Cancer Research · January 1, 1981 Cite

Prophylactic antibiotics in hospitalized granulocytopenic patients

Journal Article Clinical Research · January 1, 1981 Cite

Cis-diamminedichloroplatinum (CDDP) and bleomycin (B) in advanced squamous cell carcinoma of the head and neck (SCCHN)

Journal Article Proceedings of the American Association for Cancer Research · January 1, 1981 Cite

Early death in patients with electrocardiographic (EKG) abnormalities receiving lithium carbonate (LC)

Journal Article Proceedings of the American Association for Cancer Research · January 1, 1981 Cite

Serum lithium level and the attenuation of chemotherapy myelosuppression

Journal Article Proceedings of the American Association for Cancer Research · January 1, 1981 Cite

Adjunctive agents in systemic chemotherapy.

Journal Article Compr Ther · October 1980 Link to item Cite

Lithium carbonate during chemotherapy.

Journal Article N Engl J Med · June 12, 1980 Full text Link to item Cite

The use of lithium carbonate to reduce infection and leukopenia during systemic chemotherapy.

Journal Article N Engl J Med · January 31, 1980 To investigate whether lithium ameliorates the infectious complications that accompany systemic chemotherapy, we studied 45 patients with small-cell bronchogenic carcinoma receiving combination chemotherapy and radiation therapy. Twenty received lithium ca ... Full text Link to item Cite

Treatment results and toxicity of lithium carbonate (L) in the combined modality management of small cell lung cancer

Journal Article Proceedings of the American Association for Cancer Research · January 1, 1979 Cite

Combination chemotherapy and radiation therapy of undifferentiated small cell bronchogenic carcinoma.

Journal Article South Med J · May 1978 We reviewed 76 cases of small cell bronchogenic carcinoma seen at the University of South Florida Medical Center. One third of the 55 patients who have subsequently died did so within one month of diagnosis. Thirty-five patients were treated with cyclophos ... Full text Link to item Cite

Fibrinogen kinetics in patients with neoplastic disease.

Journal Article Cancer · March 1978 Fibrinogen half-life was determined in 30 patients with active or inactive malignancies by monitoring survival of administered 125I-labeled autologous fibrinogen. Six patients had no evidence of active disease and served as controls having fibrinogen level ... Full text Link to item Cite

METABOLISM OF FIBRINOGEN IN CANCER-PATIENTS

Conference PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · 1978 Cite

Carcinoma of unknown primary: natural history and response to therapy.

Journal Article J Med · 1978 Twenty-three consecutive patients with metastatic carcinoma of unknown primary referred to a medical oncology service over the past two years were studied. In the majority of patients, death occurred within one year of diagnosis and a priamry site of disea ... Link to item Cite

FACTORS AFFECTING MORALE OF INPATIENT STAFF IN A CANCER-TREATMENT CENTER

Conference PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · 1977 Cite

Acute myelogenous leukemia subsequent to therapy for a different neoplasm: clinical features and response to therapy.

Journal Article Am J Hematol · 1977 The clinical characteristics of 10 patients with acute myelogenous leukemia (AML) which developed subsequently to treatment for another neoplasm are described. This disease appears to differ from "spontaneous" AML in being associated with lesser degrees of ... Full text Link to item Cite

Phospholipid membrane stabilization by dimethylsulfoxide and other inducers of Friend leukemic cell differentiation.

Journal Article Biochim Biophys Acta · October 19, 1976 A large number of low molecular weight polar cryoprotective agents have recently been found to induce erythroid differentiation of Friend leukemic cells in vitro. The effect of these agents on membrane fluidity in phospholipid vesicles was studied by deter ... Full text Link to item Cite

Membrane action of DMSO and other chemical inducers of Friend leukaemic cell differentiation.

Journal Article Nature · July 29, 1976 DMSO and other cryoprotective agents produce a pronounced increase on the phase transition temperature of phospholipid membranes, indicating an increased stability. The effects of DMSO and other cryoprotective agents, divalent cations, and local anaestheti ... Full text Link to item Cite

Inducers of Friend leukaemic cell differentiation in vitro--effects of in vivo administration.

Journal Article Br J Cancer · June 1976 Studies were conducted of the in vivo therapeutic potential of compounds which induce the differentiation of Friend leukaemia cells (FLC) in vitro. DBA2/J mice were inoculated with Friend leukaemia cells grown in tissue culture and at various times thereaf ... Full text Link to item Cite

APPARENT CONVERSIONS OF LYMPHOCYTIC TO MYELOCYTIC-LEUKEMIA

Conference PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · 1976 Cite

Membrane action of DMSO and other chemical inducers of Friend leukaemic cell differentiation

Journal Article Nature · 1976 DMSO and other cryoprotective agents produce a pronounced increase on the phase transition temperature of phospholipid membranes, indicating an increased stability. The plateau phase of DMSO and the other cryoprotective agents, divalent cations, and local ... Cite

Differentiation of erythroleukemia cells in vitro: properties of chemical inducers.

Journal Article Cell Differ · June 1975 Murine erythroleukemia cells growing in vitro can be induced to differentiate. The physical properties of chemical inducers has been defined and has permitted the recognition of a variety of potent inducers. The compounds can be linear, branched, or aromat ... Full text Link to item Cite

PROPERTIES OF COMPOUNDS WHICH INDUCE DIFFERENTIATION OF FRIEND LEUKEMIA-CELLS (FLC) INVITRO

Conference PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · 1975 Cite